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If we knew what it was we were doing, 
It would not be called research, would it? 
(A. Einstein) 
 
 
 
 
 
 
 
 
 
 
 
Abstract (English) 
 
One great innovation brought about the knowledge of the genetic processes leading to 
neoplastic transformation is the possibility to identify cancer-promoting molecular lesions that 
can be selectively targeted with rationally designed therapeutic agents. 
Targeted therapy represents a revolutionary road to overcome the aspecificity of oncogenic 
treatment and to strike the biomolecular cause of neoplastic pathological processes.  
Advances in computing are vital to cancer research. They are opening up opportunities to 
discover new drugs from the molecular basis of disease; this is proving to be a cost-effective 
method of identifying compounds that block the action of many proteins suggested by biology 
as important factors in different kind of cancer. 
In this work we will use a wide set of molecular simulation techniques to study different 
problem facing during the application of chemotherapy.  
The understanding of new details on mechanisms leading to cancer allowed the identification 
of new and more precise target protein to tackle the process without collateral damage to the 
neighboring healthy cells.  In particular, here are reported some details about three different 
new targets: the ς1 receptors, -catenin and dendrimer development for gene silencing 
therapy. 
However, despite the clinical success of targeted therapies, most patients that respond 
eventually relapse as a result of acquired resistance; the development of resistance can occur 
after a variable period of chronic treatment probably involving mutation that leads to a 
conformational rearrangement of the protein involved.  
In silico molecular modeling can be used to predict the occurrence of all activating but drug-
resistant secondary mutations and to develop a multi-drug targeted prevention strategy. 
In this context, it will be discussed in particular mutations involved in c-Kit and Smoothened 
receptor, pre and after treatment.    
The extensive series of examples illustrated and discussed here emphasized the role and 
potentiality of molecular modeling in the development of cancer targeted therapy. In silico 
evaluation can take into account the molecular specificity of the problem and dramatically 
reduced the time and cost required to formulate new compounds and therapeutic 
intervention. 
 
 
 
Abstract (Italiano) 
 
Le recenti scoperte sulla natura dei processi genetici, implicati nelle trasformazioni neoplastiche, ci 
hanno permesso di identificare le principali lesioni cellulari che portano alla formazione del tumore, 
individuando in questo modo target selettivi sulla base dei quali progettare nuovi agenti terapeutici 
efficaci. 
La terapia bersaglio ha rappresentato una rivoluzione permettendo di superare l’aspecificità del 
trattamento antitumorale e colpendo, nello specifico, la causa biomolecolare del processo patologico 
neoplastico. 
I recenti sviluppi della modellistica molecolare si sono resi indispensabili per la ricerca oncologica.  
Questi, infatti, aprono delle opportunità per la scoperta di nuovi farmaci attraverso la comprensione 
delle basi molecolari delle malattie; si tratta di un metodo conveniente per identificare dei composti 
che siano in grado di bloccare l’azione di molte proteine, suggerite come fattori fondamentali in 
diversi tipi di neoplasie. 
In questo lavoro di tesi verrà adoperata un’ampia gamma di tecniche di simulazione molecolare al 
fine di studiare differenti problemi che possono comparire durante il trattamento chemioterapico. La 
scoperta di nuovi dettagli nei meccanismi che conducono alla carcinogenesi ha permesso di 
identificare proteine target innovative e più precise per affrontare la terapia senza effetti collaterali 
per le cellule sane. In particolare, saranno riportati in dettaglio gli studi che coinvolgono tre nuovi 
differenti target: il recettore ς1, la proteina -catenina e lo sviluppo di dendrimeri per una terapia di 
silenziamento genico. 
Tuttavia, nonostante i successi clinici della terapia bersaglio, molti pazienti che inizialmente hanno 
risposto positivamente manifestano una recidiva, come risultato di una resistenza acquisita; questo 
tipo di risposta può manifestarsi dopo un periodo variabile di trattamento cronico.   
L’approccio delle tecniche in silico può essere utilizzato per predire l’avvento di mutazioni secondarie 
attivanti e al contempo resistenti alla terapia e quindi aiutare nello sviluppo di una strategia di 
prevenzione focalizzata su una terapia multi-farmaco. In questo lavoro, verranno discusse in 
particolare delle mutazioni che coinvolgono i recettori c-Kit e Smoothened, pre e post trattamento.  
L’ampia serie di esempi illustrati e discussi qui enfatizza il ruolo e le potenzialità del modeling 
molecolare nello sviluppo della terapia bersaglio anti tumorale. Una valutazione in silico permette di 
prendere in considerazione la specificità molecolare del problema e ridurre drasticamente i tempi e i 
costi richiesti per formulare nuovi farmaci e strategie di intervento. 
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Introduction 
In the year 2013, there were estimated 1,5 million new cases of cancer and 500,000 cancer 
deaths worldwide. Some good news, however, has emerged: cancer mortality for both men 
and woman in the USA declined during the last decade of the 20th century. Thus, there has 
been progress, but the problem is still overwhelming. There are now dramatic improvements 
in therapeutic responses and 5-year survival rates with many forms of malignancy, notably the 
leukemias and lymphomas. A greater proportion of cancers is being cured or arrested today 
than ever before.1  
 
Figure1.1 Estimated number of new cancer cases and deaths by sex, US, 2013.1 
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1.1 Molecular basis of disease 
Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal 
cells. If the spread is not controlled, it can result in death. Causes are both external factors 
(tobacco, infectious organism, chemicals and radiation) and internal factors (inherited 
mutations, hormones, immune conditions and mutations that occur from metabolism). These 
causal factors may act together or in sequence to initiate or promote the development of 
cancer. Ten or more years often pass between exposure to external factors and detectable 
cancer. Cancer is treated with surgery, radiation, chemotherapy, hormone therapy, biological 
therapy and targeted therapy. 
Nonlethal genetic damage lies at the hearth of carcinogenesis. Such genetic damage may be 
acquired by the action of environmental agents, such as chemicals, radiation, or viruses, or it 
may be inherited in the germ line. The term “environmental”, used in this context, involves any 
acquired defect caused by exogenous agents or endogenous products of cell metabolism. Not 
all mutations, however, are “environmentally” induced. Some may be spontaneous and 
stochastic.2 A tumor is formed by the clonal expansion of a single precursor cell that has 
incurred the genetic damage. The most commonly used method to determine tumor clonality 
involves the analysis of methylation patterns adjacent to the highly polymorphic locus of the 
human androgen receptor gene (HUMARA). The frequency of HUMARA polymorphism in the 
general population is more than 90%, so it is easy to establish clonality by showing that all the 
cells in a tumor express the same allele. For tumors with a specific translocation, such as in 
myeloid leukemias, the presence of the translocation can be used to assess clonality. 
Four classes of normal regulatory genes (the growth-promoting proto-oncogenes, the growth-
inhibiting tumor suppressor genes that regulate programmed cell death/apoptosis and genes 
involved in DNA repair) are the principal targets of genetic damage. Mutant alleles of proto-
oncogenes are considered dominant because they transform cells despite the presence of a 
normal counterpart. In contrast, both normal alleles of the tumor suppressor gene must be 
damaged for transformation to occur, so this family of genes is sometimes referred to as 
recessives oncogenes. However, there are exceptions to this rule, and some tumor suppressor 
genes lose their suppressor activity when a single allele is lost or inactivated. This loss of 
functions of a recessive gene caused by damage of a single allele is called haploinsufficiency. 
Genes that regulate apoptosis may be dominant, as are proto-oncogenes, or they may behave 
as tumor suppressor genes. 
DNA repair genes affect cell proliferation or survival indirectly by influencing the ability of the 
organism to repair nonlethal damage in other genes, including proto-oncogenes, tumor 
suppressor genes, and genes that regulate apoptosis. A disability in the DNA repair genes can 
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predispose to mutations in the genome and hence to neoplastic transformation. Such 
propensity to mutations is called a mutator phenotype. With some exceptions, both alleles of 
DNA repair genes must be inactivated to induce such genomic instability, in this sense, DNA 
repair genes may also be considered as tumor suppressor genes. 
Carcinogenesis is a multistep process at both the phenotypic and the genetic levels. A 
malignant neoplasm has several phenotypic attributes, such as excessive growth, local 
invasiveness and the ability to form distant metastases. These characteristics are acquired in a 
stepwise fashion, a phenomenon called tumor progression. At the molecular level, progression 
results from accumulation of genetic lesions that in some instances are favored by defects in 
DNA repair. 
 
1.2 The long road of cancer chemotherapy 
The use of chemotherapy to treat cancer began at the start of the 20th century with attempts 
to narrow the universe of chemicals that might affect the disease by developing methods to 
screen chemicals using transplantable tumors in rodents. 
Surgery and radiotherapy dominated the field of cancer therapy into the 1960s until it became 
clear that cure rates after ever more radical local treatments had plateaued at about 33% due 
to the presence of micrometastases and new data showed that combination chemotherapy 
could cure patients with various advanced cancers. The latter observation opened up the 
opportunity to apply drugs in conjunction with surgery and/or radiation treatments to deal 
with the issue of micrometastases, initially in breast cancer patients, and the field of adjuvant 
chemotherapy was born. Combined modality treatment, the tailoring of each of the three 
modalities so their antitumor effect could be maximized with minimal toxicity to normal 
tissues, then became standard clinical practice.3 In 1990s, something else has happened to 
change the landscape of drug development.  Information about the molecular aberrations that 
occur in cancer cells has become available, random screening is being replaced by screening 
against specific critical molecular targets. As the market for cancer drugs has grown, so has the 
willingness of the industry to invest in new drugs, and discovery and development are now 
largely in the hands of a segment of the pharmaceutical industry that did not exist before the 
advent of the CCNSC (Cancer Chemotherapy National Service Center). As a consequence, many 
new drugs and new classes of anticancer drugs have been introduced since the 1980s and are 
now available to clinicians.4  
The advent of monoclonal antibodies has enhanced the effects of chemotherapy. Hybridomas 
were described in 1975, and monoclonal antibodies were proven clinically useful starting in 
the mid-1990s. Although they are not chemotherapy per se, they seem to work best when 
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they are used in conjunction with chemotherapy, as is the case for trastuzumab in breast 
cancer, cetuximab and bevacizumab in colorectal cancer, and rituximab in non–Hodgkin's 
lymphoma, and each are an integral part of chemotherapy regimens for these common 
tumors. 
Chemotherapy has, in fact, transitioned to the age of “targeted therapy.”  
 
1.3 Targeted therapy 
One great innovation brought about by the knowledge of the genetic processes leading to 
neoplastic transformation is the possibility to identify cancer-promoting molecular lesions that 
can be selectively targeted with rationally designed therapeutic agents.    
For decades, the hallmark of medical treatment for cancer has been intravenous cytotoxic 
chemotherapy. These drugs target rapidly dividing cells, including cancer cells and certain 
normal tissue.  Targeted therapies have expanded the concept of individually tailored cancer 
treatment because some of these drugs may be effective in patients whose cancers have a 
specific molecular target, but they may not be effective in the absence of such a target. This 
distinction may be influenced by patient ethnicity and sex, as well as by tumor histology. 5 
Traditional cytotoxic chemotherapy works primarily through the inhibition of cell division. In 
addition to cancer cells, other rapidly dividing cells (e.g. hair, gastrointestinal epithelium, bone 
marrow) are affected by these drugs. In contrast, targeted therapy blocks the proliferation of 
cancer cells by interfering with specific molecules required for tumor development and 
growth. Some of these molecules may be present in normal tissues, but they are often 
mutated or overexpressed in tumors.6 
For example, most cases of chronic myeloid leukemia (CML) are caused by the formation of a 
gene called BCR-ABL. This gene is formed when pieces of chromosome 9 and chromosome 22 
break off and trade places. 
One of the changed chromosomes resulting from this switch contains part of the ABL gene 
from chromosome 9 fused to part of the BCR gene from chromosome 22. The protein normally 
produced by the ABL gene (Abl) is a signaling molecule that plays an important role in 
controlling cell proliferation and usually must interact with other signaling molecules to be 
active. However, Abl signaling is always active in the protein (Bcr-Abl) produced by the BCR-
ABL fusion gene. This activity promotes the continuous proliferation of CML cells.7 
Therefore, Bcr-Abl represents a good molecule to target.1  
The molecular pathways most often targeted in the treatment of solid tumors are those of the 
epidermal growth factor receptor (EGFR)8, vascular endothelial growth factor (VEGF)9 and 
Her2. Such pathways can be inhibited at multiple levels: by binding and neutralizing ligands; by 
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occupying receptor binding site; by blocking receptor signaling within the cancer cell; or by 
interfering with downstream intracellular molecules. 
The best models for this approach are proteins with kinase activity which become one of the 
most intensively pursued classes of druggable molecules, with approximately 30 distinct 
kinase-inhibiting agents undergoing clinical trials. The choice of protein kinases as drug targets 
is motivated by the convergence of several factors: i) every signal transduction process is 
regulated by kinases; ii) kinases are frequently activated by mutation/gene amplification in a 
variety of human cancers; iii) despite the high degree of conservation in the ATP binding site, 
highly selective small molecules with favorable pharmaceutical properties can be developed; 
iv) inhibition of kinase activity in normal cells is often tolerated. Efficient approaches, 
benefiting immensely from crystallography and 3D modeling, allowed the development of 
potent and selective inhibitors. To date the most successful clinical use of a kinase inhibitor is 
represented by imatinib, a drug designed specifically to target a molecular defect associated 
with cancer (Table 1.1). By binding the catalytic domain imatinib inactivates the BCR-ABL1 
oncogene of chronic myeloid leukaemia (CML), revolutioning the management of the 
disease10,11. The discovery of imatinib as a multikinase inhibitor of c-Abl, c-KIT and PDGFR 
allowed the rapid extension of the success of imatinib to gastrointestinal stromal tumours 
(GIST), thus providing the first example of successful kinase-targeted therapy in solid tumors. 
 
Despite the impressive clinical success of kinase-targeted therapies, most treatment-
responsive patients eventually experience relapse as a result of acquired resistance. 
Among the resistance mechanisms, a Darwinian type selection appears to play a major role. In 
fact, under the pressure exerted by the necessary chronic treatment, there are appearance 
and expansion of tumour clones expressing a new mutation in the targeted kinase that is no 
longer drug-sensitive. It is currently debated whether the resistant mutations are pre-existing 
or acquired following inhibitor treatment. Both mechanisms have been recently demonstrated 
in CML with acquired resistance to imatinib. 
The use of targeted has markedly changed outcomes for some diseases. Imatinib has had a 
dramatic effect on chronic myeloid leukemia, and rituximab, sunitinib and trastuzumab have 
revolutionized the treatment of non-Hodgkin’s lymphoma, renal cell carcinoma, and breast 
cancer, respectively.12-14 In addition to prolonging survival in patients with certain cancers, 
targeted therapies provide treatment options for some patients who may not otherwise be 
candidates for anticancer therapy. 
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Many targeted cancer therapies have been approved by the U.S. Food and Drug 
Administration (FDA) for the treatment of specific types of cancer. Others are being studied in 
clinical trials, and many more are in preclinical testing. 
 
Drug Target FDA-approved 
indications 
Imatinib  
(Gleevec) 
BCR-ABL, c-KIT, 
PDGFR 
Acute lymphocytic 
leukemia, CML, 
GIST, 
hypereosinophilic 
syndrome, systemic 
mastocytosis 
Dasatinib (Sprycel) BCR-ABL, SRC 
family, c-KIT, 
PDGFR 
CML, acute 
lymphocytic 
leukemia 
Erloyinib (Tarceva) EGFR Non-small cell lung 
cancer, pancreatic 
cancer 
Gefitinib  
(Iressa) 
EGFR Non-small cell lung 
cancer 
Lapatinib 
 (Tykerb) 
HER2, EGFR Breast cancer with 
HER2 
overexpression 
Sorafenib 
(Nexavar) 
BRAF, VEGFR, 
EGFR, PDGFR 
Renal cell cancer, 
hepatocellular 
carcinoma 
Sunitinib  
(Sutent) 
VEGFR, PDGFR, c-
KIT, FLT3 
Renal cell cancer, 
GIST 
Bosutinib  
(Bosulif) 
BCR-ABL CML 
Vandetanib 
(Caprelsa) 
EGFR, VEGFR Medullary thyroid 
cancer 
 
Table 1.1 Small molecule inhibitors for cancer treatment. 
 
1.4 Problems during cancer therapy  
 
Chemotherapy is one of the principal modes of treatment for cancer, but the effectiveness of 
chemotherapy is limited by drug resistance. Resistance to chemotherapeutics can be divided 
into two broad categories: intrinsic or acquired. Intrinsic resistance indicates that before 
receiving chemotherapy, resistance-mediating factors preexist in the bulk of tumor cells that 
make the therapy ineffective.  Acquired drug resistance can develop during treatment of 
tumors that were initially sensitive and can be caused by mutations arising during treatment,15 
as well as through various other adaptive responses, such as increased expression of the 
therapeutic target and activation of alternative compensatory signaling pathways. Moreover, it 
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is increasingly recognized that tumors can contain a high degree of molecular heterogeneity, 
thus drug resistance can arise through therapy-induced selection of a resistant minor 
subpopulation of cells that was present in the original tumor.16 As our understanding of the 
molecular biology of cancer has advanced, drug development has shifted towards agents that 
target specific molecular alterations in tumors. These “molecularly targeted therapies” have 
had varying degrees of success because a diverse range of resistance mechanisms have limited 
patients responses. Importantly, the mechanism of resistance to cytotoxic chemotherapies and 
targeted drugs largely overlap, thus knowledge gained from earlier research into the 
mechanism of resistance to cytotoxic drugs can be applied to help anticipate and elucidate 
mechanisms of resistance to emerging molecularly targeted agents.   
Mechanisms of resistance to anticancer agents may include increased drug efflux, 
modifications within the target protein, activation of downstream or redundant pathways, and 
induction of cell survival pathways. In cancers driven by kinase oncogenes, resistance 
mechanisms frequently engage the underlying tumor dependency elaborated by these 
oncogenes. As a general rule, oncogene-addicted tumors tend to develop resistance to 
oncogenic pathway inhibition by reactivating that pathway rather than by engaging completely 
new oncogenic pathways, although there can be exceptions to this rule. In principle, then, any 
mechanism that reactivates an oncogenic pathway in the setting of therapeutic inhibition has 
the potential to engender acquired resistance.17   
Cancers are often highly dependent on specific oncogenic mutations that occur in kinases; 
however, the outgrowth of cells with gatekeeper residue mutations is a common mechanism 
of resistance to agents that target these oncogenic kinases. 
This type of target –associated resistance has also been observed, as said before, for imatinib, 
which is a highly effective inhibitor of the BCR-ABL oncogenic kinase that causes chronic 
myeloid leukaemia (CML).  The first mutation identified in patients with CML that relapsed on 
the selected treatment was T315I, in the gatekeeper residue. This mutations hampers imatinib 
binding while preserving the catalytic activity that is needed for the oncogenic function of BCR-
ABL1.18 Second generation BCR-ABL1 inhibitors have been developed; nilotinib, dasatinib and 
bosutinib have been approved for the treatment of patients who have developed imatinib 
resistance, these inhibitors are active against all of the common mutations except T315 .19,20 
Although therapeutics directed against oncogenic kinases may yield dramatic responses and 
improved survival in cancers driven by a dominant oncogene, such tumors invariably become 
resistant to these agents. Thus, elucidating the mechanism of acquired resistance (or de novo) 
is essential to the development of new treatment strategies that improve the clinical benefit. 
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In parallel, diagnostic advances that exploit increasingly powerful genomic technologies may 
be needed to profile individual tumors for the acquisition of specific resistance mechanisms. 
 
New approaches to win the battle 
Considering all the point explained up to here, cancer therapy is based on two different tasks: 
the individuation of new possible targets during the carcinogenesis processes and the study of 
the effects due to resistance mechanism for secondary mutations in order to predict the 
possible outcome of the disease exploiting, for instance, computational techniques, saving life 
and money. 
 
1.5 Individuation of new more specific and accurate targets  
The understanding of new details on mechanisms leading to cancer allowed the identification 
of new and more precise target protein to tackle in order to block the process.  In particular, 
here are reported some details about three different new targets: the ς receptors, -catenin in 
desmoid tumors therapy and dendrimers development as nanovector for gene silencing.  
1.5.1 Sigma receptors as new entry in cancer therapy 
ς receptors represent a class of proteins that were first discovered in 1976; initially proposed 
to be subtypes of opioid receptors they were subsequently confused with the PCP binding site. 
Finally studies revealed that ς binding sites are a distinct class of receptors that are located in 
the central nervous system as well as in a variety of tissues and organs.21 22  
1 receptors were first postulated based on the actions of SKF 10,047 (N-allylnormetazocine) 
and related benzomorphans. The name ‘‘’’ originated from the first letter ‘‘S’’ in SKF 10,047, 
which was thought to be the prototypic ligand for these binding sites. Unfortunately, SKF 
10,047 is now recognized as a non-selective ligand, which contributed to the turbulent early 
history surrounding these enigmatic receptors. To date, two subtypes of the ς receptor have 
been identified, the ς1 and ς2 receptors, which are distinguishable by their pharmacology, 
function, and molecular mass.23,24 
One distinguishing feature of the 1 receptor is its promiscuity in binding a wide range of 
different pharmacological agents although, how binding of these various compounds 
translates into function(s) through the 1 receptor is currently not clear. 
 Since the discovery of the 1 receptor, many preclinical studies have implicated the receptor 
in many important human diseases, from maladies of the central nervous system to cancer. 
 
 
9 
 
The ς1 receptor was cloned
25; it is a 25 kDa single polypeptide and it shares no sequence 
homology with any known mammalian proteins but shows approximately 30% identity with a 
yeast sterol C8-C7 isomerase26. Data about ς2 receptor are poor: they have not yet been 
cloned and have an apparent molecular weight of 21.5 kDa according to photolabeling 
studies.27 
The radioligand pentazocine (Figure 1.2) has a high affinity for the ς1 receptor and a low 
affinity for the ς2 receptor, whereas DTG is equipotent at both ς1 and ς2 receptors. Several 
psychoactive drugs show high to moderate affinity for ς1 receptors such as the antipsychotic 
haloperidol, the psychostimulants cocaine and methamphetamine, the antidepressant drugs 
fluvoxamine and sertraline; furthermore phenytoin, an anticonvulsivant drug, allosterically 
modulates ς1 receptors.
28 In 2009, Fontanilla et al. identified as probable ς1 endogenous ligand 
N,N,dimethyltryptamine (DMT).29 
Their localization is in the plasma membrane and in subcellular membranes, mainly in the 
endoplasmic reticulum, where they play a modulatory role in intracellular Ca2+ signaling.30 
Autoradiographic studies have shown that, at the anatomical level, ς receptors are mainly 
distributed in different areas of the central nervous system (CNS), focused in the brain where 
they are concentrated in specific areas involved in memory, emotion and sensory and motor 
functions.31 In the periphery ς receptors are expressed in blood vessels, genital system, 
gastrointestinal tract, steroid-producing organs, immune system, liver and eyes. Their large 
distribution in the CNS seems to explain the modulatory role in cellular, biochemical and 
neurotransmission systems.32 For this reason ς1 ligands may be involved in the treatment of 
diseases such as depression, anxiety, cognitive impairments, psychosis, analgesia and against 
the effects of drugs of abuse.33 In addition, and also due to the modulatory role of ς1 
receptors, the combined administration of ς1 receptor ligands and drugs with a known 
therapeutic effect has been shown to improve the effects of the latter, resulting in the need 
for lower doses to reach therapeutic concentrations.34 
 
Figure 1.2 Chemical structure of pentazocine, high selective σ1 ligands 
1receptor structure is still unveiled. The only data known are about the secondary structure. 
The gene encodes a protein consisting of 223 amino acids with an intracellular N-terminal end, 
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two transmembrane spanning domains (10-30 and 80-100 a.a.) linked by an extracellular loop 
and a C-terminal end partially arranged (Figure 1.3).35 There is also a typical arginine-arginine 
endoplasmic reticulum locating signal near the N terminal end. It is significant that 1 receptor 
contains two GXXXG motifs, tool which occurs with high frequency in membrane proteins that 
favor helix-helix interactions.36 
 
Figure 1.3 Structure of the 1 receptor. The protein is constituted by two transmembrane domain and the 
SBDL (Steroid binding domain like-) 1, and 2. 
Involvement in cancer 
Overexpression of  receptor in cancer tissues was first shown in brain tumors, by means of 
homologous competition binding assays using DTG (di-o-tolylguanidine).  receptor binding 
was detected in 15 of the 16 tumors analyzed and very high levels were found in a 
neuroblastoma and a brain metastasis from a lung adenocarcinoma. Later, elevated  receptor 
expression was also observed in various cancer cell lines, including nonsmall cell lung 
carcinoma (NSCL), breast, lung, melanoma, leukemia, glioblastoma, neuroblastoma, and 
prostate tumour (Figure 1.4).37 
Both 1 and 2 receptors exhibit a subcellular localization: plasma membrane, endoplasmic 
reticulum and mitochondria. These locations involve organelles that are known to play a role in 
both caspase-dependent and caspase-independent cell death pathways.     
All these data thus suggest the conclusions that  ligands should be evaluated as potential 
chemotherapeutic anticancer agents38 39 40.       
The potential usefulness of  receptor ligands in cancer diagnosis and therapy are the 
overexpression in tumor cells, the ability to internalize their ligands, and the fact that several  
ligands contain an iodine or fluoride atom in their chemical structure motivated the 
development of  receptor ligands for diagnostic imaging using PET41; different studies42 
highlighted the possibility of using  ligands for targeting drugs to human cancer cells, in 
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particular a benzamide analog was incorporated into liposomes containing doxorubicin to 
specifically target the drug to DU-145 prostate cancer cells, which are known to overexpress  
receptors; the role of 1 ligands was tested for enhancing standard cancer therapy in diffusive 
and migrant glioblastoma. 
It has been demonstrated that 1 receptor ligands potentiate calcium mobilization and 
contribute to both lipid raft formation and cytoskeletal protein modulation in normal and 
cancer cells. Each of the signal transduction pathways potentially involved in such actions is of 
interest in the context of cancer research. 
They are, also, involved in sphingomyelin, glucosyl-ceramide, and cholesterol regulation 43 44 . 
It is possible to hypothesize that overexpression of  receptors in cancer cells is useful 
primarily to support the high lipid production required for plasma membrane formation in 
highly proliferative cells. So concerning cancer therapy, it has been hypothesize that high levels 
of  receptor could induce a drastic decrease of RhoGDI expression, which enables the Rho 
GTP ase activation required for the translocation of  receptor/IP3R3 complexes45 and results 
in the inhibition of ion flux, notably Ca2+, and a concomitant deregulation of the ceramide 
biosynthesis pathway. These two effects contribute to the disruption of the synthesis of major 
lipid membrane components, leading to mitotic arrest and/or anoikis of the cancerous cells 
that overexpress  receptors. These effects might also contribute to the specific sensitization 
of 1 receptor overexpressing cancer cells to ER-stress agents.  
The putative role in cancer development and the lack of ς1 receptor’s crystallographic 
structure have led to create a 3D model using homology modeling to find out more details 
about its physiology and new ligands design. 
 
Figure 1.4 Correlation between the expression of 1 receptor and their localization in normal and cancer 
tissues; the y axis values range from -4 to +4 where 0 is basal expression of  receptor in human body. 
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1.5.2 The role of  catenin in Desmoid tumors  
 
Desmoid tumors are rare mesenchymal lesions with an annual incidence of five cases per 
million, <3% of soft tissue sarcomas and about 0.03% of all malignancies46.  Lacking metastatic 
capacity, DTs are very infiltrative and possess high local recurrence risks despite adequate 
surgical resection with negative margins47,48. Most sporadic DTs (85%) harbor specific 
mutations in the gene encoding for β-catenin located on the short arm of chromosome 3 
(CTNNB1)49; the remainder do not harbor any mutation in CTNNB1. 
Desmoid tumors may affect all sites, including the extremities, trunk, and abdomen50. The age 
of occurrence is between 15 and 60 years, but particularly during early adolescence, and with a 
peak age of about 30 years. Two different types of desmoid tumors are described: sporadic 
and FAP-associated. The first-line therapy for patients with locally circumscribed desmoid 
tumors remains surgical resection. However, “wait&see” approach might be an option for a 
subgroup of patients. The growth pattern of these tumors is deep infiltrating, and there is no 
tumor capsule. Because the boundaries of the tumors are difficult to distinguish 
intraoperatively from scars or connective tissue, complete resection is not always possible and 
adjuvant radiotherapy is therefore often applied following sarcoma protocols. Desmoids, 
however, have a high local relapse rate after surgery and/or radiotherapy and exhibit locally 
aggressive growth, but can often take a multiply relapsing, multifocal course and therefore are 
not amenable to curative surgical treatment. In this situation, pharmacotherapy is often used 
to prevent disease progression51. The primary aim is to preserve the patient's quality of life, 
which is threatened by the loss of function and pain caused by proliferative disease. 
Therapeutic approaches to the treatment of recurrent or nonresectable desmoid tumors 
comprise antihormonal therapy (e.g., tamoxifen), nonsteroidal anti-inflammatory drugs 
(NSAIDs, e.g. cyclooxygenase [COX]-2 inhibitors), and classic chemotherapy regimens, with 
highly variable results52. Since the difficulty in standardization therapy a multidisciplinary 
evaluation of patients is substantial, and treatment approaches may comprise surgical 
intervention and/or radiotherapy and antiproliferative treatment53.  
Molecular mechanism of Wnt/-catenin pathway 
The Wnt/-catenin pathway drives the pathogenesis of both sporadic and FAPassociated 
desmoid tumors. FAP-associated tumors frequently have adenomatous polyposis coli gene 
(APC) mutations. APC contributes to regulate the protein level of  -catenin54.  
Approximately 85% to 90% of sporadic desmoid tumors are associated with somatic mutations 
in the  -catenin gene.   
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In endothelial cells -catenin is not only a cell-adhesion molecule, but also plays a role in 
nuclear transcription. Accumulation of -catenin, by constitutive activation of the Wnt ligand 
pathway, loss of APC protein function, and inability to phosphorylate -catenin or mutations in 
the CTNNB1 gene, allows translocation of cytoplasmic -catenin into the nucleus and, in 
conjunction with other proteins, promotes abnormal proliferation (Figure 1.5).55 
Recognizing the central role of -catenin in desmoid tumors, evaluation of CTNNB1 could be 
used as a potential diagnostic test in tumors that are challenging to identify.56 In addition, 
targeting the Wnt/-catenin pathway may be a future therapeutic option of value. 
The -catenin destruction complex sits at the heart of the canonical Wnt signaling pathway, 
playing a critical role in keeping the levels of -catenin low in the absence of an exogenous 
Wnt signal.  
 
Figure 1.5 Wnt signaling pathway 
Destruction complex 
Initially, the destruction complex does not contain -catenin. As catenin is synthesized in 
the cytosol, it joins the destruction complex by binding at a site on Axin between GSK3 and 
CK1-binding site. APC binds -catenin in a C-terminal region of the armadillo repeats using one 
of its three 15 residues repeats. The binding of -catenin allocates the flexible N-terminus of -
catenin in the proximity of CK1, which phosphorylates -catenin at Ser45, priming it for GSK3 
phosphorylation. The flexible N-terminal tail then encounters GSK3, which adds phosphates in 
a C-terminal to N-terminal direction at, successively, Thr41, Ser37 and Ser33.57 
Phosphorilation of -catenin results in its ubiquitination and subsequent degradation through 
a proteasome-dependent pathway. If catenin phosphorylation or its subsequent ubiquitination 
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are blocked, catenin is thus diverted from the proteasome, accumulates, and enters the 
nucleus where it activates expression genes, leading to the formation of tumors.  
To better understand the main role in carcinogenesis processes of interaction complex -
catenin/gsk3, some details are presented below about the mechanism of phosphorylation in 
GSK3 (Figure 1.6). 
When GSK3 is in the active state, substrate that already has a priming phosphate binds to a 
specific pocket, aligning them in such a way that GSK3 can phosphorylate a serine or a 
threonine located four residues amino terminal to the priming phosphate. After agonist 
stimulation, GSK3 becomes phosphorylated at a serine residue near its amino terminus, which 
is serine 21 in GSK3. This transforms the amino terminus into a “pseudosubstrate” inhibitor, 
the phosphoserine occupying the same binding site as the priming phosphate of the substrate, 
and blocking access to the active site58.  
 
Figure 1.6 The molecular mechanism by which phosphorylation inhibits GSK358. 
 
3D structure of -catenin 
From the structural standpoint -catenin is composed by 781 residues and organized in several 
domains. The core domain is composed of 12 copies of a 42 amino acid sequence motif known 
as Armadillo repeats domain (Figure 1.7)59. The 12 repeats form a super helix of helices that 
feature a long, positively charged groove of the proteolyse resistant fragment. The N terminal 
part is about 150 aminoacids and contains the phosphorilation motif60 while the C-ter part has 
the main role on the binding of co-transcriptional factors. 
 
Figure 1.7 Structure of -catenin protein, highlighted the phosphorylation motif (in yellow) and the 
Armadillo repeats motif (in green). 61 
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1.5.3 Development of dendrimeric nanocarriers for gene therapy 
The application of nanotechnology for targeted drug delivery is widely expected to bring 
breakthrough and create novel therapeutics capable of changing the landscape for 
pharmaceutical and biotechnology industries.62,63 Particularly exciting are the recent efforts to 
apply nanotechnology to engineer nanovectors for RNA interference (RNAi) technology, giving 
birth to an entirely novel RNAi-therapeutics. 64 
RNAi makes use of small interfering RNA (siRNA) molecules, which are of 21-23 bp in length 
and break down the target mRNA in a sequence-specific manner. It is broadly, yet specifically, 
applicable to any target gene with known sequence. Compared with antisense 
oligonucleotides, siRNAs are more resistant to nuclease degradation, and show a more potent 
and prolonged therapeutic effect due to the catalytic mechanism. The promise that siRNA can 
efficiently and specifically down-regulate “undruggable” genes brings new hope to the 
incurable diseases or the diseases which are difficult to cure due to drug resistance and/or the 
absence of efficacious drug candidates, creating a new era of pharmaceutical science which 
have the potential to revolutionize medicine.  
Nevertheless, the clinical applications of siRNA-based therapeutics are hampered by a number 
of undesirable physiochemical and biopharmaceutical characteristics, including enzymatic 
lability, lack of tissue specificity, poor cellular uptake, ecc.65 
A breakthrough of RNAi technology in therapeutic application requires, however, safe and 
easy-to-handle siRNA delivery systems, which can protect siRNA during the extra- and intra-
cellular delivery and bring siRNA to the site of interest. Both viral and nonviral delivery systems 
have been explored for siRNA delivery. Viral delivery is very effective, but the disadvantages 
are safety concerns and high cost. Lipids and polymers are the most common non-viral vectors 
which based on nanotechnology for delivery. They are able to assemble siRNA into 
nanoparticles, which can further protect siRNA from degradation and promote cell uptake. 
After internalization, siRNA will be dissociated from the vector complexes and undergo RNAi 
mechanism to silence the targeted gene.  
Dendrimers are one of the main promising groups of nanovectors for siRNA delivery. The word 
“dendrimer” originated from two words, the Greek word dendron, meaning tree, and meros, 
meaning part. 
Dendrimers are a class of well-defined nanostructured macromolecules that possess narrow 
mass or size polidispersivity and tree-like architecture distinguished by exponential numbers of 
discrete dendritic branches radiating out from a common core. These unique structural 
attributes confer a spherical shape to dendrimers after several layers of branching owing to 
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surface congestion. The precise nanoscale sizes, shapes, surface chemistries and architectures 
of these dendritic macromolecules distinguish these materials as model systems  for 
understanding a wide range of crucial nano-medical issues, including polyvalent 
nanopharmaceuticals, DNA or siRNA delivery vectors, nanodiagnostics, MRI contrast agents 
and drug delivery. 66 
Dendrimers are built from a starting atom, such as nitrogen, to which carbon and other 
elements are added by a repeating series of chemical reactions that produce a spherical 
branching structure. As the process repeats, successive layers are added, and the sphere can 
be expanded to the size required by the investigator. The result is a spherical macromolecular 
structure whose size is similar to albumin and hemoglobin, but smaller than such multimers as 
the IgM antibody complex (Figure 1.8). 
The generation number of dendrimers could be defined as the number of focal points when 
going from the core towards the dendrimer surface; for instance a dendrimer having five focal 
points when going from the centre to the periphery is denoted as the 5th generation 
dendrimer, usually abbreviated to simply a G5-dendrimer. The core part of the dendrimer is 
sometimes denoted generation “zero”, in fact the core structure thus presents no focal points, 
as hydrogen substituents are not considered focal points. Intermediates during the dendrimer 
synthesis are sometimes denoted half-generations, a well-known example is the carboxylic 
acid-terminated PAMAM dendrimers. 
 
Figure 1.8 Basic structure of dendrimer: core, interior and surface. Example of generation from G0 to G5.    
 
Usually, the functionalization of dendrimer was successfully obtained using Michael addition 
and other synthetic methodologies such as Williamson reaction, ester coupling, cross-
methathesis. Unfortunately, all of these reactions showed some problem. Nevertheless, the 
discovery, in 2001, by Sharpless and coworkers, of “click chemistry” has overcome a lot of 
limitations. The catchy term “click” refers to energetically favored, specific, and versatile 
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chemical transformations, which lead to a single reaction product. This kind of reactions 
showed high yields, tolerance toward functional groups and virtually no side-reactions.67   
Up to now, few efforts have been made for targeted siRNA delivery using dendrimers as 
nanovectors. One of the key issues is to critically balance the targeting ability with the delivery 
efficiency in order to achieve both efficient and targeted delivery. In this project, we would like 
to explore dendrimer conjugates for targeted delivery of siRNA, which is expected to further 
enhance the efficacy and safety profile, in the view to move the academic research to 
applications in nanomedicine.  
The procedure for finding the correct vectors in preclinical stages is time, resource and cost 
intensive. Thus, the combination of computer-based molecular modeling and parallel 
assessment of biochemical and biological properties by experimental methods can open new 
avenues in this field of scientific research by providing powerful tools for rationale design and 
optimization of dendrimer-based nanovectors for RNAi therapeutics targeting different cancer 
type. 
 
Application in cancer treatment 
The field of oncology could soon be revolutionized by accurate strategies to identify and cure 
by dendrimer-based nanotherapeutics. Of course, the best anticancer drug will target only 
cancerous cells by individuating some parameters.  
It is now possible to design specific dendrimers that can not only identify specific target on 
cancer cells but also deliver one or more therapeutic agents without collateral damage to the 
neighboring healthy cells; for achieving this objective a “Trojan horse” strategy could be 
employed.  
In gene therapy the dendrimers seem to offer many advantages over viruses as vehicles of 
genes. They may be much less toxic and they may offer advantages in term of cost. For 
example they could be used, in couple with specific siRNA, in the treatment of prostate cancer.   
In Europe and the United States, prostate cancer is the most common solid neoplasm and the 
second leading cause of deaths due to cancer in men. The use of prostate-specific antigen 
(PSA) as a prostate cancer screening tool has led to a downstaging and downgrading of the 
disease at the time of diagnosis and a reduction in prostate cancer mortality. However now 
different targets have been identified and silencing through specific siRNA could be a novel 
strategy for therapeutic in this cancer. For example in the case of prostate cancer some 
proteins (e.g. Hsp27, TCTP) that seem to play a major role in the development are now under 
studies68 and the gene silencing by dendrimer-siRNA approach used as innovative approach.   
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1.6 Study of mutations in cancer development and their 
interaction with drugs 
The limits of cancer therapies are the development of drug resistance. For instance, recent 
analysis based on patterns of DNA mutations and RNA expression in 2000 specimens, revealed 
10 different molecular types of breast cancer. In addition, cancer is characterized by extensive 
genetic and epigenetic alterations and mutations in drug targets, causing structural changes, 
may also be responsible for increased drug resistance. In this context, the data discussed 
regards in particular mutations involved c-Kit receptor in GISTs and SMO receptor in BCC. 
 
1.6.1 Gastrointestinal Stromal Tumors (GISTs) and the c-KIT 
receptor role 
Gastrointestinal stromal tumour (GIST) is the most common sarcoma of the intestinal tract, 
known to be notoriously refractory to conventional chemotherapy or radiation.  
Constitutive activation of the KIT receptor tyrosine kinase is a central pathogenetic event in 
most GISTs and generally results from oncogenic point mutations which can involve either 
extracellular or cytoplasmic domains of the receptor. Oncogenic mutations enable the KIT 
receptor to phosphorylate various substrate proteins, leading to activation of signal 
transduction cascades which regulate cell proliferation, apoptosis, chemotaxis, and adhesion. 
KIT mutations can be broadly assigned to 2 groups, those that involve the “regulatory” regions 
responsible for modulating KIT enzymatic activity and those that involve the enzymatic region 
itself. 
KIT is a member of the type III transmembrane receptor tyrosine kinase (RTK) family, which 
comprise five extracellular immunoglobulin domains, a single transmembrane region, an 
inhibitory cytoplasmic juxtamembrane domain and a split cytoplasmic kinase domain 
separated by a kinase insert segment69. Under physiological conditions, binding of the KIT 
ligand, stem cell factor (SCF), to the extracellular domain of the receptor results in receptor 
dimerization, activation of the intracellular tyrosine kinase domain through 
autophosphorylation of specific tyrosine residues, and receptor activation70. The downstream 
signal transduction pathways include the mitogen-activated protein kinase (MAPK), 
phosphatidylinositol 3-kinase (PI3K) and Janus kinase/signal transducers and activators of 
transcription (JAK/STAT) pathways. The intracellular signalling through KIT plays a critical role 
in the development of several mammalian cell types. 
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In the active kinases, a characteristic DFG-motif or catalytic triad (D810, F811, G812), which is 
located immediately before the A-loop, adopts a conformation whereby the aspartic acid and 
phenylalanine are oriented toward the binding site (DFG-in). Different inactive states have 
been identified; one of these states is called DFG-out. In the presence of an activating 
mutation, the equilibrium between the DFG-in and DFG-out forms is shifted toward the active 
open (DFG-in) conformation of the receptor. This change allows enhanced binding of ATP and, 
hence, increased level of phosphorylation of the tyrosine kinase domain.71    
The best characterized KIT regulatory region is the intracellular juxtamembrane (JXM) domain, 
encoded by exon 11. Contrarily to previous structural hypotheses, it has recently been shown 
that the JXM region of the c-Kit forms a compact hairpin loop that inserts directly into the 
domain interface between the kinase N- and C- lobes. Approximately 20 amino terminal 
residues of the JXM domain - from Y547 to G565 – comprise the inner buried half of this 
hairpin loop and form specific interactions that disrupt the conformation of the kinase DFG 
motif and A-loop. 
It is well known that this β hairpin loop acts as an autoinhibitory domain: when the receptor is 
in the active conformation, the β hairpin loop has a peculiar shape and the DFG motif keeps 
the A loop in the closed conformation blocking the ATP to enter in this pocket.  
To date, several types of mutations have been described and the main mutational “hot spot” is 
represented by c-Kit exon.     
Regulatory-type mutations found in the c-Kit JXM region are associated with human 
gastrointestinal stromal tumors and include base substitutions and/or deletions in residues 
550-560.72  
A key feature of all these JXM region regulatory-type mutations is that the KIT oncoproteins 
have essentially the same active enzymatic site as that in native KIT. Therefore, kinase 
inhibitors such as Imatinib-mesylate (Gliveec, Novartis, Basel) are also effective inhibitors of 
these constitutively activated molecules.  
 
Imatinib as first choice therapy  
GIST patients harbor different oncogenic mutations in KIT and PDGFRA, which have distinct 
responses to imatinib. Imatinib mesylate (Gleevec) is a selective tyrosine kinase inhibitor 
whose targets include ABL, BCR-ABL, KIT and PDGFR (Figure 1.9). Imatinib is a2-phenyl-amino-
pyrimidine derivative, which specifically binds to the inactive conformation of the ABL kinase 
or the inactive form of KIT. Imatinib was first applied in 1998 to refractory chronic myeloid 
leukaemia (CML) and subsequently to advanced GIST patients in 200073 74.  
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Imatinib achieves partial responses or stable disease in nearly 80% of GIST patients, and 
remarkably the 2-year survival in advanced GIST is now 75–80%. The long-term outcome of 
imatinib treatment for metastatic GIST has emerged from several large trials. Approximately 
45% of patients with metastatic GIST have a measurable response after administration of 
imatinib, while about 30% will have at least stable disease. 
However, responses to imatinib depend on the functional domain affected [46]. Patients with 
KIT exon 11 mutations have a partial response rate of 84% compared with a 0% partial 
response rate among patients without KIT mutations75. By analogy with other receptor 
tyrosine kinases, the juxtamembrane domain may function as a negative regulator of the KIT 
kinase and disruption of the conformational integrity of this domain may impair its negative 
regulatory function. Deletion of Y567 and V568 in the normal KIT gene have been shown to 
enhance agonist induced KIT signaling by altering the specificity of docking sites for 
cytoplasmic signaling molecules in the activated KIT receptor. By contrast, mutations in exon 9 
of KIT, which encodes the fifth extracellular immunoglobulin-like loop, are less responsive, 
although this limitation can be partially overcome by a high-dose regimen (400 mg twice daily). 
Activating oncogenic mutations within the ectodomain of KIT map to the D5–D5 interface, 
which presumably stabilizes receptor dimers and thus activates the kinase in the absence of 
ligand. In spite of an activated KIT pathway, the imatinib response in GIST patients with a wild-
type genotype for KIT/PDGFRA/BRAF has been disappointing. Furthermore, tumours with 
activation loop mutations in particular show the least response to imatinib inhibition. 
Tyrosine kinase inhibitors (TKI) therapy is standard of care for patients with 
metastatic/advanced GIST and, although the optimal duration of treatment is not known, it is 
recommended to continue therapy indefinitely or as long as they are experiencing a clinical 
benefit. Imatinib interruption in patients with advanced GIST controlled with the drug is often 
associated with a high risk of disease progression within 1 year. In most patients, however, the 
disease is controlled with imatinib re-challenge, with no statistically significant differences in 
imatinib-refractory progression-free survival between interruption and continuation 76. 
No apparent difference was seen in sunitinib activity between the intermittent and continuous 
daily dosing schedules. 
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Figure 1.9 Chemical structure of Imatinib (Gleevec). 
1.6.2 Basal cell carcinoma and the activation of Hedgehog 
pathway 
Basal cell carcinoma (BCC) is the most frequent cutaneous cancer accounting for 
approximately, 70% of all malignant diseases of the skin. The incidence has increased 
dramatically over the years, and the number of women under 40 years diagnosed with BCC has 
more than doubled in the last 30 years.77 
The incidence of BCC is strongly associated with exposure to UV radiation; tumors develop 
primarily on the sun-exposed skin of elderly individuals with fair skin phototypes, are rarely 
found on palmoplantar surfaces or in children, and never appear on the mucosa. Additional 
established risk factors include ionizing radiation (IR), arsenic, and immune suppression78. 
However, a variety of hereditary syndromes can result in an increased risk of developing BCC 
tumors, including nevoid BCC syndrome, Bazex–Dupré–Christol syndrome, Rombo syndrome, 
Oley syndrome, and xeroderma pigmentosum. 
Treatment for BCC mainly consists in local approaches, with surgery (including different 
techniques) as the most effective strategy, followed by radiotherapy, photodynamic therapy, 
imiquimod as alternative treatments79,80. Radiation therapy is employed in case of surgical 
residual not amenable to resection or in patients not surgical candidates, if feasible. 
However, the occurrence of locally aggressive and invasive tumors, a bare prognosis upon 
metastatic spread, and a significant rate of recurrence often associated with increased 
aggressiveness, as well as the multitude of tumors appearing in high-risk populations such as 
BCNS patients, provide strong reasons to search for new preventive and therapeutic strategies.  
The Hedgehog pathway plays a critical role in embryonic development and is not active in 
most adult tissues, with the exception of stem cells, hair follicles, and skin cells in which the 
pathway is important for cell maintenance.81 Hedgehog pathway signaling starts with the 
Hedgehog (Hh) ligand binding to a 12-pass transmembrane receptor known as PTCH (Figure 
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1.10). In 1993, three mammalian homologs of the Hh ligand were described, including Sonic 
Hedgehog, and also Indian Hedgehog and Desert Hedgehog. The “Hedgehog” name was coined 
based on the description of Drosophila melanogaster  larvae, which took on the appearance of 
the spiky hedgehog when the gene was mutated.82 
In the absence of the Hh ligand, the PTCH receptor acts as a tumor suppressor by inhibiting the 
next protein in the pathway known as Smoothened (SMO), which is a G-protein-coupled 
receptor. When the Hh ligand binds to PTCH, the inhibitory effects on SMO are released 
allowing the signal to propagate83. Although the mechanisms following SMO inhibition release 
have not been completely elucidated, SMO activation ultimately results in the release of 
inhibition of glioma-associated protein (Gli) through the suppressor of fused molecule (Sufu). 
The Gli family of proteins (Gli-1–3) are zinc finger transcription factors that are capable of 
activating a number of target genes, which can result in an oncogenic effect on the cell. Among 
the genes that are upregulated through Gli transcriptional activation are PTCH1 (provides 
negative feedback of pathway), Gli-1 (positive pathway feedback), and other gene pathways 
that aid in the survival of the cell, such as angiogenesis, cell cycle regulation, and antiapoptosis 
pathways. The Hedgehog pathway also conducts significant crosstalk with other molecules and 
pathways including p53, Wnt, PI3 K/aKT/mTOR, and retinoic acid. These interactions create a 
complex network, which may promote a variety of resistance mechanisms for drug targeting of 
this pathway. A variety of diseases have been linked to abnormal Hedgehog pathway signaling 
besides BCC, including medulloblastoma, hematologic malignancies, and other solid tumors. 
In particular, the inappropriate activation of Hh pathway is involved in the pathogenesis of 
BCC: loss of function of the transmembrane receptor Patched (PTCH1), or gain of function of 
the Smoothened (SMO), Sonic Hh (SHH), and GLI family transcription factors can be ligand-
independent oncogenic drivers of this disease84. 
 
  
Figure 1.10 Hedgehog signaling pathway inhibition, arranged
85
. 
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New therapeutics  
The first evidence that the Hh signaling pathway is sensitive to inhibition by small molecules 
stemmed from the observation of cyclopia in lambs, induced by the maternal ingestion of corn 
lilies (Veratrum californicum). 
Cyclopamine was, then, isolated from the Veratrum californicum plant. This discovery has led 
to a variety of more potent and selective SMO antagonists, which have been developed and 
incorporated into clinical research for a variety of cancer types, including patients with 
advanced BCC. 
New derivatives of cyclopamine with improved pharmaceutical properties are now in clinical 
trials. Excellent results were obtained with the orally administered SMO inhibitor GDC-0449 
(vismodegib) in a phase I trial of patients with locally advanced or metastatic BCC86,87. 
Vismodegib is a first-in-class, orally bioavailable inhibitor of SMO (Figure 1.11). Based on the 
efficacy and tolerability results of recent clinical studies, vismodegib (150 mg once daily) 
received US Food and Drug Administration (FDA) approval on January 2012 for the treatment 
of adults with BCC that has recurred following surgery or patients unsuitable for surgery or 
radiation. It represents a breakthrough in the management of advanced BCC, especially, for 
patients ‘with high surgical morbidity and inoperable tumors. The median duration of 
treatment in trials has been 10.2 months and is continued until disease progression or 
unacceptable toxicity. 
 
Figure 1.11 Chemical structure of GDC-0449 (Vismodegib) 
 
Case of primary resistance in medulloblastoma 
Although treatment of BCC with vismodegib and similar agents has resulted in dramatic 
responses, resistance to SMO inhibition occurs resulting in new tumor development or growth 
of previously responding tumors. A recent analysis into the mechanism of resistance to 
vismodegib has recently shed light into the complex nature of this process. In a patient with 
medulloblastoma with a known PTCH mutation, the initial response to vismodegib was seen 
with subsequent progression of disease88. Comparison of before treatment tumor samples and 
samples obtained from a vismodegib-resistant tumor demonstrated a novel finding. The pre-
existing PTCH mutation found in the pre-treatment tumor was still present in the resistant 
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tumor; however, a new mutation in SMO (D473) was seen. Similar to alterations in BCR–ABL, 
which confer resistance of CML cells to imatinib, this SMO-D473 mutation was found to confer 
resistance to vismodegib. Further evaluation implicated that this particular mutation affected 
vismodegib binding to Smo. 
 
1.7 Molecular simulation in cancer therapy  
The complexity of cancer and the vast amount of experimental data available have made 
computer-aided approaches necessary.  
Many details on a given protein’s functions and how it is altered by different mutations, 
become clear once the protein ‘structure is known. Proteins, however, are not static and it is 
their dynamic landscape that determines their roles. Computer-aided studies can complement 
molecular studies and yield details that are not available to the experiment. Molecular 
modeling approaches therefore become increasingly useful in many clinically-oriented studies.  
Today, “molecular modeling” refers to the application of computer-generated models in 
molecular studies ranging from a few atoms to multitude of biomolecules. These models are 
used to simulate processes that may be as fast as 10-5 s or as slow as a few seconds. Clearly, 
the accuracy and level of detail depend on the size and timescale of the system. In general the 
more accurate the method at hand, the more time and computational resources will be 
needed to get a meaningful result. The choice of the modeling method is therefore made 
based upon the problem at hand.89 
A fast and noninvasive global approach based on an in silico analysis represents a useful tool 
that, coupled with traditional biochemical molecular evidence, may help to overcome the 
problem of resistance in cancer treatment.  
In silico analysis, which uses the three-dimensional structure of the target protein, has multiple 
uses. The method can predict structural changes introduced by mutations, measure the 
strength of the interactions between the protein model and the drug, determine whether the 
drug can be effective or not by calculating the binding affinity, and evaluate to what extent 
decreasing efficacy could still be counteracted by increasing the drug dose or by using a 
different compound.  
The individuation of new target, that unfortunately could not biologically evaluated cause of 
lack of structural information, could be helped by the application of new techniques that 
exploiting homology modeling and advanced simulation assay give details for further strategies 
in order to inhibit the process of cancer development.  
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1.8 Future perspectives 
The Darwinian selection of mutated variants of target proteins could be harnessed with the 
intelligent design of drugs directed against the single new variants. This innovative multi-drug 
targeted prevention, which can potentially change the natural history of a disease, has been 
proposed in the setting of chronic myeloid leukemia.  
By predicting the mutations, and classifying them according to their degree of probability, it 
could be possible to administer a drug as soon as patients display such mutations, so that 
disease recurrence can be prevented, rather than waiting for the mutation to emerge to select 
the right compound. 
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Materials & Methods 
 
In recent years, the use of computer simulations as a tool for bridging between microscopic 
length and time scales and the macroscopic world of the laboratory has been increasing 
exponentially. This success is attributed, by using computational chemistry and physics, to the 
guess for the interactions between molecules can be provided, and `exact' predictions of bulk 
properties can be obtained. The predictions are `exact' in the sense that they can be made as 
accurate as we like, subject to the limitations imposed by the available computer budget. 
The actual computational modeling of biological macromolecules, mainly based on molecular 
dynamics (MD) simulations, commonly revolves around structure representations in atomic or 
near-atomic detail, with a classical description of physical interactions. In a typical MD 
simulation, the atomic trajectories of a system of N (e.g., 223) particles are generated by 
numerical integration of Newton’s equation of motion, for a specific interatomic potential, 
with certain initial and boundary conditions. Such models have been quite successful in 
complementing experimental data with structural, dynamic, and energetic information, but 
involve substantial computational resources for larger systems, or when long time scales have 
to be considered.  
 
2.1 The atomistic scale of simulation 
 
The molecular mechanic (MM) is the branch of the molecular simulation that studies the 
equilibrium conditions of a certain molecular system. The goal is the determination of the 
reliable configuration that a certain molecule assumes in given conditions (equilibrium in 
physiological condition). The instrument used to reach this result is the minimization of the 
total energy of the molecular system. It is worth noting that all the measured energetic and 
structural quantities are statistic and thus the result is a statistical equilibrium. 
There are some minimum information that are necessary to characterize the whole systems 
and analyze the equilibrium conditions: i) the position of atoms that compose the molecule in 
space; ii) the description of how these atoms are bonded together and how “they feel” each 
other. 
For an accurate description of the energetic of a system, it is necessary to determine all the 
forces that are applied on the atoms that constitute the molecule (Figure 2.1). Thus, the 
determination of the total energy of the system is determined as the sum of all the forces that 
are acting on each atom of the system itself. 
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Figure 2.1 Schematic representation of energies. 
Fundamentally, proteins derive their properties from the interaction between their constituent 
atoms. These basic interactions make the atoms assemble in a particular structure. The same 
interactions also define how the atoms prefer to arrange themselves on the surface or around 
a vacancy. Therefore, to understand the behavior of a protein, it is necessary and sufficient to 
study the collective behavior of atoms that constitutes the complex. This handout discusses 
the basic features of the interactions between atoms and different models that describes 
them. 
When put close together, atoms interact by exerting forces on each other. Depending on the 
atomic species, some interatomic interactions are relatively easy to describe, while others can 
be very complicated. This variability stems from the quantum mechanical motion and 
interaction of electrons. Henceforth, rigorous treatment of interatomic interactions should be 
based on a solution of the Schrodinger’s equation for interacting electrons, which is usually 
referred to as the first principles or ab initio theory.  
The atomistic scale of molecular simulation has a pure classical expression and no quantum 
term is taken into account, since the electrons of each atom are not explicitly considered. To 
represent the atoms that constitute a certain molecule it could be useful to think as balls, 
identified by coordinates and connected each other to obtain a certain geometry. While the 
starting position is described as cartesian x,y,z coordinates in a configuration file, the 
connection between atoms is a rather more complex issue. The starting point is that molecules 
follow classical laws in MM and MD, the atoms are simply connected by springs with a certain 
force constant. These constants depend on the atoms coupled and on the bond type they are 
able to form.  
 
The force field could be used to represent these interactions. The definition of force field by 
Otto Ermer said “the analytical expression that describes the potential energy of the studied 
molecular complex and all the parameters needed to describe”. The force field is a file that 
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contains a data bank of bond and non-bond parameters for different atoms. There are 
different force fields dedicated to different branches of applications of molecular modeling, 
e.g. life science. When some parameters are missing in the force filed – i.e. when not all the 
atoms in the system are present in the force field, like a Fluorine atom in a life science 
dedicated force filed, the software is not able to recognize what this atom is and how it is 
supposed to bond to each other. The missing parameters could be derived by experimental 
results or, if it is not possible, by ab initio techniques.  
Therefore, when the system can describe completely, the reaching of the equilibrium is 
described by equation. 
     
   
   
 
where the potential energy Epot is function of the coordinates ri of the atoms of the system. 
Even if molecular mechanic is useful to reduce bad energetic configurations that typically occur 
in the early steps of the simulation, it is considered nothing more than a preliminary step for 
complex systems, since it does not take care of the temperature, that in MD appears only in 
the kinetic energy term and, thus, where the time evolution is considered. 
Ekin=
 
 
         
Molecular dynamic (MD) is simply an iteration in time of molecular mechanic – at each time 
step of the simulation the system moves toward the equilibrium. The concept of this technique 
is conceptually rather simple: given a starting configuration for the molecular system of 
interest, corresponding to the position of atoms, the forces that are acting on each atom are 
calculated, and thus trajectories can be computed as the evolution at each time step of the 
system toward the equilibrium. Differently form the MM, in MD an initial set of random 
velocities are calculated from temperature– a starting condition that is defined by 
temperature. This creates atomic movements – the system moves to reach the equilibrium – 
and new positions and velocities for all the atom of the system are calculated at each dynamic 
step. Obviously, the system fluctuates toward the equilibrium maintaining the total energy 
(Etot) constant. 
Etot= Epot + Ec = constant 
It means that, if the new velocities are too low or too high to maintain the constancy, at each 
step they are rescaled in order to be consistent with the temperature of the system and with 
the Etot with the so-called thermostats and velocity scaling algorithms. 
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As starting point we could consider the Schrӧdinger equation, that could describe, the motion 
of molecules, time indipendent: 
                                                                                 HΨ(R,r)=EΨ(R,r)                                                                         
Where: 
- H  is the Hamiltonian operator 
- Ψ is the wave function depending on r (electronic coordinates) and R (nuclear coordinates) 
- E  is the energy of the state 
 
During MD the electrons are not taken in account in the calculation. Thus, the Schrödinger 
equation assumes the following form, according to the Born-Oppenheimer approximation that 
allows the wave function of a molecule to be broken into its electronic and nuclear 
components. 
This equation loses the explicit description of electrons - the system becomes dependent only 
on the nucleus position and velocity of each atom. All the quantum effects are lost, and can be 
expressed in classical form as follows: 
- 
         
  
 =m 
   
   
 
In fact, to solve a MD problem, means to solve across time an equation like: 
ai(t) = 
     
  
 
It is thus necessary to calculate the force F(t), dependent on the position of each atom in 
space, from the potential V(R). This will be done for all the atoms that constitute the system: 
 Fi= -   Vi (R1,……...,Rn)  
The potential V(R) is, as said, defined by the force field. Once F(t) is calculated – and thus the 
acceleration a(t) is known – by integration it is possible to calculate the new coordinates for all 
the atoms of the system with the so-called Verlet algorithm that is represented by the 
following equations: 
Ri (t + t) = Ri(t) + vi(t)t + 
 
 
 ai(t)t
2 
Ri (t - t) = Ri(t) - vi(t)t + 
 
 
 ai(t)t
2 
 
that can be summed to give: 
Ri (t + t) = 2 Ri(t) - Ri (t - t) + ai(t)t
2 
 
With this algorithm it is possible to compute the new positions of each atom of the system and 
thus to calculate the new potential energy, as sum of the potential energetic contribution 
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given by each atom, Epot. Moreover, it is possible to calculate the new velocities of all the 
atoms: 
vi(t) = 
[                   ]
   
 
in order to calculate the new values of the kinetic energy as: 
Ekin, i = 
 
 
 mi [      
 ] 
and the constancy of the total energy can be expressed as in described equation. This 
procedure is iteratively repeated at each time step for the whole length of molecular dynamic 
simulation. 
 
2.2 Force field and software  
Many of the problems that involve the definition of a system in molecular modeling are linked 
to the parameterization.   
The application of force field methods that could calculate the energy of a system taking into 
account only the nuclear position is a possible solution. 
The reliability of the model depends on the choice and usage of the proper force field, 
dedicated to the simulation of a certain class of molecules. For instance, a force field that is 
dedicated to general material science could give completely wrong results for proteins 
simulations, or in most cases could be unable even to start the calculation. 
Transferability is an indispensable property to choose a force field, indeed it allows to use a set 
of parameters tested on a small number of cases and apply it in very different situations. 
The studies presented in this work were all carried out exploiting AMBER (version 11)1 is a set 
of molecular mechanics force fields for molecular dynamics of biomolecules originally 
developed by the Peter Kollman's group at the University of California (San Francisco) and, at 
the same time, refers to a simulation package that implements these force fields. 
The form of the AMBER force field is: 
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It represents the harmonic force (ideal spring) linked to the energy between covalently bonded 
atoms. This is a good approximation near the equilibrium bond length, but becomes 
increasingly poor as atoms separate. Kb is a constant that determined the strength of the kind 
of atoms involved in the bond;  
∑         
 
      
 
It Is associated to the variations in the angle term   respect to the ideal value   . It  represents 
the energy due to the geometry of electron orbitals involved in covalent bonding; 
∑
 
 
  [           ]
        
 
The third term is the potential function associated with the torsional angles. It represents the 
energy for twisting a bond depending on bond order (e.g. double bonds) and neighboring 
bonds or lone pairs of electrons; 
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The last term involves the non-bonded energy between all atom pairs as decomposed by van 
der Waals (first term) and electrostatic (second term of summation) energies. 
 
All the constant (kb, ka, etc.) express in the main equation are unknown. In order to use the 
AMBER force field, it is necessary to have values for the parameters of the force field (e.g. 
force constants, equilibrium bond lengths and angles, charges). The AMBER software contains 
a fairly large number of these parameter sets. Each parameter set has a name, and provides 
parameters dedicated to certain types of molecules. 
 “ff” followed by the year of creation (i.e. 95): peptide, protein and nucleic acid 
parameters. 
 GAFF (Generalized AMBER force field): parameters for small organic molecules to 
facilitate simulations of drugs and small molecule ligands in complex with 
biomolecules (e.g. protein). 
 GLYCAM: parameters for simulating carbohydrates. 
In all the calculations presented in this thesis, the ff032 was used, being the most widely used 
in the study of proteins. All the amino acids forming proteins are parameterized with the 
constant values present in ff03. 
However, ff03 provides a very exhaustive description of proteins and nucleic acids, but 
parameters for molecules different for the conventional organic ones are missing. GAFF is 
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completely compatible with AMBER ff, for this region is used to integrate missing parameters. 
The full list of modules present in the AMBER package are the following: 
 leap is the tool that is used for preparing files necessary to start the 
simulation.antechamber calculates the missing parameters for small organic molecules 
using GAFF forcefield3. 
 sander (Simulated Annealing with NMR-Derived Energy Restraints) is the central 
simulation program and provides facilities for energy minimization and molecular 
dynamics with a wide variety of options. 
 Pmemd (Particle mesh Ewald molecular dynamics) is a new version of Sander by Bob 
Duke. It is optimized to improve the performance of the simulations. 
 Nmode (Normal Mode analysis) calculates the entropy of the system. 
 ptraj is an analysis program for simulation results. AMBER does not include 
visualization capabilities. 
In these studies the most used visualization tools was UCSF Chimera, that is a program to 
visualize and analyze molecular structures and their data deriving from Molecular Dynamics 
simulation. It is possible to analyze trajectories, sequence alignments, docking results, 
conformational changes and obtain images. 
By using ab initio (or semiempirical) techniques, we can calculate parameters for small 
molecules that are not originally present in the force field (i.e. small drug molecules). In all the 
studies described in this thesis, a semiempirical Austin model (AM1) calculation method with 
the antechamber module within AMBER 11 was use for missing GAFF parameters. 
 Antechamber is used during MM studies to recognize atom type, bond type, generate 
residue topology file and find missing force field parameters and supplying reasonable 
and similar substitute. 
 This Austin model is implemented with BCC method (ab initio term bond) that is one of the 
more precise charge calculation method  and can guarantee results with precision comparable 
to the one of pure quantum-mechanic calculations reducing the computational time. 
 
 
 
 
 
 
 
Figure 2.2 Steps of the molecular simulation process. 
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2.3 Creation of the “wild type” complexes 
The molecular simulation allowed us to explore different properties for the system analyzed, 
however to start a simulation first of all we need to proceed building the system of interest. 
In this work we evaluated different kind of systems: protein structure, protein/drug complex 
and protein/protein complex. In addition, some of those were studied in different 
conformational states, starting from wild type (WT) to the mutated complex. 
Here we present the procedure that was followed for the creation of the WT molecular 
complexes, subject of the simulation studies. 
It is worth noting that, since we want to simulate a system as close as possible to the reality, it 
is fundamental to mimic its real conditions. In these studies, the main characters are proteins 
and drugs that are naturally inserted in physiological condition of the human body. 
To obtain an accurate simulation we will evaluate the complex in the correct salt concentration 
corresponding to the human ionic strength (NaCl 150 mM) and surrounded by a water 
environment.  
The starting point is the building of the initial file with coordinates information. 
As default topology files, AMBER 11 is able to read a series of different formats (.pdb, .xyz, 
etc.). Typically, for protein structure, the format that is most widely used is the .pdb file. The 
extension .pdb  means Protein Data Bank.  
This database (http://www.rcsb.org/pdb/home/home.do) is a free online tool containing the 
.pdb files for X-ray/NMR studied protein and organic structures. The file .pdb is a simple 
coordinates file and contains the atom numbers and names, the name of the residues to 
whom these atoms belong and the coordinates of each atom within the structure. In our case 
the residues belonging to the class of aminoacids since the systems studied involve protein 
(Figure 2.3). 
The first column refers to ATOM meaning known residue. There could be atoms within the 
structure with the statement HETATM also – this is used to identify which atoms belong to a 
residue that common force fields are able to recognize or not. 
Typically, HETATM is used to identify a small inhibitor drug inside the .pdb file, that is not 
included in any force field and require a separate parameterization (Figure 2.4). 
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Figure 2.3  Example of a .pdb file. Columns represent (starting from the second left colum)  the atom 
number, name, the residue and chain of belonging. The first three floating point numbers are x, y and z 
coordinates of each atom expressed in angstroms (Å). The next three columns are the occupancy, 
temperature factor, and the element name, respectively. 
 
 
Figure 2.4 Coordinates .pdb file for the imatinib drug (residue name: STI). The meaning of other columns 
is the same as above. 
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As it appears evident, .pdb files do not include the Hydrogen atoms. In fact, AMBER software, 
automatically, adds H atoms once the .pdb file is loaded. 
In this thesis work, different proteins and drugs were studied corresponding to a wide set of 
.pdb files. 
Below we will proceed with a general procedure that could be used in all the cases studied; the 
single exception of protein complexes will be further described in their relative case study. 
Conceptually, to run a simulation it is necessary to obtain from the coordinate .pdb file two 
different files, whose extensions are .prmtop and .inpcrd. From a .pdb file, in fact, we can 
obtain only the positions of atoms and their name while no information about how they are 
connected and how they feel each other are present. The software reads the .pdb file and 
interprets it depending on the force field that was chosen for the correct system description. 
Thus, .prmtop and .inpcrd files are coupled and descript plenty the molecular system.  
 inpcrd: coordinates file, the position of atoms that compose the molecule in space. 
 .prmtop: parameters file, the values of the constants taken from the force field that 
was chosen for calculations (bond constants, torsions, atomic partial charges, etc.). 
In the case of a protein/drug complex, a preliminary step was required before to import the 
.pdb complex inside the AMBER11 suite of programs and to obtain the respective .prmtop and 
.inpcrd files. This consists with the creation of missing parameters for the drug (imatinib, 
vismodegib, etc.). While importing the .pdb complex file, about these small molecules 
AMBER11 recognises only positions, but no information about the bond and non-bond 
constants are present. In fact, in importing a .pdb for both protein and drug molecules, it is 
obvious to obtain an error due to the impossibility to recognize the drug by the leap module – 
the module dedicated to the creation of complexes. 
In order to obtain the missing parameters for drug molecules, it is necessary to resort to 
calculation methods that are able to obtain all the parameters for a molecule from its 
coordinates only.  
There are the quantum calculations methods (ab initio) that, taking into account in the 
calculation the electrons, are able to give these parameters but these calculation methods are 
based on the explicit solving of the Schrödinger equation and are extremely heavy from the 
point of view of computational time.  
The antechamber module of AMBER 11 allows different methodology for calculation of missing 
parameters (HF, semiempirical methods) and it presents a different request of CPU time for 
the resolution. In the studies presented in this thesis we used, as said, the AM1-BCC 
calculation method, able to produce for such small molecules data of similar precision of the 
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most advanced quantum mechanics methods with a notable reduction in the computational 
time. 
The antechamber module accept as input file the .pdb file of the molecule analyzed  and 
generates for this an input file .prepin. The .prepin file lists all the calculated parameters, 
readable by GAFF, for the drug. In the case antechamber fails to complete the calculations for 
all the constants, the parmchk utility available in AMBER 11 substitutes the missing bond and 
angle values with the one that it find to be more “similar” in the data base of the selected 
force field. In the case of the small molecules the .pdb file needs to contain the Hydrogen 
atoms. 
Ones this step is accomplished, it is possible to load into leap the .pdb file of the whole 
complexes. As said, the “.ff” AMBER force fields are not “closed”, but they accept the 
parameters that are calculated with antechamber. While the AMBER force fields use caps lock 
names (i.e. C3) for force field types of atoms, the “GAFF” force field type calculated with 
antechamber are expressed with small capitals (i.e. c3). The leap module is able to accept both 
force field types without making any confusion and to write a .prmtop file in which the atoms 
of the complex are identified by both indexes. 
 
 
Figure 2.5 Part of the .prepin file for the imatinib drug (residue name: STI). The third column report the 
force field types for each atom.  
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Figure 2.6 Part of the .frcmod file for the imatinib drug (residue name: STI). Unknown parameters in 
.prepin files are here substituted with the closer available inside the force field. 
 
Ones .prepin and .frcmod files are loaded and accepted by the leap module, the residue STI 
(used here as an example – the procedure is the same for all the drug considered) will be listed 
between all the available inside the force field, as it would has ever been comprised in the 
known residues. 
After this step, it was possible to load the .pdb file of the protein-inhibitor correctly. The leap 
screenshot report the total charge of the protein-inhibitor complex. 
The total charge of the complex is -1. Since the imatinib does not carry any charge, this is due 
to the protein and, more precisely, to some of the residues that constitutes the proteic chain. 
In fact, as we already known, protein is composed by 20 different residues (Figure 2.7). These 
are aminoacids, organic compounds composed by an amine and a carboxylic acid functional 
group and characterized by a side-chain specific to each amino acid. The sidechain influence 
the total charge of the residue at physiological pH (7.4), in particular: Aspartic and Glutamic 
acids are characterized by a negative charge while Lysine and Arginine by a positive charge. 
During the building of the complex it is important to consider the total charge of our protein to 
reach a neutral final complex. 
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Figure 2.7 Chemical representation of all the amino acids. 
 
As the complex is loaded in leap without giving errors, and before proceeding to arrange the 
environment with the same conditions of the human body, three couples of .prmtop and 
.inpcrd files were saved, for the protein and the drug taken separately and for the complex 
drug/protein. This operation is requested for the further energetical analysis. 
 
The next two steps for the creation of the molecular system that will be simulate are: 
 Solvation of the system: the complex solute is immersed in a water box of variable 
dimensions. 
 Addition of counterions: a suitable number of Na+ and Cl- ions is added in the solution 
in order to guarantee the system neutrality and to reproduce the correct physiological 
ionic strength (150 mM NaCl). 
 
About these two steps, few comments must be done. The simulations that will be presented in 
the next sections will be carried out under periodic boundary conditions (PBC) – the geometry 
of the water box have to be consistent with this condition that will be expressed as the 
replication in the three dimensions of the same box.  
A realistic model of a solution requires a very large number of solvent molecules to be 
included along with the solute. Simply placing the solute in a box of solvent is not sufficient, 
 
 
44 
 
however, since while some solvent molecules will be at the boundary between solute and 
solvent and others will be within the bulk of the solvent a large number will be at the edge of 
the solvent and the surrounding vacuum. This is obviously not a realistic picture of a bulk fluid. 
In order to prevent the outer solvent molecules from “boiling” off into space, and to allow a 
relatively small number of solvent molecules to reproduce the properties of the bulk, periodic 
boundary conditions are employed. In this method the particles being simulated are enclosed 
in a box which is then replicated in all three dimensions to give a periodic array, a two-
dimensional representation of which is shown below 
During the simulation only one of the particles is represented, but the effects are reproduced 
over all the image particles with each particle not only interacting with the other particles but 
also with their images in neighboring boxes. Particles that leave one side of the box re-enter 
from the opposite side as their image. In this way the total number of particles in the central 
box remains constant. 
 
Upon initial inspection such a method would appear to be very computationally intensive 
requiring the evaluation of an infinite number of interacting pairs. However, by employing a 
technique known as the Ewald sum, or its more modern equivalent the Particle Mesh Ewald 
(PME)4 method it is possible to obtain the infinite electrostatics. 
This involves dividing the calculation up between a real space component and a reciprocal 
space component. The VDW interactions are still needed though which means we cannot 
make the cut-off too small. For production calculations the ideal range is between 8 and 10 Å. 
This from the calculation point of view is carried out with the condition that all the atoms and 
molecules that get off the original box from one side, come in again from the opposite. In this 
way it is guaranteed that the content of the periodic box is always the same. 
Basically, there are two geometries for the water box that are used for this purpose: the 
tetrahedric and octahedric geometries. The dimensions can be chosen explicitly, or only the 
minimum distance between the solute atoms and the side of the box can be defined. In this 
case, the water buffer must be grater that the cutoff radius that is used for calculations. 
In general, the geometry of the water box is chosen dependently on the geometry of the 
solute, and in order to reduce as much as possible the presence of water molecules in the 
system. In fact, if the solute presents a spherical symmetry, to choose an octahedric water box 
allows a consistent saving of “useless” atoms in the system. On the other hand, if the solute is 
strongly un-spherical and present a geometry that is not isotropic (i.e. DNA strands), to choose 
an octahedric box (very similar to a soccer ball) will create a final system full of water molecule 
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that are practically useless for the description of the system. In this case, the tetrahedic 
geometry is more indicated and guarantees more flexibility. 
There are different molecular models to describe the water inside AMBER. We used the TIP3P 
water model.5 
This simple water models use between three and five interaction sites and a rigid water 
geometry. The TIP3P model uses a total of three sites for the electrostatic interactions; the 
partial positive charges on the hydrogen atoms are exactly balanced by an appropriate 
negative charge located on the oxygen atom. The Van der Waals interaction between two 
water molecules is computed using a Lennard-Jones function, no Van der Waals interactions 
involving the hydrogen atoms are calculated. 
This model for water has the peculiarity that the angle between the two hydrogen atoms is 
maintained rigid. Thus the water molecules are something “rigid” in the calculation – this is a 
simplification, but decreases notably the CPU time required to simulate the system (the 
greatest part of atoms in the system belong to water molecules of the solution). 
Once we “immersed” the complex into the water, it is necessary to add the counterions in the 
system. In fact, ions can affect consistently the ability to move of the solute, influencing the 
final dynamic trajectories. The correct amount of ions to add to the system depends on the 
volume of the water box, in order to respect the 150 mM [NaCl] condition. The Na+ and Cl- 
ions can be added in the system with the Leap module – they are inserted in the system 
following the electrostatic potential surface of the solute. If during the addition of counterions 
positional conflict (superposition) with water molecules, constituting the box, are verified, the 
entire water molecule is substitute with the ion that is placed in the water molecule centre of 
mass. Since the number of water molecules in the box is rather high, usually almost all the 
counterions substitute a water molecule. This create a non-uniformity in the box, since one 
single atom (Na+ or Cl-) is replacing three atoms (H-O-H) – there are single points of lower 
density. That is why, for instance, during the first period of NPT dynamic (which allows the 
volume of the water box to change) the box reduces its dimensions in order to adjust the 
density. In conclusion, in the calculation of how many ions should be added to the system, the 
fact that each ion will replace an entire water molecule and that the final equilibrated volume 
will be smaller than the one of the initial box constructed by leap must be taken into account. 
Once the system is completed it is possible to save the .prmtop and .inpcrd files for the whole 
system – these are files that characterize the system that is going to be simulated. 
 
 
 
 
 
46 
 
 
 
 
 
 
 
 
 
 
Figure 2.8 The  catenin/GSK3 receptor complex in theTIP3P box water.  
 
2.4 Creation of mutated complexes 
The section above described the wild type complex, so in absence of mutations. However, 
during the carcinogenesis process, it is very frequent to find mutations in important proteins 
that could be targeted for the therapy or could lead to drug resistance, usually called 
“secondary” mutations. Changes in the DNA sequence can occur at the level of the 
chromosome, in which large segments of chromosomes are altered. In this case, fragments of 
chromosomes can be deleted, duplicated, inverted, translocated to different chromosomes, or 
otherwise rearranged, resulting in changes such as modification of gene dosage, the complete 
absence of genes, or the alteration of gene sequence. The type of variation that occurs when 
entire areas of chromosomes are duplicated or lost, called copy number variation (CNV), has 
especially important implications for human disease and evolution.  
While a mutation is defined as any alteration in the DNA sequence, biologists use the term 
"single nucleotide polymorphism" (SNP) to refer to a single base pair alteration that is common 
in the population. Specifically, a polymorphism is any genetic location at which at least two 
different sequences are found, with each sequence present in at least 1% of the population. 
Note that the term "polymorphism" is generally used to refer to a normal variation, or one 
that does not directly cause disease. Moreover, the cutoff of at least 1% prevalence for a 
variation to be classified as a polymorphism is somewhat arbitrary; if the frequency is lower 
than this, the allele is typically regarded as a mutation. 
SNPs are important as markers, or signposts, for scientists to use when they look at 
populations of organisms in an attempt to find genetic changes that predispose individuals to 
certain traits, including disease. On average, SNPs are found every 1,000–2,000 nucleotides in 
the human genome, and scientists participating in the International HapMap Consortium have 
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mapped millions of these alterations (International Human Genome Sequencing Consortium, 
2001). 
1.Point mutation:  
 Substitution: one base is incorrectly added during replication and replaces the pair in 
the corresponding position on the complementary strand. 
 Insertion: one or more extra nucleotides are inserted into replicating DNA, often 
resulting in a frameshift. Deletion: one or more nucleotides is “skipped” during 
replication or otherwise excised, often resulting in a frameshift. 
2. Chromosomal mutation:  
 Inversion: one region of a chromosome is flipped and reinserted.  
 Deletion: a region of a chromosome is lost, resulting in the absence of all the genes in 
that area.  
 Duplication: a region of a chromosome is repeated, resulting in an increase in dosage 
from the genes in that region.  
 Translocation: a region from one chromosome is aberrantly attached to another 
chromosome. 
In this section, we proceed building the “mutated” complex in order to compare these results 
between wild type and mutates complex and to analyze the effects in the protein/protein or 
protein/drug interaction occurred following the mutation. We will briefly describe how we 
introduced point mutations or amino acid deletions inside the protein chain.   
All the computational mutagenesis procedure has been carried out exploited the Rotamers 
module of Chimera (UCSF Chimera package, University of California, San Francisco). 
Each mutated complex was then equilibrated in explicit water solvent to allow for relaxation of 
the structure following the stress from mutation. Each system was subjected to a minimization 
of 1000 steps, and then the solvent molecules were equilibrated for 100 ps at 310K. Finally, 
the entire system is equilibrated for 2 ns at 310K. Then the complex is subjected to MD 
simulation. 
 
Figure 2.9 Panel of Chimera visualization program for generation of rotamers. 
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For the aminoacids that have several possible rotamers (for instance acid aspartic and 
glutamic), each rotamer structure is generated and minimize separately. We proceed with a 
systematic conformational search for 100 different conformations for the mutated residue. 
For each conformation obtained, a check of the steric bump is planned to avoid sterical clash 
between all the residue in the protein and the mutant. In particular, the conformation of the 
mutated residue is not taken in account if the new residue is closer than 1 Å to any aminoacid 
in the protein. Each surviving complex is minimized using the Sander module of Amber11 with 
steepest descent algorithm for the first 200 steps, and then subsequently with a conjugate 
gradient approach. A cutoff of 10 Å and a distance-dependent dielectric are applied. Then we 
perform a minimization consisting on different steps. At first, the mutated residue is minimized 
for maximum 1000 steps and all the system is fixed; then, the hydrogen atom are minimized 
for maximum 1000 steps and at the end all the atoms are minimized for 2000 steps.  
The structure containing the rotamer characterized by the lowest final energy is  selected to 
proceed with MD assays. 
   
Looking at the final structure, while a point mutation provokes only adjustments in the 
secondary structure of the protein, a consistent deletion can provoke drastic distortions and 
final configurations that are considerably distant from the “wild type” protein. Thus, it is 
perfectly clear that the huger the deletion, the more consistent the simplification and the risk 
that the final mutated protein conformation in the model could be completely different from 
the real one. 
 
 
Figure 2.10 Examples of point mutation in the complex between c-KIT receptor and Imatinib. Highlighted 
in blue the Trp557 mutated into Gly, in green Tyr578. 
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Once the mutation has been inserted, the same steps of solvation and addition of counterions 
described in the previous section followed – a .prmtop and an .inpcrd file were obtained also 
for the mutated case, ready to be simulated. 
With the two files containing parameters (.prmtop) and starting configurations (.inpcrd) we 
had everything is needed as a starting point to run a molecular simulation. 
 
2.5 Molecular simulation 
Once we have our input files we can progress to the next step of the simulation process.  
Since the default geometry that we obtained, building our structure, might not correspond to 
the actual minima in the selected force field and could result in conflict and overlap with atom 
in other residues, it is always a good idea to minimize the structure before starting molecular 
dynamics. 
Sander.MPI (Simulated Annealing with NMRDerived Energy Restraints) and pmemd modules of 
AMBER were used to conduct a short minimization run. Both modules are parallel calculation 
tools, but while Sander.MPI allows many facilities and tools for energy minimization, molecular 
dynamic, restraints, etc., pmemd presents only few options. In fact, with pmemd, only periodic 
boundary condition simulations without restraints applied on the molecule are allowed, but a 
better scaling during the parallelization is possible. 
The system is in the configuration described by the .inpcrd file.  
All the cases studied in this thesis followed this procedure: 
 Minimization: a preliminary phase, only necessary to remove bad contacts between 
atoms after the solvation, obtaining for each step .out file that contains energetical 
information and .rst file to give the input for the next step. 
 Constrained dynamic: a phase in which the solute is constrained in its starting position, 
during this phase the simulation temperature is reached, and start the solution density 
optimization. 
 Equilibrium dynamic: without any restraint – it is the phase in which the system reach 
the equilibrium (NPT, temperature and pressure constant). 
 Production dynamic: without restraints in NVT condition (temperature and volume 
constant), the trajectories of this phase will be further processed and analyzed. 
 
In detail, the molecular systems were relaxed for 500 steps using Sander.MPI applying a 
restraint on all the atoms of the solute with elastic constant of 2 N Å-1 in order to let move all 
 
 
50 
 
the atoms belonging to the solution by first. This was followed by other 500 steps of 
conjugate-gradient minimization identical to the first, but in absence of restraints on the solute 
was run to remove bad contacts between atoms of the complex. After the minimization part, 
the system was gradually heated to a temperature of 300 K in intervals of 50 ps of NVT 
dynamic, with a time step of 1 femtosecond (fs). Both these two first dynamic steps were 
conducted with the solute maintained restrained on the starting position applying an elastic 
force with a 2 N Å-1 elastic constant.  The density of the system was subsequently equilibrated 
via MD runs in the isothermal- isobaric ensemble (NPT), with isotropic position scaling and a 
pressure relaxation time of 1.0 ps, for 50 ps with a time step of 1 fs. All restraints on the 
protein atoms were then removed, and each system was further equilibrated using NPT MD 
runs at 300K, with a pressure relaxation time of 2 ps.  
More precisely, this phase can take from few to tens of nanoseconds, depending on the 
conformation of the solute. We preferred to use in the previous steps 1 fs time step in order to 
avoid too large deviations due to the rising of temperature and to the high fluctuations of the 
molecules belonging to the solvent.  
This Particle Mesh Ewald (PME) method was applied to treat long-range electrostatic 
interactions. Briefly, since the electrostatic interaction can be divided in short- and long- range 
effects.  
The SHAKE6 method was also used to constrain all of the covalently bound hydrogen bonds, 
while long-range nonbonded Van der Waals interactions were truncated by using dual cutoffs 
of 6 and 12 Å.   
The equilibrium phase, thus, has not a pre-defined length, it depends on how long the reaching 
of the equilibrium takes to the complex. During the simulation, some values could be checked 
to verify the status of the equilibrium of the system. The quantities that usually are plotted to 
the time to check the status of the system are temperature (T), pression (P), Volume (V), Epot, 
RMSD (root mean square deviation), in particular: 
 
 The potential energy (Epot): strictly correlated to the total energy of the system Etot. 
The energy of the system usually converges almost immediately (i.e. until the first 
picoseconds of the equilibrium phase). 
 
 The root mean square deviation (RMSD) of the atoms of the backbone 
 
While the first parameter tends reach an equilibrium immediately (in correspondence of the 
stable reaching of the 300K temperature), the second takes a longer. 
 
 
51 
 
If the equilibrium is reached, both the curves of potential energy and RMSD should be 
horizontal. On the other hand, if the RMSD has not reached the equilibrium (it is growing) 
despite a constancy of the energetic of the system, it means that the complex, in order to 
maintain the constancy of the energy, is vibrating stronger and stronger at each dynamic step - 
thus, while the energetic equilibrium is reached, the vibrational one has not. 
As reported by Figure 2.11, the energies converge sooner than RMSD – the real equilibrium is 
reached after ~6 ns in this case, thus this is the starting point from which the data collection 
can be considered as reliable. In conclusion, the equilibrium phase has not a pre-defined 
length, but it depends on the time required to the solute to reach the equilibrium. It is also 
worth noting that a good oscillation for RMSD is between 1 and 3 Å around the equilibrium 
position, as shown from the graph in the terminal part of the RMSD curve (last 2-4 ns) the 
fluctuation of atoms around their equilibrium position is really below these values. 
The equilibration phase was followed by a data production run consisting of 4 ns of MD 
simulation in the canonical (NVT) ensemble. Only the last 2 ns of each equilibrated MD 
trajectory were considered for statistical data collection. In all these simulations step a cutoff 
was used. The role of the cutoff is to exclude from an explicit non-bond calculation all the 
atoms that are not inside a sphere defined by the cutoff radius (R cutoff). This is done for 
shake of CPU time saving. Since the cutoff value can vary depending on the single systems, the 
individual parameters and details changed for each case studied.  
 
 
Figure 2.11 Examples of Epot, Etot and RMSD profiles of a protein-drug complex (KIT “wild type”-
imatinib). The time scale is expressed in nanoseconds, the energies in kcal mol-1 and the RMSD in 
angstroms (Å). The last 2 ns of these profiles belong to the production phase of the dynamic. 
 
However, since all the atoms do not enter in the calculation explicitly, a corrective term (an 
external constant) must be inserted, in order to correct the error given by the exclusion of part 
of the atoms from calculation.  
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In conclusion the total length of each simulation is around 10 ns (depending on each system, 
but the complexes presented in this thesis are rather similar). 
The single simulation details (number of atoms of the system, number of water molecules, 
cutoff used, etc.) concerning each single case studied will be reported in the each paragraph 
dedicated to each single system simulated. 
Once the simulation is finished we can proceed analyzing the results; in particular we can look 
at the movie, through a visualization program. The files .mdcrd (trajectory) and .prmtop are 
used for this purpose. Have a look at the trajectory could help to understand conformational 
changes occur during the simulation and particular behavior of our system. However it is also 
interesting to compute the binding free energy for the system studied, applying MMPBSA 
methodology. Let see more in details, the MMPBSA approach in the next section.  
 
2.6 Affinity energy analysis (MM-PBSA) 
Once the simulation, described in the previous section, is finished, the output files could be 
processed by the application of the MM/PBSA approach7 to estimate the binding free energies. 
At the end of the simulations the output files obtained are below: 
 .out: the output file. It reports all detail about the energetic of the system at each step 
of the simulation. It also list all the parameters listed in the input files. 
 .rst: file restart. It is equivalent to the .inpcrd – it is a coordinate file that is written 
after a given time interval. In dynamic regime, differently from the .inpcrd file, it 
reports also the velocities of the atoms. 
 .mdcrd: the trajectory file. These files have huge dimensions and report the “history” 
of the simulation for each atom of the system. 
These last trajectory files are used to perform a MM-PBSA analysis on the complex in order to 
evaluate, at each step of the simulation, the free energy for each molecular species, complex, 
ligand and receptor. 
The MM-PBSA methodology (Molecular Mechanic – Poisson Boltzmann Solvent Accessible 
area) is a tool, implemented in AMBER, that allow to calculate the affinity energy for the 
association of two molecules (protein/protein and protein/drug) in solution. 
The main aim of the MM-PBSA method is to calculate the free energy difference between two 
states which most often represent the bound and unbound state of two solvated molecules or 
to compare the free energy of two different solvated conformations of the same molecule. 
Ideally, the free energy of binding for the association of a ligand (L: drug) and a receptor (R: 
protein) can be expressed by the following representation:  
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Figure 2.12 The two states “bound” and “unbound” of ligand (yellow) and receptor (green) in solution 
(blue).Adapted
8
 
 
The ability to accurately calculate G, the average free energy for a given macromolecular 
system in various different conformations structures, adds a very important methodology to 
the available tools. This has been possible before with free energy perturbation, but only for 
small systems and very limited conformational or topological changes. By using a continuum 
model, we are implicitly integrating out all the solvent coordinates and simplifying the 
problem. Also, by calculating the absolute free energy directly between the two “end points” 
instead of calculating the relative free energy along a mapping coordinate, we are avoiding 
computations on less interesting intermediate states. Nonetheless, it is clear that applications 
of the equation will have intrinsically much larger errors than free energy 
perturbation/thermodynamic integration calculations. However, despite the larger 
uncertainties, we can most of the times, calculate G in respectable agreement with 
experiment. It could be used to study: relative free energies of macromolecules, protein-ligand 
interactions and its deconvolution per residues energies, protein-protein interactions.  
In the simulation of these solvated states the majority of the energy contributions would come 
from solvent-solvent interactions and the fluctuations in total energy would be an order of 
magnitude larger than binding energy of the two molecules of interest. Thus the calculation 
would take an enormous amount of CPU time to converge. In order to simplify, the MM-PBSA 
method is based on the following thermodynamic cycle: 
 
 
 
Figure 2.13 Thermodynamic cycle to exploit G bind, vacuum to solve Gbind, solv. Adapted
8 
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In the MM-PBSA approach the different contributions to the binding free energy above are 
calculated in various ways: solvation free energies are calculated by either solving the 
linearized Poisson Boltzman equation9 for each of the three states (this gives the electrostatic 
contribution to the solvation free energy) and adding an empirical term for hydrophobic 
contributions. 
From the scheme we derived: 
 
                                         (                             ) 
 
That could simplify in:  
                                  
Whereas        is coming from the solvatation of the complex:  
                 
 
     is estimated using DelPhi
10 which solves the Poisson-Boltzmann equations numerically. 
The non polar solvation contribution was determined using the following relationship9: 
               
 
In which   = 0.00542 kcal/(mol Å2), β = 0.92 kcal/mol and SA is the molecular surface area 
estimated by means of the MSMS software11.  
While ΔGbind,vacuum is obtained by calculating the average interaction energy between receptor 
and ligand and taking the entropy change upon binding into account: 
                           
Where         is the entropy contribution and it is estimated by performing a normal mode 
analysis with the Nmode of AMBER11. The normal mode analysis calculations are 
computationally expensive and are the one that introduce in the results the larger margin of 
error and the higher uncertainty in the result. 
The molecular mechanics energy EMM was calculated as the sum of the Van der Waals and 
electrostatic interactions: 
                                   
EMM is a measure for the tendency of the ligand and complex to bind each other in a stable 
complex, rather than keeping two isolate conformations. The more negative the ΔE, the more 
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stable the complex, in other words in certain condition the complex has lower energy than the 
two of protein and drug taken separately and, thus, its formation is favored. 
So it is possible to rewritten the binding energy as: 
                             
Or 
                                    
 
The methodology that is adopted in this thesis for the calculation of each energetic term is the 
“single trajectory” technique. In fact, starting from the assumption that the conformational 
change of protein and drug will not be heavily affected due to the binding, the single 
conformations of protein, drug and complex for which the energies will be calculated at each 
steps will be taken from the single trajectory of the system we simulated. Practically, from the 
single dynamic trajectory of all the periodic box, we define “what” is complex and “what” is 
ligand and receptor respectively – this is what is needed for the calculation of each energetic 
component for the calculation of the free energy of binding ΔGbind. 
However, in such simplified approach, the presence of water and ions is no more taken into 
account into the energetic calculations but only in the effect on the trajectory of these 
molecules along the dynamic.  
In practice, to minimize the effects due to different conformations adopted by individual 
snapshots, and due to the high computational demand of this approach, we averaged the 
estimation of entropy over MD 40 snapshots for each molecular complex that were evenly 
extracted from the last 2 ns of each corresponding trajectory.  
So in summary, this is a post-processing method in which representative snapshots from an 
ensemble of conformations are used to calculate the free energy change between two states 
(typically a bound and free state of a receptor and ligand). Free energy differences are 
calculated by combining the so-called gas phase energy contributions that are independent of 
the chosen solvent model as well as solvation free energy components (both polar and non-
polar) calculated from an implicit solvent model for each species. Entropy contributions to the 
total free energy may be added as a further refinement. The entropy calculations can be done 
successively. 
MM/PBSA typically employs the approximation that the configurational space explored by the 
systems are very similar between the bound and unbound states, so every snapshot for each 
species is extracted from the same trajectory file, although MMPBSA.py will accept separate 
trajectory files for each species. Furthermore, explicit solvent and ions are stripped from the 
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trajectory file to hasten convergence by preventing solvent-solvent interactions from 
dominating the energy terms. 
With AMBER software package there are two different approaches to calculate the MMPBSA 
(both applied in this thesis work).  The first uses the mm_pbsa.pl script of AMBER for the 
complex, and the protein and drug unbound. After this, the same mm_pbsa.pl script was used 
in order to compute the free energy of binding of each complex of interest. The second one 
applied the MMPBSA.py and it doesn’t need to extract snapshot with the .pl script. 
The effectiveness of a certain inhibitor drug is defined by the half maximal inhibitory 
concentration (IC50) that is defined as the amount of drug to put into the solution in order to 
inhibit the activity of the specific biological target of the 50%.  
The correspondence between IC50 and the free energy of binding is defined as follows: 
G= -RT ln (IC50) 
Thus, until this point, we were able to produce results consistent with experimental 
measurement, indicating that the procedures and the molecular models used for the cases 
faced in this thesis are reliable.  
 
 
2.7 Per residue decomposition analysis 
The interactions between the drug and each separate aminoacids may be evaluated applying a 
further energetical analysis, in previous section we explained the methodology used for the 
calculation of the free energy of binding ΔGbind.   
In particular this methodology allows us to identify the role of a point mutation in the total 
protein systems, evaluating energetical contribution of the surrounding residue. 
The concept is rather simple; it is possible to split the total interaction energy that exists 
between ligand and receptor on all the residues constituting the protein: 
 
∆EMM,j = ∆EvdW,i + ∆Eele,i 
 
By calculating each ΔEj it is possible to evaluate the role of each residue in the stabilization of a 
protein-drug complex, the more negative the ΔEj, the stronger is the favorable action of the 
residue in stabilizing the complex. In details, the gas-phase in vacuo energies (Egas) for each 
residue is composed of electrostatic and van der Waals interaction contributions (Eele and EvdW, 
respectively). 
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The result is an enthalpy division between all the residues constituting the protein, and gives 
precious indications in which are the residues that are crucial in binding – the residue that 
most interact favorably with the inhibitor molecule. 
The single energetical contribute per residue could help to understand the particular “domino 
effect” that rearrange the all structure or the identification of particular residue for the binding 
sites. 
The ΔΔEi,tot value represents the effect of the mutation on the affinity between a precise 
residue and the drug. In fact, if ΔΔEi,tot < 0 it indicates a negative effect of the mutation on the 
attraction ability of the single residue toward the drug (the ΔEi,tot) mutated is less negative 
(favorable) than ΔEi,tot-“wild type”, meaning that this precise residue tends to stabilize more 
the binding in the naive conformation of the protein than in presence of a given mutation 
along the amino acidic chain. It is worth noting that of course the residues that will report the 
most evident getting worse due to the presence of the mutation will be the ones in close 
proximity to the mutation itself. 
This energetic analysis can be rather useful because it is able to provide unique details in the 
binding between protein and inhibitor drugs. Such details are impossible to obtain with other 
experimental techniques, and evidence this approach and the modelling in general as an 
extremely powerful instrument for the exploration and the analysis of the potentiality of 
different small inhibitor molecules. 
The new method separates nonpolar contribution into two terms: the attractive (dispersion) 
and repulsive (cavity) interactions. Doing so significantly improves the correlation between the 
cavity free energies and solvent accessible surface areas for branched and cyclic organic 
molecules. 
This is in contrast to the commonly used strategy that correlates total nonpolar solvation 
energies with solvent accessible surface areas, which only correlates well for linear aliphatic 
molecules. In the new method, the attractive interaction is computed by a numerical 
integration over the solvent accessible surface area that accounts for solute solvent attractive 
interactions with an infinite cutoff.  
This analysis was carried out using the MM/GBSA approach,12,13 and was based on the same 
snapshots used in the binding free energy calculation. 
The general procedure is to edit the decomp.in file, you just need to prepare prmtop files for 
receptor, ligand, and complex using LEaP; if you are just doing "stability" calculations, only one 
of the prmtop files is required.  
The output files are labeled ".out", and the most useful summaries are in the "statistics.out" 
files. 
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2.8 Pharmacophore modeling 
The pharmacophore is the group of properties that form a vital part of a drug. A 
pharmacophore may be defined as the ensemble of steric and electronic features that is 
necessary to ensure the optimal supramolecular interactions with a specific biological target 
structure and to trigger its biological response. Pharmacophore mapping is one of the major 
elements of drug design in the absence of structural data of the target receptor. The tool 
initially applied to discovery of lead molecules now extends to lead optimization. 
Pharmacophores can be used as queries for retrieving potential leads from structural 
databases (lead discovery), for designing molecules with specific desired attributes (lead 
optimization), and for assessing similarity and diversity of molecules using pharmacophore 
fingerprints. It can also be used to align molecules based on the 3D arrangement of chemical 
features or to develop predictive 3D QSAR models. 
The model structures of all compounds are built using the 2D-3D sketcher of Discovery Studio 
Catalyst (DS v. 2.5, Accelrys, San Diego, CA, USA). High quality conformational models are 
crucial for the development of predictive pharmacophore models. Accordingly, in this thesis 
we employed an ad hoc procedure to derive molecular conformations, instead of using those 
automatically generated by DS Catalyst, for a better quality in covering the low-energy 
conformational space. Each molecular structure is subjected to energy minimization using the 
generalized CHARMM force field until the gradient dropped below 0.05. The minimized 
structures are used as the starting point for subsequent conformational searches. A 10000-
step Monte Carlo torsional sampling conformational search is conducted for each compound. 
Unique low energy conformations within 20 kcal/mol of the corresponding global energy 
minimum are collected for each molecule. A conformation is considered unique only when the 
maximum displacement of at least one heavy atom is greater than 0.5 Å. A maximum of 250 
unique conformations are recovered for each compound. The classical conformational search 
is also carried out using the Poling algorithm and the CHARMM force field as implemented in 
DS Catalyst program for comparison. The “best quality” generation option is adopted to select 
representative conformers over a 0 – 20 kcal/mol interval above the computed global energy 
minimum in the conformational space, and again the number of conformers generated for 
each compound is limited to a maximum of 250. The main drawback of this technique, 
however, is that it takes considerable longer to generate the relevant conformational models. 
Nonetheless, as the spirit of the work is the generation of a predictive 3D pharmacophore 
model for these classes of compounds, we considered it worthwhile to use more accurate 
conformational models. 
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Based on the conformations for each compound, the DS Catalyst Hypothesis module was used 
to generate three-dimensional pharmacophore models. During hypotheses generation, the 
software attempts to minimize a cost function containing two main terms: the first penalizes 
the deviation between the estimated affinities of the training set molecules and their 
experimental values, whilst the second penalizes the complexity of the hypothesis. The 
uncertainty factor for each compound represents the ratio range of uncertainty in the affinity 
value based on the expected statistical irregularity of biological data collection. Uncertainty 
influences the first step – also called the constructive phase – of the hypothesis generating 
process. An uncertainty value of 3.0 is the default factor, but sometimes if  the experimental 
affinities of compounds barely span the required four orders of magnitude an uncertainty of 
1.1 is preferred.  
Different functional groups characterizing compounds allow to individuate defined features. 
For example in the case studied in this thesis work for 1 receptor the identified features 
correspond to hydrophobic aromatic (HYAr), aliphatic (HYAl) and generic hydrophobic (HY) 
features, hydrogen bond acceptors (HBA), and positive ionizable (PI).  
The overall costs of a model consist of three cost components, namely, the weight cost, the 
error cost and the configuration cost. The weight component is a value that increases in a 
Gaussian form as this function weights in a model deviate from the ideal value of two. The 
error cost represents the difference between estimated and measured activities of the training 
set. The configuration cost quantifies the entropy of the hypothesis space.  
In addition the following three cost values are calculated during the generation of 
pharmacophore models: the fixed cost, the total cost and the null cost. The fixed cost is the 
lowest possible cost representing a hypothetical simplest model that fits all data perfectly. 
Another cost parameter, the null cost, represents the maximum cost of a pharmacophore with 
no features and estimates activity to be the average of activity data of training set molecules. 
The null cost value is equal to the maximum occurring error cost. For every pharmacophore 
generation ten total cost values and each of fixed cost and null cost values are calculated by 
the pharmacophore generation protocol in the unit of bits. For a meaningful pharmacophore 
model, the fixed cost should be lower and the null cost should be higher and the total cost 
value should be closer to the fixed cost and away from the null cost value. 
Three validation procedures are, usually, used to determine the statistical relevance and the 
validity of the proposed 3D pharmacophore models: the test set prediction method, the 
CatScramble method, and the leave-one-out procedure. A larger difference between the fixed 
and null costs than that between the fixed and total costs signifies the quality of a 
pharmacophore model. In this work, the first procedure consisted of the collection of further, 
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different compounds into a test set, and in performing a regression analysis by mapping the 
test set molecules onto the best pharmacophore hypothesis. The high correlation coefficients 
obtained using the test set compounds revealed the good correlation between the actual and 
estimated affinities and, hence, the predictive validity of the corresponding 3D hypothesis. The 
CatScramble validation procedure is based on Fisher’s randomization test. The goal of this type 
of validation is to check whether there is a strong correlation between the chemical structures 
and the biological activity. This is done by randomizing the affinity data associated with the 
training set compounds, generating pharmacophore hypotheses using the same features and 
parameters employed to develop the original pharmacophore model.  
 
The statistical significance is calculated according to the following formula: 
 
significance = 100 x [1 - (1 + x / y)] 
 
where x is the total number of hypotheses having a total cost lower than the original (best) 
hypothesis, and y is the total number of DS Catalyst Hypothesis runs (initial + random runs). 
Thus, 49 random spreadsheets (i.e., 49 DS Catalyst Hypothesis) have to be generated to obtain 
a 98% confidence level. Should any randomized data set result in the generation of a 3D 
pharmacophore with similar or even better cost values, root-mean-square deviations, and 
correlation coefficients, then it is likely that the original hypothesis does reflect a chance 
correlation. 
Finally, the leave-one-out test checks if the correlation between experimental and computed 
affinities is heavily dependent on one particular molecule of the training set by re-computing 
the pharmacophore model with the exclusion of one molecule at a time. For each run, the 
hypothesis characterized by the lowest total cost was employed to predict the affinity of the 
excluded compound and to estimate the new correlation coefficient. 
The data used in the particular case analyzed in this thesis work will be discussed in the 
appropriate section of Results & Discussion. 
 
2.9 Homology modeling technique 
One of the goals of protein modeling is to predict a structure from its sequence with an 
accuracy that is comparable to the best results achieved experimentally. This could help in 
different contexts when experimental techniques fail (i.g. the protein is too large for NMR 
analysis): structure-based drug design, analysis of protein function, interactions, antigenic 
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behavior, and rational design of proteins with increased stability or novel functions. In 
addition, protein modeling is the only way to obtain structural information if experimental 
techniques fail. 
The 3D protein structure is entirely determined by its aminoacidic sequence; however when 
proteins are in optimal temperature and solvent conditions, as into the cell, they 
spontaneously fold to reach the native state structure. In some cases it is necessary the help of 
some “chaperonine” to fold in the correct way, but they just act to catalyse the folding and not 
interfere with the direction. 
Since the sequence contains the sufficient data to specify the 3D structure of protein, it would 
be possible to develop an alghorithm to predict the structure of the protein using the only 
aminoacidic sequence. Really the sequence could only determine 60-70% of the total 
secondary structure and you need a lot of other information to complete the secondary and 
tertiary structures. 
During evolution, the structure is more stable and changes much slower than the associated 
sequence, so that similar sequences adopt practically identical structures, and distantly related 
sequences still fold into similar structures. Thanks to the exponential growth of the Protein 
Data Bank (PDB), Rost (1999) could  derive a precise limit for this rule. As long as the length of 
two sequences and the percentage of identical residues fall in the region marked as “safe,” the 
two sequences are practically guaranteed to adopt a similar structure. 
 
 
Figure 2.14 Different zones of sequence alignments (twilight and safe). Sequence are guaranteed to fold 
into the same structure if their sequence identity fall into the region marked as safe (for example gray 
cross). 
 
It is possible to distinguish in three different methods to predict the 3D structure: homology 
modeling, fold recognition, and ab initio prediction. 
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The first approach can be used when there is a high degree of similarity (more than 30%) 
between the protein of interest and a known structure template. In this case, we can use the 
template structure as reference to build the model of study. 
In the case of no homology with other known protein, an alternative method consists on 
Threading, based on fold recognition. The aim is identified the most compatible fold with the 
aminoacidic sequence of the target protein. It is a necessary requirement that the fold of the 
unknown protein already exists in the structure protein data bank.  
In practice, homology model is a multistep process as summarized below: 
1. Template recognition and initial alignment 
2. Alignment correction 
3. Backbone generation 
4. Loop modeling 
5. Side chain modeling 
6. Model optimization via Molecular Dynamics (MD) simulation 
7. Model validation 
 
 
 
 
Figure 2.15 Schematic representation of homology modeling procedure. 
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The steps to homology model 
The first step consists on the downloading of the primary sequence of the target protein from 
UniProt database. Then we resort to the application of a comparative PSI-Blast search through 
different database: MODWEB (http://modbase.compbio.ucsf.edu/scgi/modweb.cgi) , ExPASy 
Proteomic Server (http://expasy.org) and NCBI website (www.ncbi.nlm.nih.gov). 
To identify hits, the programs work comparing the query sequence to all the sequence 
belonging to the known structures in the protein data bank using two different matrices: a 
residue exchange matrix and an alignment one. 
Having identify one or more possible modeling templates, it is now necessary to evaluate the 
possibility of improve our first alignment applying a multiple sequence alignment. This could 
implicitly contains information about the hardest possibility to have an exchange on the 
hydrophobic core than on the surface. If there is an exchange between hydrophobics 
aminoacids the residue is probably buried. Considering these aspects during the alignment you 
could derive position specific scoring matrices, the profiles.  
Other information could be very useful to proceed toward a realistic model. In particular, for 
the identificatiuon of transmembrane zone or the overall prediction of the secondary 
structure, it is possible to, comparatively, employ TMPRED, DISOPRED, PredictProtein, 
HMMTOP and Secondary Structure Prediction tool of DS (Discovery Studio).  
At this point the predictions and all the alignments are ready, the actual model building can 
start. 
Experimentally determined proteins are sources of errors, for instance poor electron density in 
the X-ray diffraction map. So the best option is to combine the good parts of both templates in 
one model.  
The crystal structures of the template proteins identified are used as template for building the 
3D structure. Each initial template-based structure is obtained using MODWEB, checked by 
Build and Homology Models of DS and compared to the corresponding template through 
Structure Comparison-Match Maker feature of Chimera. 
Loop modelling 
In the majority of cases, the alignment between model and templates sequence contains gap. 
Two different approaches could be applied: a knowledge based (involving search in PDB for 
known loops with similar endpoints) and an energy based (ab initio fold prediction, judging 
quality by energy function). 
At least for short loops, these two methods have a reasonable chance of predicting a loop 
conformation that superimposes well on the true structure.  
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Some extended portions of the protein, usually the intrinsically disordered as N-ter and C-ter 
parts, could sometimes show no homology with any other protein in databases; in these 
particular cases the procedure employs a de novo building through Build and Edit Protein 
modulus of DS. 
The structure is, finally, adjusted taking into account the results of secondary structure 
predictions and optimized for side chain conformation. All successful approaches to side chain 
placement are at least partly knowledge based. They use libraries of common rotamers 
extracted from high resolution X-ray structures. The various rotamers are tried successively 
and scored with a variety of energy functions. 
Model optimization  
Once we checked all the alignment with previsions and rearranged loop conformation, the 
most straightforward approach to model optimization is simply to run a molecular dynamics 
simulation of the model that contains implicitly entropic effects that are otherwise difficult to 
treat.  
Model validation 
The stereochemistry quality of the obtained model is checked using different online program: 
PROCHECK, WHATIF, PROSA, VERIFY 3D. 
PROCHECK generates a Ramachandran plot of the main torsional angles of the model 
distinguishing between most favored region, additionally allowed regions, disallowed region. 
Other stereochemical parameters to consider are peptide planarity, bad nonbonded 
interactions, main-chain hydrogen bonding energy and standard deviation of xi angle.  
The same program could also give the G-factor value that for reasonable structures fall 
between 0 and –0.5. 
WHATIF gives an idea of the reliability of the model by the normality index (z-score) that needs 
to be < -5.0. 
Concerning PROSA we will obtain a quality of the model by corresponding PROSA normalized z-
score, <0.70 is predictive for a good structure. This parameter is derived from the nature of 
residue-residue interaction energies, directly linked to backbone contacts.  
VERIFY 3D has a compatibility score depending on the side chain environments, a good value 
means an overall self-consistency in terms of sequence-structure compatibility. 
A further optimization could be done by another cycle of MD simulation and a comparison 
between the parameters, previously, obtained and the second ones.  
In this thesis, we exploit the homology modeling to build different proteins having different 
degree of complexity, and we wil interpret further the results obtained. 
 
 
 
65 
 
2.10 Steered Molecular Dynamics (SMD) 
In the discovery and study of safe and effective drugs the aim is to achieve inhibitors that bind 
tightly to active sites, in other words that possess a negative free energy of binding; this allow 
the use at low doses. As explained in the section regarding the calculation of binding free 
energy, the most used approach uses MD trajectories by MMPBSA technique. However a 
direct calculation of the change in free energy in some complexes is difficult for the natural 
change in conformation. An alternative approach is to use Steered molecule dynamics (SMD) 
to compute the force that is required to extract inhibitors from complexes with protein.14,15 
The simulation runs and all atoms adjust to the forced change in structure so that 
conformations may be sampled along a particular pathway. In theory the change could happen 
spontaneously during the simulation, but we would have to wait a very long time to see it.  
Thus, we accelerate a process in order to understand how the systems energy changes.  As the 
force is executed and motion occurs along a coordinate, the potential energy of the system is 
calculated.  This potential of mean force (PMF) is related to the free energy change for the 
process.  SMD is therefore one of the methods used to calculate free energy changes. 
The potential of mean force (PMF) is an averaged quantity.  Formally, it is obtained from 
theory using the Jarzynski equality: 
 
PMF= -RT ln (exp(-W/RT)) 
 
where W is the work, R is the gas constant and T is the temperature.  The bracket means that a 
configurational average is to be carried out.  In practice we will run 10 simulations and average 
them to obtain the effect of the bracket.  The work, W results from the resistance met by the 
pulling force.  When the system meets with resistance it does not “keep up” with the pulling 
trajectory.  The force needed to keep it moving is calculated as it moves and output to the out 
file.  These forces will then be used to calculate the work W, and ultimately the potential of 
mean force. 
Since the average factor is related to the equilibrium constant, the PMF is related to the free 
energy change for the process. 
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Figure 2.16 System in which a small spring is connected to the ligand in the protein-ligand complex and 
then pulled at constant velocity into the surrounding water. 
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Results & Discussion 
As anticipated in the introduction in this thesis different case studies will be presented.  
The individuation of new targets for cancer therapy could involve the interest for some protein 
that are characterized by partially unknown structure or mechanism or simply are in an 
indirect pathway that leads to carcinogenesis paragraph 3.1, 3.2, 3.3). 
In the meantime some kind of cancer could present particular mutations, primary or acquired 
as response to the therapy; an accurate evaluation of the conformational and energetical 
effects due to these variations help clinicians in a tailored therapy (see more on paragraphs 
3.4, 3.5).  
 
3.1 1 RECEPTOR AS NEW TARGET IN CANCER THERAPY: 
STRUCTURAL CHARACTERIZATION AND DRUG DESIGN 
 
3.1.1 BUILDING OF 3D HOMOLOGY MODEL OF 1 RECEPTOR
1  
In this work, we present for the first time a 3D model for the 1 receptor based on a molecular 
modeling and simulation ansatz involving the following sequential steps: i) generation and 
optimization of the complete 3D model of the receptor by homology modeling techniques;2 ii) 
further 3D homology model refinement exploiting information derived from ligand docking,3 a 
3D pharmacophore model4 and mutagenesis experiments5 as spatial restraints; iii) docking of a 
series of bioactive ligands into the putative binding site, estimation of their binding affinity via 
the MM/PBSA methodology,6 and comparison with the available experimental activities; iv) 
design of a set of new ligands with high affinity based on the derived receptor model. All 
detailed information about each single step mentioned above can be found in the next 
Experimental Section. 
The initial stage of step i) consisted in the modeling of the transmembrane (TM) regions (three 
-helices spanning residues 10-30, 80-100, and 180-200, respectively), and the prediction of 
the overall secondary structure of the protein, which included a few β-strands in the C-
terminal half (e.g., residues 155-158 and 181-185), and some loops. The search for a suitable 
template to build the 3D receptor structure yielded 4 different protein sequences having both 
a considerable identity (≥ 30%) with specific portions of the ς1 sequence and an X-ray structure 
available in the Protein Data Bank (PDB entries 3CIA,1I24, 2Z2Z, and 2Q8I).  
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Figure 3.1.1 The 1 receptor and its ligand 1c. a) View of the 1 receptor MD-optimized homology model 
in complex with 1c. b) 2D schematic representation of postulated interactions between the 1 receptor 
and 1c, established by analyzing published sequence-structure relationships, mutagenesis data, 3D 
pharmacophore model requirements, and direct affinity measurements. The lines/arrows indicate 
proposed key interaction between the receptor and its ligand. The interactions essential for the binding 
of ligand 1c are 1) an hydrogen bond (HB) between the 1c piperidine –NH donor and the protein Asp126 
–COO- acceptor (1st 3D pharmacophore requirement); 2) the HB between the backbone –NH donor of 
the peptidic bond linking Thr151 and Val 152 on the receptor side and the acceptor oxygen atom of the 
benzoxazolone moiety of 1c (2nd 3D pharmacophore requirement); 3) T-stacking -- interaction 
between the protein residue Trp121 and the heteroaromatic condensed rings of 1c (3rd 3D 
pharmacophore requirement); 4) parallel-stacking -- interaction between the protein residue Tyr173 
and the benzoxazolone phenyl ring of 1c (4th 3D pharmacophore requirement); 5) highly stabilizing van 
der Waals and electrostatic interactions between Arg119 and Glu172 with the p-Cl-phenyl and the 
benzoxazolonic heterocycle of 1c, respectively; 6) general hydrophobic favorable interactions between 
the side chains of Ile128, Thr151, and Val152 with both the aliphatic and aromatic portions of the ligand. 
c) View of the final 1 receptor homology model in complex with 1c. d) Modeled complex of the 1 
receptor with 1c showing the key interactions proposed in the topographical interaction model depicted 
in part b. The main protein residues involved in these interactions are Arg119 (red), Trp121 (cyan), 
Asp126 (blue), Ile128 (forest green), Thr151 (sienna), Val152 (orange), Glu172 (yellow), and Tyr173 
(magenta). 
 
Accordingly, each corresponding receptor/template sequence was aligned, and the Cartesian 
coordinates for 1 residues in structurally conserved regions were obtained from the 
corresponding sequence in the template PDB file. The first part of the N-terminal domain of 
the protein (residues 1-16) showed no homology with any other proteins in all queried 
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databases and thus was built de novo. Finally, the overall receptor 3D structure was built 
linking the different template-based homology models and creating/optimizing the missing 
loop portions via several refinement processes. The structure was further adjusted manually to 
fully match the results of secondary structure predictions, and optimized for backbone and 
side chain conformation. This initial 3D model was then subjected to extensive molecular 
dynamics (MD) simulations in explicit solvent to reach an energetically reasonable 
conformation. The MD-refined homology model (Figure 3.1.1a), characterized by a very high 
stereochemical quality (more than 98% of residues in the favored or additional allowed regions 
of Ramachandran plot and only two residues in the disallowed region), was employed in the 
successive step. 
Step ii) required the initial identification of a putative binding site in the receptor model, based 
on preliminary information on sequence-structure relationships, mutagenesis studies,5and 
some ligand-binding pharmacophore requirements.4 In detail, a protein isoform missing 
residues 119-149 was found devoid of ligand binding capacity, and the conversion of residues 
D126 and E172 to glycine led to a several-fold reduction in ligand-binding function for the 1 
receptor.5 Moreover, a hydrophobicity analysis performed in the present study identified, 
aside for the TM regions, a third hydrophobic region matching the SBDLII region and centered 
on Asp188, a residue specifically photolabeled by [125I]IACoc (3-iodo-4-azido cocaine).7 Having 
localized this protein region as a possible zone for ligand binding, a thorough search for a 
sequence satisfying the chemical features imposed our recently developed 3D model was 
performed and successfully retrieved. Thus, compound 1c was into the 1 putative binding 
pocket. In the set of docked ligand conformations a solution was found that best reproduced 
the key interactions depicted in the derived topographical model (Figure 3.1.1b). 
Subsequently, new homology models were generated explicitly considering bound compound 
1c. The best-scored amino acids were merged in a combinatorial fashion, the resulting 
molecular complex was relaxed by energy minimization and MD simulations, and finally a 
model without unfavorable van der Waals interactions was obtained (Figure 3.1.1c). Figure 
3.1.1d shows the ligand-binding site of the resulting 1/1c complex, which convincingly 
reproduces the proposed interactions in the 2D topological model. 
In step iii), the refined 1 homology model was used for the docking of a series of bioactive 
ligands (including 1c) into the putative binding site, estimation of their binding affinity via the 
MM/PBSA methodology,6 and comparison with the available experimental activities. Table 
3.1.1 shows the results of the MM/PBSA ranking, from which the excellent agreement 
between computed and experimental affinities of these ligand series is apparent. 
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Table 3.1.1. Binding free energies Gbind (kcal/mol) for a set of 9 bioactive ligands and the 1 receptor 
homology model. Errors are given in parenthesis as standard errors of the mean. The experimental and 
calculated Ki (nM), as estimated from the corresponding Gbind values, are also reported for 
comparison. 
[a]
 Ki was calculated from Gbind according to the following relationship: Gbind = -RT lnKi. 
 
Cpd 1c 1a 1j 2a 2d 3a 
Gbind 
-12.05 
(0.37) 
-10.93 
(0.44) 
-8.38 (0.46) -8.87 (0.48) -8.22 (0.42) 
-10.53 
(0.39) 
Ki(calc.)
[a]
 1.48 9.80 730 315 945 19.1 
Ki(exp.) 0.098 358 1017 223 1147 2.60 
Cpd 3d 7a 7b FEN PTZ HALO 
Gbind 
-10.67 
(0.45) 
-10.24 
(0.39) 
-10.99 
(0.43) 
-12.44 
(0.43) 
-10.02 
(0.45) 
-10.61 
(0.42) 
Ki(calc.)
[a]
 15.3 31.4 8.70 0.77 45.5 16.8 
Ki(exp.) 7.1 22.5 12.9 0.01 15.0 5.7 
 
 
The quality of the model was further validated by probing its ability to accommodate other 
known 1 ligands belonging to structurally diverse compound classes. Thus, the strong 1 
agonist pentazocine (PTZ),8 and the two high-affinity 1 ligands fenpropimorf (FEN)
9 and 
haloperidol (HALO) were docked into the 1 binding site and scored according to the same 
protocol employed for 1c and related compounds. Importantly, the adopted binding modes of 
these three compounds (Figure 3.1.2) were also in agreement with the proposed 2D 
interaction model (Figure 3.1.1b), and the MM/PBSA was able to rank their affinity not only in 
the correct order but also with an outstanding agreement between computed and 
experimental Ki values.10 
Lastly, in step iv) all information presented above and the new 3D homology model derived in 
this work were exploited for the design of a new series of 1 ligands starting from the structure 
of the lead compound 1c. Subsequently, step iii) of the multistep procedure outline above was 
applied to predict their affinity towards the protein. According to preliminary tests performed 
in vitro, several of them showed affinity in the nanomolar range. In particular, compound EL-1 
exhibited a very promising Ki value of 1.87 nM, in utter agreement with the MM/PBSA 
predicted value of 8.40 nM. As shown in Figure 3.1.3, compound EL-1 adopted a binding mode 
within the receptor putative binding pocket which satisfies all proposed 2D/3D interaction 
model. 
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Figure 3.1.2. Structure of a) pentazocine (PTZ), b) fenprofimorf (FEN), and c) (haloperidol (HALO). 
Modeled complex of the 1 receptor with d) PTZ, e) FEN, and f) HALO, showing the key interactions 
proposed in the topographical interaction model depicted in Figure 1b. The main protein residues 
involved in these interactions are Arg119 (red), Trp121 (cyan), Asp126 (blue), Ile128 (forest green), 
Thr151 (sienna), Val152 (orange), Glu172 (yellow), and Tyr173 (magenta). c) Superposition of the 1 
receptor binding site in complex with 1c (blue) and g) PTZ (magenta), h) FEN (red), and i) HALO (cyan). 
 
Figure 3.1.3. Structure of compound EL-1 designed exploiting the 2D/3D interaction model and the 3D 
homology model of the 1 receptor developed in this work. b) Modeled complex of the 1 receptor with 
EL-1 showing the key interactions proposed in the topographical interaction model depicted in Figure 
3.1.1b. The main protein residues involved in these interactions are Arg119 (red), Trp121 (cyan), Asp126 
(blue), Ile128 (forest green), Thr151 (sienna), Val152 (orange), Glu172 (yellow), and Tyr173 (magenta). c) 
Superposition of the 1 receptor binding site in complex with 1c (blue) and EL-1 (rosy brown). 
 
In conclusion, the multistep homology modeling procedure adopted in this work produced a 
reliable 3D structure of the 1 receptor that can successfully be employed as a platform for 
structure-based drug design. Overall, this works illustrates that explicit ligand information can 
be successfully employed to finely shape, optimize, and the binding site model. This approach 
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can be especially helpful when modeling proteins with highly flexible binding sites, or targets 
that are difficult to characterize experimentally, and/or pockets with low homology to 
available template structures, as in the present case of 1 receptors. A thorough model 
validation was performed by a docking/MMPBSA-based small-scale virtual screening, and by 
the receptor model-based design of a new series of potent 1 ligands featuring activity in the 
nM range. Although medicinal chemistry is still eager to obtain new x-ray structures of protein 
targets, this study with 1 receptor demonstrates that its derived 3D homology model is 
already an excellent substrate. Given the intense ongoing efforts in designing new compounds 
as potent 1 ligands, this work is rather an encouraging account. 
Experimental section 
For the identification of the transmembrane (TM) helical domains and the prediction of the 
overall secondary structure of the 1 receptor, we employed the programs TMPRED,  
DISOPRED,  Predict Protein,  HMMTOP,  I-TASSER,  and the Secondary Structure Prediction tool 
of Discovery Studio (DS) (v. 2.1, Accelrys, San Diego, USA) in a comparative fashion. 
All programs identified the same three TM domains, spanning the protein residues 10-30, 80-
100, and 180-200, respectively. A prediction of the secondary structure of the entire protein 
was also obtained by running different programs and comparing the corresponding output for 
quality, reliability, and matching. Again, very similar results were obtained, according to which 
the 1 secondary structure should feature, aside the already described TM domains, a few β-
strands in the C-terminal half (residues 111-116, 133-135, 144-146, and 158-164), and some 
loops, as shown in Figure 3.1.4. 
 
 
Figure 3.1.4 General secondary structure prediction of the 1 receptor. The main protein structural 
motifs (-helices, -sheets, and loop/coils) are highlighted below the primary sequence as follows: 
orange/red large tubes: -helices; light blue arrows: -sheets; gray thin tubes: loops/coils. 
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Template searching, initial 1 receptor 3D model building, and preliminary model validation 
The primary sequence of the 1 receptor was obtained from SWISS-PROT database (accession 
number Q99720)11.  A comparative PSI-Blast search against the non-redundant protein 
database via the NCBI website (http://www.ncbi.nlm.nih.gov), the ExPASy Proteomic Server 
(http://expasy.org), and MODWEB (http://modbase.compbio.ucsf.edu/scgi/modweb.cgi) did 
not identify one single protein with high homology for the target receptor sequence, as 
expected. However, all these searches retrieved 4 different protein sequences having both a 
considerable identity (≥ 30%) with specific portions of the 1 sequence and an X-ray structure 
available. The sequence alignment between the receptor target sequence and the templates 
was conducted automatically by applying different scoring matrices, gap penalties, and gap 
length penalty parameters in order to achieve the highest sequence homology. In detail: i) 
cold-aminopeptidase (PDB code 3CIA)  gave 22% sequence identity (SI) and 37% sequence 
similarity (SS) between residues 432-458 and 1 residues 17-43; ii) Udp-Sulfoquinovose 
Synthase (PDB code 1I24)  featured 17% SI and 31% SS between residues 58-186 and 1 
residues 44-156; iii) for Tk-subtilisin (PDB code 2Z2Z),  366-396 residues shared 39% SI and 55% 
SS with 1 residues 157-187; and iv) pyruvate dehydrogenase kinase isoform 3 (PDB code 2Q8I)  
residues 140-178 yielded 42% SI and 55% SS with residues 188-223 of the 1 receptor (see 
Figure 3.1.5). 
Accordingly, the crystal structures of these 4 proteins were used as templates for building the 
different sections of the 1 homology structure. Each initial template-based structure was 
obtained using MODWEB, was checked using the Build Homology  Model of DS, and compared 
to the corresponding template through the Structure Comparison -> Match Maker feature of 
Chimera.  
The first part of the N-terminal domain of the protein (residues 1-16) showed no homology 
with any other protein in all queried databases; therefore, it was built de novo using the Build 
and Edit Protein modulus of DS. Finally, the overall receptor 3D structure was built linking the 
different template-based homology models and creating/optimizing the missing loop portions 
via several refinement processes. The structure was further adjusted manually to fully match 
the results of secondary structure predictions and optimized for side chain conformation. The 
stereochemistry quality of the resulting model was checked using PROCHECK12,  WHATIF13,  
and PROSA14.   
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(A) 
  
(B) 
  
(C) 
  
(D) 
Figure 3.1.5 Sequence alignment of different portions of the human 1 receptor with : (A) cold-
aminopeptidase (PDB code: 3CIA); (B) Udp-Sulfoquinovose Synthase (PDB code 1I24); (C) Tk-subtilisin 
(PDB code 2Z2Z); and (D) pyruvate dehydrogenase kinase isoform 3 (PDB code 2Q8I). 
 
The analysis of the Ramachandran plot produced by PROCHECK of the main torsional angles of 
the preliminary model revealed that a total of 95.8% of the protein residues were in the most 
favored regions of the plot, with 2.7% in additionally allowed regions, giving a total of 98.5%. 
Bond lengths and angles were all found within their normal range, and no bumps 
(corresponding to high van der Waals energies) were detected. Other stereochemical 
parameters, such as peptide planarity, bad nonbonded interactions, main-chain hydrogen 
bonding energy, and standard deviations of 1 angle (i.e., the first torsion angle of the side 
chains) were also examined and checked for validity. Accordingly, the total quality G-factor 
was – 0.27, revealing the good quality of the initial 1 model structure since reasonable values 
for the G-factor in PROCHECK fall between 0 and – 0.5, with the best models displaying values 
closest to 0. The packing quality of the 3D model was assessed for the absence of steric clashes 
between any pair of atoms. The results of the WHATIF quality report showed a normality index 
(z-score) of -1.89, a value which falls in the acceptable range for a valid structure (z-score < -
5.0). The analysis of the PROSA results revealed that, for most regions in the initial 1 model, 
the residue-residue interaction energies were all attractive, indicating no bad backbone 
contacts for the model in these regions. Lastly, the good overall quality of the model was also 
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reflected in the corresponding value of the PROSA normalized z-score = 0.92, being z-score > 
0.70 indicative of a good structure. 
 
Model refinement via molecular dynamics (MD) simulations and final model validation 
The preliminary 3D homology model of the 1 receptor was further refined and its stability 
verified via a cycle of MD simulations in water environment. All MD simulations were carried 
out using the Sander and Pmemd modules of the AMBER 11 suite of programs15.  The protein 
was solvated by a TIP3P16  box of water extending at least 10.0 Å in each direction from the 
solute; then, 79 Cl- and 73 Na+ counterions were added to ensure the overall charge neutrality 
of the system and to mimic a physiological ionic strength of 0.15 M. The energy of the resulting 
system was relaxed via a multi-step minimization procedure using the AMBER ff03 force field17,  
as follows. First, the water molecules and counterions were minimized for 5000 cycles of 
steepest-descent minimization. Next, the side chains of the 1 receptor and the solvent 
molecules were further relaxed using a 1000- cycle energy minimization to relieve possible 
unexpected side-chain clashes. Lastly, the whole system was energy relaxed for further 1000-
cycles of conjugate-gradient minimization. The system was then gradually heated to T = 300 K 
in three MD intervals , allowing a 20 ps interval per each 100 K, followed by NPT MD 
simulations at 300 K for other 60 ps with the backbone of the protein restrained with an 
harmonic potential, while all water molecules, counterions, and the protein side chains were 
allowed to move. Then, the whole system was further equilibrated in the NVT ensemble for 15 
ns at 300 K, to attain a well relaxed receptor structure and to verify the stability of the 
corresponding MD trajectory. The time step used in the MD simulation was 2 fs. The periodic 
boundary condition with Berendsen temperature coupling and P =1 atm, with isotropic 
molecule-based scaling. The SHAKE algorithm18 was used to fix all covalent bonds containing 
hydrogen atoms. Long-range nonbonded van der Waals interactions were truncated by using a 
dual cut off of 6 and 12 Å, respectively, where energies and forces due to interactions between 
6 and 12 Å were updated every 20 time steps. The particle mesh Ewald method19 was used to 
treat the long- range electrostatics. A residue-based cut off of 8 Å was used for the non-
covalent interactions. During the NVT MD simulations, the coordinates of the protein were 
saved every 1 ps.  
The 1 model structure remained stable for all 15 ns of the MD trajectory, as indicated by the 
small fluctuations of the root-mean-square (RMS) deviation of the simulated position of the 
backbone atoms with respect to those of the initial structure and the corresponding total 
potential energy of the system E shown in Figure 3.1.6. 
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Figure 3.1.6 (A) RMDS of the coordinates of the backbone atoms of the initial homology model of the 1 
receptor along the 15 ns MD simulation compared with those of the initial structure. (B) time behavior of 
the total potential energy and (C) temperature of the 1 receptor 3D model in water during the same MD 
simulation. 
 
 
 
Figure 3.1.7 Top (left) and side view (right) of the last frame extracted from the equilibrated MD 
trajectory of the 1 receptor 3D homology model in a solvated membrane environment. The protein 
secondary structure is depicted as a blue ribbon. POPC molecules are shown as atom-colored CPK 
spheres. In the right panel, a mixed representation of CPK spheres and sticks was chosen to represent the 
lipid molecules for graphical purposes. Atom color code: O, red; C, light gray; N, light blue; H, white; P, 
orange. Water molecules and ions are not shown for clarity. 
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Figure 3.1.8 Ramachandran plot generated from the MD refined 3D homology model of the 1 receptor. 
 
From the above described 15 ns equilibrated MD trajectory, the protein coordinates were 
extracted from last frame of the membrane complex (see Figure 3.1.7), and the corresponding 
3D 1 receptor model was evaluated for quality and reliability. 
By comparison with the pre-refined structure, the G-factor increased from -0.27 to -0.21, 
indicating that the MD simulations relieved some bad contacts between nonbonded atoms 
without increasing the number of bad dihedral angles of the structure. The result of the - 
combination displayed by the Ramachandran plot of the MD 1 relaxed model in Figure 3.1.8 is 
consistent with this change in G-factor, with a higher percentage of the residues in the most 
favored regions (97.9%), and a smaller number in generously allowed regions (2.1%), giving a 
total percentage of 100%. Other stereochemical parameters such as dihedral angles, covalent 
geometry, and planarity were also examined. The respective G-factors were all close to zero, 
and all values were well within the acceptable limits. Utterly analogous results were obtained 
by running MOLPROBITY20.  The packing quality of the MD relaxed model was checked by the 
atomic contact analysis of WHATIF, yielding a z-score of -0.89 which testifies the improvement 
of the model after MD relaxation. The packing quality of each protein residue was also 
evaluated by the VERIFY-3D method21:  the compatibility score above zero in the VERIFY-3D 
graph shown in Figure 3.1.9 is a song of side-chain environments and suggests that the model 
is characterized by an overall self-consistency in terms of sequence-structure compatibility. 
The enhancement of the overall 3D homology model quality was also reflected in the value of 
the corresponding PROSA normalized z-score of 0.98. Such high values of the PROSA z-score 
approach those typical of high resolution crystal structures, further supporting the fact that 
the proposed model is of very good quality in backbone conformation. 
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Figure 3.1.9 VERIFT-3D graph generated for the MD refined 3D homology model of the 1 receptor. 
 
The overall accuracy of a comparative model is related to the percentage sequence identity on 
which it is based, correlating with the relationship between the structural and sequence 
similarity of the target and template proteins. High-accuracy comparative models are based on 
more than 50% sequence identity to their templates. Medium-accuracy comparative models 
are based on 30 to 50% SI, while low-accuracy comparative models rely on less than 30% of SI. 
Nonetheless, other factors such as template selection and alignment accuracy usually have a 
large impact on the resulting final model quality, especially for models based on less than 40% 
sequence identity to the templates.  We are well aware of the fact that many methods often 
fail to correctly align protein pairs with 20-30% pairwise sequence identity, and that in the 
present work a consistent portion of the 1 receptor was modeled in this “twilight zone”.  
However, since i) it is also often possible to correctly predict features of the target protein that 
do not occur in the template structure, ii) errors in functional important regions in 
comparative models are many times relatively low because the functional regions (e.g., 
binding sites) tend to be more conserved in evolution than the rest of the fold, and iii) all 1 
ligands considered were ranked for their affinity towards the 1 receptor 3D model developed 
in this work consistently with the corresponding experimental values, we are confident that 
the proposed homology model of this important protein is characterized by an overall correct 
folding 
Assisted-ligand docking into the 1 receptor 3D homology model 
To retrieve a putative binding site in the 1 receptor model structure we exploited the 
currently available preliminary information on sequence-structure relationships and 
mutagenesis studies5, and some ligand-binding pharmacophore requirements.4  In detail, some 
experiments revealed that an alternative splice variant of the 1 receptor encoding gene 
lacking exon 3 expresses a protein that has no ability to bind ligands.5 The region deleted in the 
splice variant consists of the protein residues 119-149. Thus, the putative membrane spanning 
domain should lie upstream the region coded by exon 3 and, since the transcript of this splice 
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variant is devoid of ligand binding function, we may hypothesize that the ligand binding site 
may sensible reside in the C- terminal half of the protein. This region contains 12 anionic 
residues, among which D126 and E172 were found to be directly involved in ligand binding by 
mutagenesis studies. Moreover, a further hydrophobicity analysis performed in the present 
study using PONDR7 identified, aside the TM regions, a third hydrophobic region matching the 
SBDLII region and centered on Asp188, a residue specifically photolabeled by [125I]IACoc (3-
iodo-4-azido cocaine)22. Having localized this protein region as a possible zone for ligand 
binding, a thorough search for a sequence satisfying the chemical features imposed our 
recently developed 3D pharmacophore model was performed (see Figure 3.1.10(A)), and 
successfully retrieved. Thus, compound 1c was initially selected for docking into the putative 
1 binding site. AUTODOCK 4
23 with AUTODOCK TOOLS 1.4.6 on a win64 platform was used for 
all docking experiments. The general docking methodology was based on a consolidated 
procedure24,25; accordingly, it will be described here only briefly. The size of the binding site 
was defined via DISCOVERY STUDIO (DS) Studio (v.2.1, Accelrys Inc., San Diego, CA, USA), using 
an opening site of 10 Å and a grid size of 0.7 Å.  
 
   (A)       (B) 
Figure 3.1.10 (A) 1 receptor 3D pharmacophore mapping of compound 1c. The hypothesis features are 
portrayed as mashed spheres, color-coded as follows: red, positive ionizable; light blue, hydrophobic 
aromatic; purple, hydropbobic aliphatic, light green, hydrogen bond acceptor. The last feature is actually 
represented as a pair of spheres (the smaller sphere represents the location of the hydrogen bond 
acceptor atom on the ligand and the larger one the location of an hydrogen bond donor on the receptor). 
(B) Compound 1c docked into the putative binding pocket of the 1 3D homology model. Black lines 
denote polar interactions. The protein residues involved in these interactions are: Arg119 (red), Trp121 
(cyan;  interaction, hydrophobic aromatic from pharmacophore model), Asp126 (blue; salt bridge 
NH-piperidine/OD2Asp, positive ionizable), Ile128 (forest green), Thr151 (in sienna), Val152 (in orange) 
(H-bond O-benzoxazolone/NH-backbone-Val; hydrogen bond acceptor ), Glu172 (yellow), and Tyr173 (in 
magenta;  interaction, hydrophobic aromatic from pharmacophore model). 
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The AUTODOCK grid box dimensions, based on the identified cavity from DS, were large 
enough to cover all possible rotations of the ligand. AMBER12 and Lennard-Jones parameters 
were used in modeling van der Waals interactions and hydrogen bonding (N-H, O-H and S-H), 
respectively. In the generation of the electrostatic grid maps, the distance dependent relative 
permittivity of Mehler and Solmajer was applied26.  300 hundred Monte Carlo/Simulated 
Annealing (MC/SA) runs were performed, with 100 constant temperature cycles for simulated 
annealing. For these calculations, the GB/SA implicit water mode27 was used to mimic the 
solvated environment. The rotation of the angles  and , and the angles of side chains were 
set free during the calculations. All other parameters of the MC/SA algorithm were kept as 
default. Following the docking procedure, the structure of all compounds were subjected to 
cluster analysis with a tolerance of 1 Å for an all-atom root-mean-square (RMS) deviation from 
a lower-energy structure representing each cluster family. The resulting docked conformations 
were clustered and visualized. Interestingly, the most populated cluster was not only the one 
characterized by the lowest (i.e., more favorable) AUTODOCK energy but also the only one in 
which the 3D pharmacophore required interactions were satisfied by compound 1c, as shown 
in Figure 3.1.10(B). 
 
             
  1c   1a   1j   2a 
             
  2d   3a   3d   7a 
             
  7b   FEN   PTZ          HALO 
 
Scheme 3.1.1 Chemical structures of the 1 ligands considered for docking, scoring, and model assisted 
drug design/virtual screening. 
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The same docking procedure was then applied to the entire list of compounds shown in 
Scheme 3.1.1 (see Table 3.1.2 for IUPAC nomenclature) with a twofold purpose: i) checking the 
validity of the entire docking procedure on an extensive set of molecules (compounds 1a-7b), 
and ii) probing the ability of the 3D 1 homology model to accommodate other known 1 
ligands belonging to structurally diverse compound classes (PTZ, FEN, and HALO). 
 
Table 3.1.2 Chemical formula and IUPAC names of the compounds 
Compound Formula IUPAC name 
1c C20H21ClN2O2 3-[[1-(4-Chlorobenzyl)piperidin-4-yl]methyl]benzo[d]oxazol-2(3H )-one 
1a C20H22N2O2 3-((1-benzylpiperidin-4-yl)methyl)benzo[d]oxazol-2(3H)-one 
1j C24H24N2O2 3-((1-(naphthalen-1-ylmethyl)piperidin-4-yl)methyl)benzo[d]oxazol-2(3H)-one 
2a C18H20N2O2 3-(3-(benzyl(methyl)amino)propyl)benzo[d]oxazol-2(3H)-one 
2d C18H19ClN2O2 3-(3-((4-chlorobenzyl)(methyl)amino)propyl)benzo[d]oxazol-2(3H)-one 
3a C19H22N2O2 3-(4-(benzyl(methyl)amino)butyl)benzo[d]oxazol-2(3H)-one 
3d C19H21ClN2O2 3-(4-((4-chlorobenzyl)(methyl)amino)butyl)benzo[d]oxazol-2(3H)-one 
7a C20H24N2O N,1-dibenzylpiperidine-4-carboxamide 
7b C20H23ClN2O N-benzyl-1-(4-chlorobenzyl)piperidine-4-carboxamide 
FEN C20H33NO 4-(3-(4-tert-butylphenyl)-2-methylpropyl)-2,6-dimethylmorpholine 
PTZ C19H27NO 2-dimethylallyl-5,9-dimethyl-2'-hydroxybenzomorphan 
HALO C21H23ClFNO2 4-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one 
 
Ligand scoring by MM/PBSA 
The resulting 1/1c complex shown in Figure 3.1.10(B), and all other best receptor/ligand 
complexes resulting from the automated docking procedure were further refined in AMBER 9 
using the quenched molecular dynamics (QMD) method.28 In this case, 1 ns molecular 
dynamics (MD) simulation at 300 K were employed to sample the conformational space of 
each ligand-receptor complex in the GB/SA continuum solvation environment. The integration 
step was equal to 1 fs. After each ps, each system was cooled to 0 K, the structure was 
extensively minimized, and stored. To prevent global conformational changes of the protein, 
the backbone atoms of the protein binding site were constrained by an harmonic force 
constant of 100 kcal/Å, whereas the amino acid side chains and the ligands were allowed 
moving without any constraint. The best energy configuration of each complex resulting from 
the previous step was allowed to relax in an 80Å × 80Å × 80Å box of TIP3P water molecules. 
The resulting systems were minimized with a gradual decrease in the position restraints of the 
protein atoms. Finally, to achieve electroneutrality, a suitable number of counterions 
neutralizing ions were added; further, the solution ionic strength was adjusted to the 
physiological value of 0.15 M by adding the required amounts of Na+ and Cl- ions. After energy 
minimization of the added ions for 1500 steps, keeping the protein, the ligand, and the pre-
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existing waters rigid, followed by an MD equilibration of the entire water/ion box with fixed 
solute for 5 ns, further unfavorable interactions within the structures were relieved by 
progressively smaller positional restraints on the solute (from 25 to 0 kcal/(mol Å2) for a total 
of 10 ns. Each hydrated complex system was gradually heated to 300 K in three intervals, 
allowing a 2 ns interval per each 100 K, and then equilibrated for 5 ns at 300 K, followed by 20 
ns of data collection runs, necessary for the estimation of the free energy of binding. 
For the calculation of the binding free energy between 1 and each ligand in water, a total of 
20000 snapshots were saved during the MD data collection period described above. 
The binding free energy Gbind of each 1 receptor/ligand complex in water was calculated 
according to a validated computational recipe28, based on the so-called Molecular 
Mechanic/Poisson-Boltzmann Surface Area (MM/PBSA) ansatz, and originally proposed by 
Srinivasan et al.6 For any details see the chapter Materials&methods.  
As discussed in the main text, by applying the MM/PBSA procedure described above we were 
able to correctly rank not only the series of compounds 1c-7b, but also the three structurally 
diverse 1 ligands (FEN, PTZ, and HALO); for all these molecules, an excellent agreement (R
2 = 
0.93) between computed and experimental affinities of these ligand series was indeed 
obtained, as can be inferred from the scatter plot shown in Figure 3.1.11 (see also Table 3.1.1). 
 
Figure 3.1.11 Linear correlation obtained between the calculated 1 receptor-ligand Ki values and the 
corresponding experimental Ki values (correlation coefficient R
2
 = 0.93) for 12 complexes. 
 
Model-assisted drug design/virtual screening 
The new 3D homology model of the 1 receptor was then exploited for the design of three 
new 1 ligands EL-1, EL-2, and EL-3 (Scheme 3.1.2), starting from the structure of the lead 
compound 1c. In details, the chemical structures of these molecules were designed according 
to the following rationale: compound EL-1 was conceived as the non-cyclic analogous of 1c; 
indeed, the benzaoxazolone moiety was replaced by a N-benzylacetamide group featuring an 
oxygen atom capable to fit the hydrogen bond acceptor feature (see Figure 3.1.3). The N-4-
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chlorobenzylpiperidine portion, essential for protein binding, was retained. Therefore, this 
compound was predicted to be a high affinity 1 ligand. On the other hand, compound EL-2 
was designed for a moderate affinity toward the receptor. In fact, despite the structure 
possesses all the necessary chemical requisites to satisfy the features of our models, its 
piperidin-1-yl-phenylmethanone scaffold yields an element of structural rigidity which, in turn, 
lowers the ability of the derivative to adopt the best conformational fitting in the binding site. 
In order to obtain a low affinity ligand, we further synthetized compound EL-3. The low 
conformational freedom of this molecule (as for EL-2), which hampers a complete fitting of the 
chemical features onto the pharmacophoric maps, and the replacement of the 4-chlorophenyl 
group with a piperidine ring, resulting in its inappropriate placement in a highly hydrophobic 
region of the receptor, concur to the quite modest affinity of this compound towards the 
protein. The steps outline above were then repeated to predict the affinity of this small new 
molecular set towards the protein. 
 
   
EL-1      EL-2 
 
       EL-3 
 
Scheme 3.1.2 Chemical structures of the new 1 ligands design to test the validity of the docking, 
scoring, and model assisted drug design/virtual screening. 
 
 
3.1.2 EXTENSIVE VALIDATION OF THE MODEL FOR 1 RECEPTOR
29 
In this work we present a further, extensive validation of the predictive capability of our 1 3D 
model in computer-assisted drug design. In brief, exploiting our 3D pharmacophore model, 
previously described, for 1 ligands we designed 33 new 1 ligands, with affinity for the 
receptor spanning 5 orders of magnitude. All these compounds were then docked – using a 
pharmacophore-guided procedure – into the putative binding site of our 1 3D receptor model 
1and ranked for affinity by extensive molecular dynamics simulation based free energy 
calculations. The binding modes of all compounds and the key receptor residues involved in 
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each ligand binding were further assessed by applying two further computational techniques: 
a per residue free energy deconvolution and in silico alanine scanning. Subsequently, all 33 
compounds were synthesized in our laboratory and then tested for 1 binding activity in vitro. 
 
3D pharmacophore-based design of new 1 ligands. 
The initial step in the present computer-assisted drug design recipe consisted in exploiting our 
previously developed 3D pharmacophore model for the in silico design of new 1 ligands. 
Recalling that the two major purposes of the present work were i) the ultimate validation of 
the 3D homology model of the 1 protein and its reliability in assisting 1 ligands computer-
based design, and ii) the formulation of a molecular-base rationale for the receptor affinity of 
the ligands, we took advantage of the validated 3D pharmacophore model and, starting from 
compounds 1e and 2c29 (Scheme Figure 3.1.3, top panels), we designed two new molecular 
series 1(a-r) and 2(a-l) (Scheme 3.1.3, bottom panels) with 1 receptor affinity 1Ki ranging 
from sub-nanomolar to micromolar values, as shown in Table 3.1.3. 
 
 
   
         
1e       2c 
   
         
1(a-r)       2(a-l) 
Scheme 3.1.3 (Top) Chemical structure of compounds 1e and 2c. (Bottom) Molecular structures of 
compounds of series 1 and 2. 
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Table 3.1.3 3D Pharmacophore Predicted 1 Receptor Affinities 1Ki,(3DPh) of Compounds 1a-r and 2a-l. 
cmpd Ary R
1
 1Ki,3DPh (nM) cmpd Ary R
1
 R
2
 1Ki,3DPh (nM) 
1a phenyl H 228 1p pyridin-2-il Bz - 810 
1b 4-chlorophenyl H 32.5 1q pyridin-3-il Bz - 1961 
1c 4-methylphenyl H 116 1r pyridin-4-il Bz - 785 
1d phenyl CH3 27.0 2a phenyl H CH3 24.1 
1e 4-chlorophenyl CH3 66.7 2b phenyl H phenyl 75.2 
1f 4-methylphenyl CH3 43.7 2c phenyl Cl CH3 1.04 
1g phenyl Bz 32 2d phenyl Cl phenyl 9.7 
1h 4-chlorophenyl Bz 83 2e 4-chlorophenyl H CH3 0.26 
1i 4-methylphenyl Bz 462 2f 4-chlorophenyl H phenyl 37.1 
1j pyridin-2-il H 520 2g 4-chlorophenyl Cl CH3 20.4 
1k pyridin-3-il H 4433 2h 4-chlorophenyl Cl phenyl 25.7 
1l pyridin-4-il H 1148 2i 4-methylphenyl H CH3 6.8 
1m pyridin-2-il CH3 1186 2j 4-methylphenyl H phenyl 319 
1n pyridin-3-il CH3 2683 2k 4-methylphenyl Cl CH3 86.5 
1o pyridin-4-il CH3 3731 2l 4-methylphenyl Cl phenyl 86.6 
 
As can be seen from this Table, both series of compounds are indeed characterized by a broad 
range (5 decades) of predicted 1Ki values; also, quite interestingly, compounds belonging to 
series 1 are generally endowed with a lower affinity towards the 1 receptor than the series 2-
based counterparts. This aspect can be easily explained by comparing, for instance, the 
mapping of two of the most active compounds of both series – i.e., 1f (1Ki,3DPh = 43.7 nM) 
and 2d (1Ki,3DPh = 09.7 nM), respectively – on the corresponding 3D pharmacophore 
features, as shown in Figure 3.1.12. 
 
 
 
 
 
A)                                                                                           B) 
Figure 3.1.12 Pharmacophore mapping of 2d (A) and 1f (B). The 3D pharmacophore hypothesis features 
are portrayed as meshed spheres, color-coded as follows: red, PI; light blue, HYAr; pink, HY; light green, 
HBA. 
 
It might be apt to recall here that the best 3D pharmacophore hypothesis for our 1 ligands 
was characterized by the following five chemical features: one positive ionizable (PI) site, one 
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hydrogen bond acceptor (HBA) group, two hydrophobic aromatic (HYAr) moieties, and one 
further hydrophobic (HY) site. Thus, when superposed on the pharmacophore model, 
compound 2d maps all the chemical features with perfect overlap (Figure 3.1.12(A)): the 
phenyl ring match the aromatic hydrophobic function, the chlorine atom fills the hydrophobic 
group of the model, the basic nitrogen atom has the function of proton acceptor, while the 
carbonyl group matches the hydrogen bond feature. On the other hand, the chemical groups 
present on compound 1f, although suitable to fulfill all chemical requirements of the 3D 
pharmacophore, cannot be perfectly superposed to the corresponding pharmacophore 
features due to a different molecular conformation and steric rigidity characterizing this 
molecule (Figure 3.1.12(B)). 
 
Assisted-ligand docking into the 1 receptor 3d homology model 
Following our pioneer work, the putative binding site and binding modes of all compounds 
from both series 1 and 2 in the 1 receptor 3D homology model structure were retrieved 
exploiting the currently available preliminary information on sequence-structure relationships 
and mutagenesis studies, the ligand-binding pharmacophore requirements, and the docking 
poses and receptor affinity ranking of compounds 1e and 2c.5 Thus, all compounds 1a-r and 2a-
l were docked into the putative binding site of receptor 3D model. In the set of docked ligand 
conformations, for each compound a solution was found that best reproduced the key 3D 
pharmacophore requirements (see Figure 3.1.13). Each resulting receptor/drug complex was 
then relaxed by energy minimization and molecular dynamics (MD) simulations and, finally, 
the relevant values of the free energy of binding - Gbind - between all compounds of series 1 
and 2 and the 1 receptor were evaluated by applying the well-known Molecular 
Mechanics/Poisson-Boltzmann Surface Area (MM/PBSA) computational ansatz7,30 as listed in 
Table 3.1.4. 
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(A)        (B) 
 
 
(C)        (D) 
 
 
(E)        (F) 
Figure 3.1.13 (A, C, and E) Zoomed view of the 3D pharmacophore-assisted identification of the binding 
modes of 2e, 1g, and 1j in the putative binding site of the 1 receptor. The main protein residues involved 
in ligand/receptor interactions are Arg119 (red), Tyr120 (aquamarine), Trp121 (cyan), Asp126 (blue), 
Ile128 (forest green), Thr151 (sienna), Val152 (gold), Val 171 (orange), Glu172 (yellow), Tyr173 
(magenta), Ile178 (khaki), Leu182 (light green), and Leu186 (coral). (B, D, and F) Details of the key 
interactions detected in the equilibrated MD snapshots of 2e, 1g, and 1j in complex with the 1 receptor 
3D homology model. In the left panels, compounds 2e, 1g and 1j are shown in atom-colored sticks: C, 
gray; O, red; N, blue, Cl, green, H, white. The 3D pharmacophore features are shown as in Figure 2. In the 
right panels, the same compounds are portrayed as atom-colored sticks-and-balls; in this case, H atoms 
are not shown but H-bonds and salt bridges are indicated as black dotted and continuous lines, 
respectively. In all images, water molecules, ions and counterions are not shown for clarity. 
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Table 3.1.4 Enthalpy (H), entropy (-TS), free energy of binding (Gbind), and corresponding 
1Ki,Gbind values for compounds 1a-r and 2a-l and the 1 receptor homology model, as estimated 
using the MM/PBSA approach. The values of two 1 ligand reference compounds, (+)pentazocine (PTZ) 
and haloperidol (HAL) are also reported for comparison. Errors are given in parenthesis as standard 
errors of the mean (SEM). 
cmpd 
H 
(kcal/mol) 
-TS 
(kcal/mol K)  
Gbind 
(kcal/mol) 
1Ki,G
bind 
(nM) 
cmpd 
H 
(kcal/mol) 
-TS 
(kcal/molK) 
Gbind 
(kcal/mol) 
1Ki,G
bind 
(nM)
1a -36.29 (0.19) -26.36 (0.34) -9.93 (0.39) 53.0 1p 
-31.89 
(0.16) 
-23.03 (0.37) -8.86 (0.40) 322 
1b -34.39 (0.21) -23.87 (0.32) 
-10.52 
(0.38) 
19.6 1q 
-30.92 
(0.18) 
-23.67 (0.34) -7.25 (0.38) 4870 
1c -36.18 (0.17) -25.75 (0.31) 
-10.43 
(0.35) 
22.8 1r 
-29.97 
(0.20) 
-22.11 (0.33) -7.86 (0.39) 1740 
1d -35.02 (0.18) -24.62 (0.35) 
-10.40 
(0.39) 
24.0 2a 
-38.31 
(0.20) 
-25.81 (0.35) -12.50 (0.40) 0.69 
1e -37.90 (0.18) -26.71 (0.30) 
-10.02 
(0.35) 
6.32 2b 
-39.01 
(0.15) 
-26.19 (0.36) -12.82 (0.39) 0.40 
1f -36.21 (0.20) -25.09 (0.31) 
-11.12 
(0.37) 
7.12 2c 
-38.81 
(0.19) 
-25.54 (0.33) -11.31 (0.38) 0.19 
1g -33.19 (0.16) -23.24 (0.35) -9.95 (0.38) 51.2 2d 
-38.39 
(0.19) 
-24.91 (0.33) -13.48 (0.38) 0.13 
1h -32.60 (0.20) -23.39 (0.36) -9.21 (0.41) 178 2e 
-40.83 
(0.21) 
-25.71 (0.30) -15.12 (0.37) 0.01 
1i -33.38 (0.19) -24.37 (0.33) -9.01 (0.38) 250 2f 
-37.76 
(0.17) 
-25.97 (0.35) -11.79 (0.39) 2.30 
1j -30.33 (0.18) -24.49 (0.35) -5.84 (0.39) 52600 2g 
-38.33 
(0.19) 
-26.38 (0.34) -11.95 (0.39) 1.75 
1k -29.89 (0.21) -23.02 (0.31) -6.87 (0.37) 9250 2h 
-37.04 
(0.18) 
-25.11 (0.36) -11.93 (0.40) 1.81 
1l -30.69 (0.17) -22.43 (0.36) -8.26 (0.40) 880 2i 
-38.61 
(0.19) 
-26.09 (0.35) -12.52 (0.40) 0.67 
1m -29.88 (0.21) -23.35 (0.31) -6.53 (0.37) 16400 2j 
-33.95 
(0.18) 
-24.35 (0.32) -9.60 (0.37) 92.5 
1n -29.24 (0.18) -22.65 (0.32) -7.75 (0.37) 14800 2k 
-34.61 
(0.19) 
-25.03 (0.31) -9.58 (0.36) 95.6 
1o -28.87 (0.22) -22.27 (0.32) -6.60 (0.39) 14600 2l 
-34.49 
(0.21) 
-24.62 (0.35) -9.87 (0.41) 58.6 
PTZ -27.56 (0.22) -17.54 (0.39) 
-10.02 
(0.45) 
45.5 HAL 
-35.17 
(0.19 
-24.56 (0.38) -10.61 (0.42) 16.8 
 
Figure 3.1.13 shows three MD snapshots extracted from the corresponding equilibrated 
trajectories of 2e, 1g, and 1j in complex with the 1 receptor, as an example. In particular, the 
left-hand panels in Figure 3.1.13 clearly indicate that the predicted binding mode for each of 
these compounds satisfies the 3D pharmacophore requirements. Among both series, 2e is the 
molecule characterized by the highest MM/PBSA predicted affinity toward the 1 receptor, 
1Ki,Gbind = 0.01 nM (see Table 3.1.4), in agreement with the corresponding estimation 
from the 3D pharmacophore model (1Ki,3DPh = 0.26 nM, Table 3.1.3). From the right panel of 
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Figure 3.1.13 it is instructive to observe how, for 2e, an hydrogen bond (HB) is established 
between the carbonyl oxygen of the ligand and the side-chain –OH group of Thr151 on the 
receptor. This HB, which persists throughout the entire MD simulation period, is characterized 
by an average dynamic length (ADL) of 1.82 ± 0.21 Å, yield a substantial contribution to 
binding. A permanent salt bridge (SB, ADL = 3.81 ± 0.10 Å) is detected between the –COO- 
group of Asp126 on the receptor side and the piperidine –NH+ moiety of the 2e ligand. The 4-
Cl-phenyl group of the compound is encased in a hydrophobic pocket, mainly lined by the side 
chains of Val171 and Ile128. An outer hydrophobic region accommodates the second phenyl 
ring of 2e, with the contribution of residues Leu182, Ile178 and Tyr120. Also, this phenyl ring is 
further engaged in a parallel  stacking interaction with Tyr120. The synergistic effect of all 
these stabilizing interactions ultimately reflects in the highly negative (i.e., favorable) value of 
Gbind (-15.12 kcal/mol, Table 3.1.4) between 2e and the 1 protein and, hence, of the 
predicted sub-nanomolar value of the corresponding 1Ki,Gbind. 
For compound 1g, MM/PBSA calculations yield an intermediate affinity for the 1 receptor - 
1Ki,Gbind = 51.2 nM (see Table 3.1.4) – a value quite close to that predicted by the 3D 
pharmacophore model (1Ki3DPh = 32 nM, Table 3.1.3). Panels (C) and (D) in Figure 3.1.13 
illustrate how the stable hydrogen bond and the salt bridge outlined for 2e are still present, 
although the hydrogen donor on the receptor side in this case is the –NH group of the 
backbone peptide bond between Thr151 and Val152. Both these interactions, however, are 
somewhat weaker than for 2e, as the corresponding ADL are 2.09 ± 0.12 Å (HB) and 4.53 ± 0.18 
Å (SB), respectively. The hydrophobic pockets again enwrap two of the aromatic rings, residue 
Trp121 playing a role in determining a T-stacked  interaction with one of the two aryl 
groups. However, the conformation of the molecule is such that last phenyl ring is not mapped 
by any suitable pharmacophore feature of 1g (Figure 3.1.13(C)); correspondingly, this 
interaction is lost within the receptor binding site (Figure 3.1.13(D)). In line with this analysis, 
the presence of these less effective, albeit still favorable interactions, reflect in the higher (less 
negative) value of the estimated free energy of binding (Gbind = -9.95 kcal/mol, Table 3.1.4). 
According to both 3D pharmacophore modeling and MM/PBSA simulations, compound 1j is 
endowed with the lowest affinity towards the 1 receptor, with Ki value of 1Ki3DPh = 520 nM 
and 1Ki,Gbind = 52600 nM, respectively. In this case, the role exerted by Tyr120 and Thr151 
in binding 1j is negligible, while the two hydrophobic pockets described above are still able to 
accommodate the two aromatic moieties of this compound. More importantly, the carbonyl 
group is positioned far too distant from any possible proton donor group on the receptor to 
set up any stabilizing HB bond. In agreement with these considerations, a very low activity is 
predicted for this compound, with a corresponding Gbind value of -5.84 kcal/mol. 
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Generally speaking, according to the MM/PBSA analysis the binding affinity of the two series of 
compounds 1 and 2 towards the 1 receptor is an enthalpy-driven process: panel (A) in Figure 
3.1.14 indeed shows that for both molecular sets the entropic contribution TS to Gbind – 
unfavorable to ligand binding – is overwhelmed by the favorable enthalpic component H, 
resulting in an overall negative value of the free energy of binding Gbind. It is also interesting 
to note that the higher MM/PBSA average 1 affinity value predicted for all compounds of 
series 2 originates solely from the difference in the enthalpic contributions between the two 
molecular sets (H = H(2) –H(1) = -4.91 kcal/mol), as the corresponding difference in the 
entropic terms is significantly smaller (TS = TS(2) – TS(1) = 1.56 kcal/mol). 
The calculated binding free energy values are encouraging also in the light of the balance of 
the energy terms contributing to them. In more detail, as observed in many other 
drug/receptor complex simulations including our own studies,31 the favorable contribution of 
the electrostatic interactions between the 1 protein and both series of compounds 1 and 2 
(Eele), is more than compensated by the electrostatic desolvation free energy upon 
complexation (GPB), so that the total electrostatic term contributes unfavorably to the 
binding (see Figure 3.1.14(B)). Interestingly, several recent papers have demonstrated that 
(natural) receptor-ligand pairs often show suboptimal electrostatic interactions that may be 
optimized, leading to increased affinity.32-35 On the contrary, van der Waals interactions 
(EvdW) contribute favorably to the binding affinity of the receptor, as does the nonpolar part 
of the solvation free energy, again in agreement with other studies mentioned above30,31,36 
(Figure 3.1.14(B)). Therefore, for both 1 and 2 molecular series, the favorable binding free 
energy for receptor/ligand complex formation stems predominantly from the nonpolar terms 
(EvdW + Gnp), while the polar interactions provide most of all the directional constraint for 
the complexation, that is, the relative positions of the molecules. 
The analysis of the entire MD simulation trajectories for all 33 compounds in complex with the 
1 receptor 3D model further reveals that the overall conformation of the protein backbone 
undergoes only minima global conformational changes upon complex formation with the 
different compounds, while a rearrangement of the side chains of several residues lining the 
receptor binding site is required for ligand binding. This is revealed by the superposition of the 
average structures of all trajectories with their respective starting structures. 
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(A)      (B) 
 
(C) 
Figure 3.1.14. (A) Average MM/PBSA values of the enthalpy (H), entropy (TS), and free energy of 
binding (Gbind) for compound series 1 and 2 in complex with the 1 receptor. (B) Average values of the 
enthalpic components of Gbind (van der Waals term Evdw, electrostatic term Eele, polar solvation 
term GPB, and nonpolar solvation term Gnp) for compound series 1 and 2 in complex with the 1 
receptor. (C) Correlation between the 1 affinity constant Ki values for compounds 1a-r and 2a-l 
estimated using the 3D pharmacophore model (1Ki,3DPh) and the MM/PBSA methodology 
(1Ki,Gbind). 
 
In its uncomplexed form, the 1 model structure remained stable for the entire 10 ns MD 
trajectory, as revealed by the small fluctuations of the root-mean-square (RMS) deviation of 
the simulated position of the backbone atoms with respect to those of the initial structure and 
the corresponding total potential energy of the system. The same parameters showed very low 
fluctuations during both MD equilibration and data harvesting steps also in the cases of all 
receptor/ligand complexes, indicating that the presence of a bound ligand does not result in 
large protein structural deviations. The first part of Table 3.1.5 reports the average RMS 
deviations of the binding site region of the 1 receptor (i.e., from residue 100 to residue 200) 
determined between average structures of the proteins in the unbound and bound states for 
2e, 1g, and 1j as an example: this region deviates by very small amounts, confirming that the 
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1 binding pocket does not experience a significantly larger-than-average conformational 
change upon complex formations with ligands 1 and 2. 
Table 3.1.5 Average root-mean-square deviations (RMSDs) of the binding site of the 1 protein in 
complex with 2e, 1g, and 1j with respect to the unbound protein and to each alternative complex. All 
values are reported in Å. 
 
2e 1g 1j 
1(bound/unbound) 0.9 1.6 2.1 
 2e/1g 2e/1j 1g/1j 
 2.5 4.2 3.5 
 
This can be further visually inspected and quantified considering the superposition of 
equilibrated snapshots extracted from the MD trajectory of the receptor in complex with 
compounds 2e, 1g, and 1j reported in Figure 3.1.15 and the relevant RMSDs values listed in the 
second part of Table 3.1.5. These evidences allows us to conclude that the present binding site 
of the 1 receptor is able to accommodate all ligands of series 1 and 2 with no major 
conformational readjustments, the difference in affinity towards the different compounds 
being ascribable to a better/worse re-arrangement of the binding pocket residue side chains. 
 
 
(A)  
(B)  
(C)  
(D)  
(E)  
(F)  
(A)       (B)    (C) 
Figure 3.1.15 Superposition of equilibrated MD snapshots of the 1 receptor in complex with (A) 2e (blue) 
and 1g (green), (B) 2e (blue) and 1j (red), and (C) 1g (green) and 1j (red). The images are zoomed views 
of the receptor binding site. The ligands are portrayed in sticks-and-ball colored according to the protein 
in the corresponding complex. Water, ions and counterions are not shown for clarity. 
 
In concluding this section, it is interesting to observe that the affinity values of all 33 
compounds towards the 1 receptor as ranked by the 3D pharmacophore model are in good 
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agreement with the corresponding values obtained from the MM/PBSA scoring, with a 
correlation coefficient of R2 = 0.84, as shown in Figure 3.1.14(C). The great quality of the 
overall linear correlation between these two Ki data sets undoubtedly constitutes the first step 
toward the definitive validation of the 1 3D homology model and the location of its putative 
binding site. 
 
Residue-based description of ligand binding to 1: per residue binding free energy 
decomposition and computational alanine scanning 
Per residue binding free energy decomposition 
Insight into the origin of binding of 1 to compounds 1 and 2 at an atomistic level may be 
obtained by decomposing the total free energy of binding Gbind in terms of contributions 
from structural subunits of both binding partners. A non-perturbing alternative approach 
related to MM-PBSA, where the electrostatic contribution to the solvation free energy is 
determined using a generalized Born model and, hence, known as Molecular 
Mechanics/Generalized Born Surface Area (MM/GBSA),36 is an attractive variant to MM/PBSA 
in that the GB model is much faster than the PB approach and allows the decomposition of the 
electrostatic solvation free energy into atomic contributions in a straightforward manner. This, 
in turn, allows an easy and rapid per residue binding free energy decomposition (PRBFED), 
yielding the residue-based HGB values required for the detailed study of the ligand/protein 
interactions at each single amino acid level, including the backbone atoms. Therefore, we 
proceeded in our analysis of the binding modes of compound series 1 and 2 to the 1 receptor 
by applying PRBFED to the analysis of some residues that , as qualitatively discussed above 
(Figure 3.1.13), are predicted to be important for the binding of these ligand to the protein. 
Figure 3.1.16 illustrates the results of the PRBFED analysis obtained for compounds 2e, 1g, and 
1j, again taken as proof-of-concept as they constitute an example of high affinity (2e), 
intermediate affinity (1g), and very low affinity (1j) receptor ligands. As can be seen from this 
Figure, in all cases three clusters of residues (I, II, and III) are found, centered around Glu123, 
Thr151, and Val177. In the case of 2e (Figure 3.1.16(A)), according to analysis of the 
corresponding MD trajectory (Figure 3.1.13(A) and (B)) the side chain of Asp126 is engaged in a 
fundamental salt bridge with the piperidine –NH+ moiety of the compound; indeed, this 
residue is responsible for the -2.54 kcal/mol favorable contribution to binding, mostly provided 
by stabilizing electrostatic interactions. The stabile hydrogen bond detected between the –CO 
group of 2e and the side chain –OH group of Thr151 is responsible for the favorable -1.31 
kcal/mol contribution provided by the electrostatic interactions.  
 
 
95 
 
The PRBFED approach then confirms that residues belonging to the two major clusters yield 
the required van der Waals and hydrophobic interactions to favorably encase the aromatic 
portions of the ligand: e.g., Arg119 (-1.58 kcal/mol), Tyr120 (-2.16 (kcal/mol), Trp121 (-1.76 
kcal/mol), and Ile128 (-3.15 kcal/mol) of cluster I, and Glu172 (-1.73 kcal/mol)), Tyr 173 (-
1.91kcal/mol), and Leu182 (-1.04 kcal/mol) of cluster II, respectively. 
 
(A)       (B) 
 
 
 
 
(C) 
 
 
Figure 3.1.16 Per residue binding free energy decomposition for 1 in complex with 2e (A), 1g (B), and 1j 
(C). Only 1 amino acids from position 100 to 200 are shown, as for all the remaining protein residues the 
contribution to ligand binding is irrelevant. 
Panel (B) in Figure 6 illustrates the PRBFED results for compound 1g. The presence of weaker (i.e., longer) 
salt bridge and hydrogen bond interactions detected along the 1g/1 MD trajectory (Figure 3(C) and (D)) 
is confirmed by the lower HGB values of the corresponding residues: -1.91 kcal/mol (SB) for Asp126 and 
-1.07 kcal/mol (HB) for Val152, respectively. The minor entity of the contributions to binding from 
residues belonging to clusters I and II (120-128 and 171-182) support the evidence that part of the 
hydrophobic and van der Waals interactions are lost in this ligand/protein complex. Of note, the 
proposed T-stacked  interaction of Trp121 with one of the two aryl groups of 1g is captured by the 
PRBFED analysis, according to which the contribution afforded by this residue to binding is equal to -1.08 
kcal/mol. 
According to our predictions, compound 1j is the ligand characterized by the lowest affinity for 
1 in both series 1 and 2. The PRBFED results shown in panel (C) of Figure 3.1.16 clearly justify 
these calculations. While the presence of a salt bridge between the –NH+ moiety of 1j and the 
–COO- of Asp126 is preserved, which provides a favorable contribution of -1.61 kcal/mol, the 
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absence of any H-bond made by the –CO group of 1j with possible acceptor groups on the 
receptor is responsible for the small contributions of residues from cluster II (e.g., Thr151, -
0.81 kcal/mol). Some residues of clusters I and II are still able to provide some favorable 
contribution to the binding, although the reorientation of Glu172 upon binding 1j is in part 
responsible for the +1.41 kcal/mol unfavorable dispersion/electrostatic contribution to the 
binding made by this side chain. 
To gain additional insights into the contributions to the binding free energy change, Figure 
3.1.17 depicts the decomposition of HGB values on a per residue basis into contributions 
from the nonpolar terms (i.e., the van der Waals energy EvdW and the nonpolar term of the 
solvation free energy Gnp) and the sum of the Coulombic interaction and the polar solvation 
free energy (Eele + GGB) for residues with HGB ≥ 1 kcal/mol for the three 1 complexes 
discussed above. The sum of electrostatic interactions in the gas phase plus the change of the 
polar part of the solvation free energy is shown instead of the separate contributions, since, in 
most of the cases, the numbers are strongly anti-correlated. 
 
 
 
 
 
 
(A)      (B) 
 
 
 
 
 
 
 
(C) 
Figure 3.1.17 Decomposition of GGB on a per residue basis into contribution of the nonpolar (EvdW + 
Gnp) and polar (Eele + Gnp) terms for residues of 1 in complex with 2e (A), 1g (B), and 1j (C) for 
which HGB ≥ 1 kcal/mol. 
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Qualitatively, major differences are obvious between residues located in the binding site in the 
case of high, intermediate, and low affinity ligands, respectively. For compound 2e 
(1Ki,Gbind = 0.01 nM), stabilizing van der Waals and nonpolar interactions, reinforced by 
favorable overall electrostatic/desolvation terms, prevail for almost all residues lining the 1 
binding pocket (Figure 3.1.17(A)). Interestingly, the overall stabilization of the salt bridge of 2e 
with Asp126 (GGB = -2.54 kcal/mol, see PRBFED analysis) is almost equivalently contributed 
by the dispersive (EvdW + Gnp = -1.37 kcal/mol) and electrostatic (Eele + GGB = -1.17 
kcal/mol) components, while the pharmacophoric H-bond involving the side chain of Thr151 
(GGB = -1.31 kcal/mol) mainly gains from a favorable electrostatic interaction (Eele + GGB 
= -1.12 kcal/mol while EvdW + Gnp = -0.19 kcal/mol). Figure 3.1.17(A) also confirm the 
dominant role played by the hydrophobic (i.e., overall nonpolar) interactions in binding of 2e 
to 1, well exemplified by the values of EvdW + Gnp for residues Arg119 (-1.38 kcal/mol, 
HGB = -1.58 kcal/mol), Tyr120 (-1.98 kcal/mol, HGB = -2.16 kcal/mol), Trp121 (-1.52 
kcal/mol, HGB = -1.76 kcal/mol), Ile128 (-2.83 kcal/mol, HGB = -3.15 kcal/mol), Glu172 (-
1.67 kcal/mol, HGB = -1.73 kcal/mol), Tyr 173 (-2.31 kcal/mol, HGB = -1.91 kcal/mol), and 
Leu182 (-1.15 kcal/mol, HGB = -1.04 kcal/mol). 
In the case of compound 1g (1Ki,Gbind = 51.2 nM), the dispersive forces benefit by a lower 
synergistic interaction with the polar terms of HGB with respect to the case of 2e (Figure 
3.1.17(B)). Notably, while the salt bridge between 1g and Asp126, although increased in length 
and, thus, decreased in strength (HGB = -1.91 kcal/mol) shows a relative contribution from 
the different HGB components which parallels that discussed for 2e, (i.e., EvdW + Gnp 
amounts to approximately 74% of the total HGB), the other, distinctive pharmacophoric 
element (i.e., H-bond with Val152) is not only weaker but features contributions from the two 
main HGB components in reverse trend with respect to 2e (EvdW + Gnp = -1.26 kcal/mol 
and Eele + GGB = -0.20 kcal/mol, respectively). Of importance is the quantification of the 
 stacking interaction between one aromatic moiety of 1g and the side chain of Trp121 
(HGB = -1.08 kcal/mol), for which the dispersive and the electrostatic interactions show 
strong contributions of opposite sign (EvdW + Gnp = -3.24 kcal/mol and Eele + GGB = 
+2.16 kcal/mol, respectively). 
Lastly, for compound 1j (1Ki,Gbind = 52600 nM) not only the number of useful contacts 
with the amino acids belonging to the putative 1 binding site, but also the overall intensities 
of the interactions between these residues and the ligand are highly decreased with respect to 
the two compounds discussed above. Also, at some specific positions already highlighted 
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during PRFEBD analysis (e.g., Trp121 and Glu172), a gain in favorable van der Waals 
interactions and the nonpolar part of solvation free energy is overcompensated by unfavorable 
contributions from the Eele + GGB components of HGB. 
 
Computational alanine scanning 
The MD simulations performed in the MM/PBSA framework of theory can be further exploited 
to perform the so-called computational alanine scanning (CAS)37,38, in which the absolute 
binding free energy is calculated for the wild type protein, as well as for several mutants in 
which one residue has been replaced by an alanine. Aside yielding complementary information 
to those obtained from a PRBFED analysis, the difference in the binding free energy of the wild 
type and of the mutants estimated by CAS may be compared directly to the results of an 
experimental alanine scanning (ASM) mutagenesis. Undoubtedly, in the CAS approach it is 
questionable whether simply modifying a given side chain to alanine in the corresponding MD 
simulation trajectory of the wild type system can lead to a good representation of the 
conformational space of the mutant, since no eventual conformation induced by the mutation 
is investigated. However, it is also questionable how the binding free energy contribution of a 
given side chain in the wild type complexation may be always representative of the change in 
the binding free energy upon mutation, since the conformational modifications induced by the 
mutations are not included in the model either. Also, on the contrary to the total free energy, 
the free energy components are not state functions, and the values of these contributions are 
thus dependent on the decomposition scheme adopted. Obviously, both CAS and the PRBFED 
methods cannot be expected to provide results exactly comparable to experimental values 
obtained from an experimental ASM; nonetheless, the application of both methodologies can 
give a good, preliminary indication of which protein residues play a key role in ligand binding, 
ultimately enabling the biochemist to avoid trial-and-error tests and perform targeted ASM 
experiments with the obvious advantages of cost and time saving. 
The CAS was applied to the entire set of molecules belonging to both classes 1 and 2; for the 
sake of brevity and in keeping with the previous discussion, Table 3.1.6 gives the results for the 
CAS for compounds 2e, 1g, and 1j. Note that, according to the definition adopted in this work, 
a negative value of Gbind value corresponds to a residue for which the wild type (wt) side 
chain is more favorable to the binding than an alanine side chain. As a first, important 
observation, from the values listed in Table 3.1.6 the pivotal role exerted by Asp 126 in ligand 
binding is clearly highlighted by the highly unfavorable free energy of binding of the Ala126 
mutant with respect to the wt protein. Also, Tyr173 is confirmed to play a substantial role in 
the complex stabilization for each compound. Interestingly, residues Ile128 and Leu182 afford 
 
 
99 
 
a significant contribution to the stabilization of the protein/ligand complex for those ligands 
with high or intermediate affinity (2e and 1g) but seem to be less critical for compounds 
endowed by a poor affinity for the receptor. 
 
Table 3.1.6 Computational alanine scanning (CAS) mutagenesis results for the 1 receptor in complex 
with ligands 2e, 1g, and 1j. Errors are given in parenthesis as standard errors of the mean (SEM). 
 

Gbind = Gbind,wt – Gbind,mut 
cmpd Gbind,wt D126A I128A T151A V152A E172A Y173A L182A 
2e 
-15.12 
(0.37) 
-3.69 
(0.42)  
-2.27 
(0.43) 
-0.67 
(0.38) 
-0.56 
(0.40) 
-2.04 
(0.37) 
-1.79 
(0.38) 
-1.11 
(0.37) 
1g 
-9.95 
(0.38) 
-3.25 
(0.39) 
-1.35 
(0.40) 
-0.71 
(0.39) 
-0.45 
(0.39) 
-1.19 
(0.40) 
-2.03 
(0.41) 
-0.79 
(0.43) 
1j 
-5.84 
(0.39) 
-2.82 
(0.43) 
-0.12 
(0.42) 
-0.57 
(0.38) 
-0.39 
(0.43) 
-0.21 
(0.39) 
-1.27 
(0.38) 
0.02 
(0.44) 
 
The importance of these hot spot residues detected by CAS can be verified by experimental 
binding assays of various 1 mutants. For instance, in their seminal work Seth et al. clearly 
proved, via in vitro binding assays of the Asp126Gly and Glu172Gly 1 mutants to radiolabeled 
haloperidol, the obligatory nature of the fully conserved Asp126 and Glu172 for the ligand 
binding function of the 1 receptor
39. Also, other mutational studies identified Tyr173 as a 
residue belonging to the 1 binding pocket critical for the cholesterol binding activity of the 
protein.40 
To summarize all in silico work discussed above, we used extensive MM/PBSA-based analysis 
to rank all 33 ligands belonging to series 1 and 2 according to their affinity towards our 
recently proposed 3D model of the 1 receptor. The 1Ki values derived from the MM/PBSA 
simulations are in excellent agreement (R2 = 0.84) with those obtained using a 3D 
pharmacophore model, previously shown to be extremely reliable in reproducing and/or 
predicting the affinity of similar compounds to the same receptor. Lastly, the combined 
application of a per residue free energy deconvolution and computational alanine scanning 
experiments allowed to dissect the contribution of each single residue belonging to the 
putative 1 receptor binding pocket to ligand binding, yielding vital information for further 
drug desing and development. Furthermore, and perhaps more importantly in the perspective 
of the present manuscript, those 1 residues experimentally found to be vital for the ligand 
binding activity of the receptor were also found critical in our 3D model, according to our 
PRFEBD and CAS simulations. 
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Synthesis and activity of new 1 ligands, and comparison with in silico predictions 
On the basis of the estimated 1 receptor affinity predicted by our complex computer-assisted 
drug design recipe presented above, the two series of phenylmethanone (1a-r) and amide (2a-
l) derivatives were then synthesized, (see details about synthesis in paper29). 
Compounds were subsequently subjected to in vitro binding assays, in order to assess their 
experimental affinity toward the 1 receptor (see Tables 3.1.7 and 3.1.8). 1Ki values for all 33 
compounds were determined using a protocol based on the competitive displacement of 
[3H](+)-pentazocine in a rat liver homogenate preparation. , 
 
Table 3.1.7 Experimental 1 receptor affinities (1Ki) and corresponding free energy of binding values 
(Gbind,exp) of compounds 1a-r. The 1Ki/Gbind,exp values for (+)-pentazocine and haloperidol as 
reference compounds are also reported, for comparison. Errors are given in parenthesis as standard 
errors of the mean (SEM). 
 
1a-r 
compd aryl R
1
 
1Ki (nM)±  
SEM
a
 
(nM) 
Gbind (sptml)
b 
(Kcal/mol) 
1a phenyl H 114 ± 7 -9.47 
1b 4-chlorophenyl H 42.3 ± 5.3 -10.05 
1c 4-methylphenyl H 139 ± 26 -9.35 
1d phenyl CH3 75.5 ± 9.7 -9.71 
1e 4-chlorophenyl CH3 30.3 ± 3.9 -10.25 
1f 4-methylphenyl CH3 36.4 ± 3.6 -10.14 
1g phenyl Bz 146 ± 27 -9.32 
1h 4-chlorophenyl Bz 124 ± 24 -9.42 
1i 4-methylphenyl Bz 201 ± 36 -9.13 
1j pyridin-2-il H 1664 ± 147 -7.88 
1k pyridin-3-il H 1031 ± 95 -8.16 
1l pyridin-4-il H 638 ± 24 -8.45 
1m pyridin-2-il CH3 1305 ± 105 -8.02 
1n pyridin-3-il CH3 1578 ± 115 -7.91 
1o pyridin-4-il CH3 1066 ± 130 -8.14 
1p pyridin-2-il Bz 506 ± 92 -8.58 
1q pyridin-3-il Bz 1401 ± 184 -7.98 
1r pyridin-4-il Bz 1020 ± 162 -8.17 
(+)-pentazocine - - 15 ± 3 -10.67 
haloperidol - - 5.7 ± 1 -11.24 
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Table 3.1.8 1 receptor affinities of compounds 2a-l. The Ki values for (+)-pentazocine and haloperidol as 
reference compounds are also reported, for comparison. 
 
2a-l 
 
 
compd aryl R
1
 R
2
 
1Ki (nM±  SEM
a
 
(nM) 
Gbind (sptml)
b 
(Kcal/mol) 
2a phenyl H CH3 9.62 ± 1.81 -10.93 
2b phenyl H phenyl 18.8 ± 2.2 -10.53 
2c phenyl Cl CH3 1.87 ± 0.29 -11.90 
2d phenyl Cl phenyl 24.3 ± 3.6 -10.38 
2e 4-chlorophenyl H CH3 0.09 ± 0.03 -13.70 
2f 4-chlorophenyl H phenyl 23.2 ± 3.2 -10.41 
2g 4-chlorophenyl Cl CH3 14.6 ± 1.4 -10.68 
2h 4-chlorophenyl Cl phenyl 10.7 ± 2.5 -10.87 
2i 4-methylphenyl H CH3 14.2 ± 2.5 -10.70 
2j 4-methylphenyl H phenyl 118 ± 28 -9.45 
2k 4-methylphenyl Cl CH3 61.8 ± 7.6 -9.83 
2l 4-methylphenyl Cl phenyl 66.6 ± 12.5 -9.78 
(+)-
pentazocine 
- - - 15 ± 3 -10.67 
haloperidol - - - 5.7 ± 1 -11.24 
 
 
 
With respect to compounds 1a-r, the results confirm the importance of the presence of a basic 
nitrogen atom substituted with a small group (H, CH3) to endow the compound with 1 
affinity. 
Actually, the N-substitution with a benzyl group decreases the 1 affinity of the derivatives 1g,i 
with respect to the corresponding derivatives 1a-f; contrarily, the presence of a -CH3 group 
linked to the basic nitrogen atom in compounds 1e (1Ki = 30.3 nM) and 1f (1Ki = 36.4 nM) 
improves the 1 affinity of this compound. However, the simultaneous absence of a small 
substituent, as chlorine or methyl group, on the para position of the benzyl moiety decreases 
the 1-receptor affinity of compound 1d (1Ki = 75.5 nM) with respect to the corresponding 
para-substituted compounds 1e and 1f. 
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Compound 1e, characterized by the presence of a chlorine atom on the para position of the 
benzyl residue and of a methyl group linked to the basic nitrogen atom, explicates the highest 
1 affinity. The para substitution with chlorine in compound 1b (1Ki = 42.3 nM) maintain 
some level of 1 affinity, inferior to that of the corresponding N-methyl derivative 1e, but 
superior to that of the analogues 1a (1Ki = 114 nM) and 1c (1Ki = 139 nM). The replacement 
of the phenyl or substituted phenyl residues in compounds 1j-r with the pyridine-2-yl, pyridine-
3-yl or pyridine-4yl moieties abolishes the 1 affinity of the corresponding compounds. In the 
derivative series 2a-l, the amide nitrogen atom is linked to variously substituted benzyl 
residues and to a 4-methylpiperidin-1-yl spacer, substituted on the benzene ring. The basic 
nitrogen atom that allows the ionic bond with a receptor acid site belongs to the piperidine 
cycle. The experimental 1 affinity of compound 2c is rather high (1Ki = 1.87 nM). Compound 
2c is substituted with chlorine on the para position of the benzyl group linked to piperidine 
nitrogen atom. The most potent compound of the series, however, is the acetamide derivative 
2e, characterized by a Ki value as low as 0.09 nM. Interestingly, the corresponding benzamide 
derivative 2f shows a much lower 1-receptorial affinity (1Ki = 23.2 nM). Actually, acetamide 
derivatives are endowed with 1-affinity higher than that of corresponding benzamide 
derivatives, except for compound 2g. The superior affinity of acetamide derivatives may be 
attributed to the electron donating effect of the acetamide methyl group that may increase 
the electronegative character of the carbonyl oxygen and further contribute to the 1 binding 
affinity as hydrogen bond acceptor. 
As declared in the beginning, one of the main purposes of the entire work was an extensive 
validation of our originally proposed 3D model of the 1 receptor. Therefore, the most 
important point of the entire discussion is undoubtedly the direct comparison of the results 
stemming from the experimental ligand binding assays and the corresponding values predicted 
by the application of the entire computational ansatz. Figure 3.1.18 thus illustrates the results 
of this direct comparison. In detail, Figure 3.1.18(A) shows the excellent agreement between 
the affinities for 1 of compounds 1 and 2 predicted by the 3D pharmacophore model and the 
corresponding experimental 1Ki values, quantified by the corresponding value of the 
correlation coefficient of 0.89. If this could be a somewhat expected result, the astounding 
correlation between the experimental Ki values and those derived from the application of the 
MM/PBSA ranking is even more gratifying: indeed, Figure 3.1.18(B) shows how well the 
calculated 1KiGbind reproduce the experimental ones (R
2 = 0.89), with a more than 
satisfactory ranking order. To further confirm the capability of the entire MM/PBSA 
computational ansatz in correctly ranking the affinities of all 33 compounds towards the 1 
receptor, if we compare the values of the MM/PBSA calculated Gbind values (Table 3.1.4) 
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with those derived from the biological assays (Tables 3.1.7 and 3.1.8), we can observe that the 
average unsigned error between these two data sets is 0.93 kcal/mol, and the corresponding 
root-mean-square deviation is 1.19 kcal/mol. 
Thus, the remarkable quality of these correlations couple with the wide range of the 1 affinity 
values properly ranked constitute a further, decisive validation of the putative 1 binding site 
and, overall, of the entire 3D homology model of this intriguingly enigmatic receptor. 
 
(A)                                      (B) 
Figure 3.1.18 (A) Plot of the experimental vs. 3D pharmacophore predicted 1Ki values for the 33 
compounds of series 1 and 2 (R2 = 0.89). (B) Plot of the experimental vs. MM/PBSA predicted 1Ki values 
for the 33 compounds of series 1 and 2 (R2 = 0.89). 
Conclusions 
Notwithstanding many pharmacologic responses have been linked to the sigma receptors, the 
function of the 1 protein is still a subject of intense study and current debate. Importantly, 
until very recent times relatively little information regarding the structure of the 1 receptor or 
its ligand binding site was available to the scientific community. Cloning of the 1 receptor 
revealed that the rat brain receptor 1 protein consists of 223 amino acids, which results in a 
molecular weight of 23 kDa. Although human and animal 1 receptors show a similarity of 
more than 95%, unfortunately there is no resemblance of this receptor to other known 
mammalian proteins. 
Lately our group published for the first time a 3D model of the 1 receptor protein as obtained 
from a complex multistep computational recipe based on homology modeling techniques. 5The 
reliability of the proposed 1 model and the validity of its putative ligand binding site was 
assessed by a docking/MMPBSA-based small-scale virtual screening of a series of available 1 
ligands, and by the receptor model-based design of three new 1 ligands, featuring activity in a 
wide range (from 1.87 to 1578 nM). To ultimately confirm the validity of our 1 3D model and 
its complete reliability as a platform for 1-ligand structure-based drug design, in the present 
work we expanded our study by designing 33 new 1 ligands, with affinity for the receptor 
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spanning 5 orders of magnitude. All these compounds were then ranked for receptor affinity 
by extensive molecular dynamics simulation-based free energy calculations, and the main 
interactions/receptor residues involved in ligand binding were thoroughly analyzed by applying 
per residue free energy deconvolution and in silico alanine scanning experiments. All 
compounds were subsequently synthesized in our laboratory and then tested for 1 binding 
activity in vitro. 
Remarkably, the experimental affinity ranking for all 33 compounds towards the 1 receptor 
was found to be fully consistent with the corresponding predictions obtained from our in silico 
procedure. Therefore, we are convinced that the computational recipe adopted here, based on 
the 1 receptor 3D structure we recently developed, cane be generally employed to estimate 
the activity of new 1 ligands prior to their synthesis, with an obvious optimization of time and 
resources. Furthemore, if we reconsider all experimental affinity data listed in Tables 3.1.7 and 
3.1.8, we can see that both sets of compounds 1 and 2 can be classified on the basis of their 
experimental activity as highly affine (Ki ≤ 40.0 nM, +++), moderately affine (40.0 < Ki < 600 
nM, ++) and poorly affine (Ki ≥ 600 nM, +). According to this classification, and looking the in 
silico ranking shown it Table 3.1.4, we can also conclude that all compounds classified as highly 
affine (+++) are characterized by Gbind values ≤ -11.00 kcal/mol, those with a moderate 
affinity (++) have -11.00 < Gbind < -8.50 kcal/mol, and finally the less affine ones have Gbind 
≥ -8.50 kcal/mol. Taking into account that the entire computational recipe are based on a 
protein model obtained via homology modeling techniques, these ranking capacity and the 
related results ultimately confirm the reliability of the 1 3D model in structure-based ligand 
design. 
 
3.1.3 STUDY OF PARTICULAR BINDING MODE OF 1 SPYROCICLIC 
COMPOUNDS41 
Our interest has been focused on the development of novel compounds with high 1 receptor 
affinity and selectivity over related receptor systems in the central nervous system. Recently 
we have shown that additional lipophilic substituents on spirocyclic 1 ligands favor the 
interactions with the ς1 receptor protein. (Scheme 3.1.4) Replacement of the methyl moiety of 
1a (Ki = 21 nM) with a phenyl group (1b, Ki = 1.5 nM) led to a 15-fold increase of 1 receptor 
binding while maintaining high 1/2 selectivity.
42,43 In the series of thiophene annulated 
spirocyclic 1 ligands 2,3 an additional aryl moiety in -position of the S-atom is well tolerated 
by the 1 receptor protein
44. These observations are in good accordance with established 
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pharmacophore models indicating the acceptance of large lipophilic substituents by the 
1receptor protein.
45 
 
 
Figure 3.1.4 Design of arylated spirocyclic thiophenes. 
 
Herein, we wish to report on the introduction of various aryl moieties in - (4-6) and -
position (7,8) of regioisomeric thiophenes by direct C-H-bond arylation using recently 
developed Pd-catalysts. Whereas the position of the additional aryl moiety of 7 and 8 
correlates with the position in the lead compounds 1b, 2 and 3, the aryl moiety of the 
spirocyclic ligands 4-6 is shifted to the “left” position of the thiophene ring. On the other hand 
compounds 4 and 5/6 represent regioisomers with respect of the position of the S-atom in the 
thiophene ring. The 1 affinity of the arylated thiophenes 4-8 are investigated in receptor 
binding studies with radioligands. The resulting data together with the affinity data of arylated 
spirocyclic 1 ligands 2 and 3 are used for the establishment and validation of a 1 
pharmacophore model. Moreover, docking of the ligands into the 1 receptor 3D model and 
affinity scoring will result in the analysis of the exact detailed ligand receptor interactions. 
Details about the chemical synthesis could be found in the paper41. 
Receptor Affinity 
The 1 and 2 receptor affinities of the arylated spirocyclic thiophenes 4-8, the synthetic 
precursors 9-11, as well as the lead and reference compounds were determined in competition 
experiments with radioligands. The potent and selective tritium labeled radioligand [3H]-(+)-
pentazocine was used as competitor for the test compounds in the 1 assay. Membrane 
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preparations of guinea pig brains served as receptor material. In the ς2 assay, homogenates of 
rat liver were the source for ς2 receptors and [3H]-di-o-tolylguanidine was employed as 
radioligand. Since di-o-tolylguanidine also binds to ς1 receptors, an excess of non-radiolabeled, 
ς1 selective (+)-pentazocine was added to mask ς1 receptors.
46,47 
 
Table 3.1.9 1 and 2 receptor affinities of the spirocyclic thiophenes and reference compounds. 
   
   Ki ± SEM [nM] (n = 3) selectivity 
compd. X Aryl σ1 σ2 σ1/σ2 
1a
a) 
OCH3 CH3 21 ± 2.3 > 1 M > 47 
1b
a) 
OCH3 C6H5 1.5 ± 0.08 > 1 M > 660 
2a
b) 
H H 0.35 ± 0.06 230 657 
2b
b) 
H C6H5 0.22 ± 0.06 806 3664 
3a
b) 
OCH3 H 4.5 ± 2.9 > 1 µM > 222 
3b
b) 
OCH3 C6H5 1.0 ± 0.4 > 1 M > 1000 
4a OCH3 C6H5 5.5 ± 1.5 530 96 
4b OCH3 p-MeOC6H4 111 ± 27 > 1 M > 9 
4c OCH3 p-CNC6H4 89 ± 72 > 1 M > 11 
4d OCH3 p-C6H4-C6H5 220 ± 99 > 1 M > 4 
5a H C6H5 2.4 ± 0.69 283 118 
6a OCH3 C6H5 16 ± 5.8 > 1 M > 63 
6b OCH3 p-MeOC6H4 56 ± 23 > 1 M > 18 
6c OCH3 p-MeC6H4 29 ± 1.0 > 1 M > 34 
6d OCH3 p-NO2C6H4 16 ± 0.9 > 1 M > 63 
6e OCH3 p-AcC6H4 59 ± 15 > 1 M > 1 
6f OCH3 p-CNC6H4 20 ± 6.7 > 1 M > 50 
6g OCH3 p-CF3C6H4 43 ± 18 > 1 M > 23 
6h OCH3 1-naphthyl 12 ± 1.8 142 12 
6i OCH3 p-C6H4-C6H5 211 ± 74 > 1 M > 5 
6j OCH3 3-pyridyl 2.5 ± 0.46 > 1 M > 400 
7a H C6H5 1.6 ± 0.7 445 278 
8a OCH3 C6H5 5.4 ± 0.97 > 1 M > 185 
8b OCH3 p-MeOC6H4 7.1 ± 2.4 > 1 M > 141 
8c OCH3 p-MeC6H4 2.7 ± 1.6 > 1 M > 370 
9
c) 
OCH3 H 0.32 ± 0.10 > 1 µM > 3000 
10 H H 1.0 ± 0.3 147 147 
11 OCH3 H 1.9 ± 0.44 > 1 M > 500 
15 OH H 16 ± 2.0 849 53 
16 C
4
=C
5 
H 3.4 ± 1.0 236 69 
haloperidol 3.9 ± 1.5 78 ± 2.0 20 
di-o-tolylguanidine 61 ± 8 42 ± 15 0.7 
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Table 3.1.9 clearly shows that introduction of aryl moieties in position 2 of the spirocyclic 
compound 9 bearing the S-atom in the “top” position 1 led to significant decrease of 1 
receptor affinity. The Ki-values of the -arylated compounds 4a-4d are 17-500-fold higher than 
the Ki-value of the parent thiophene 9. The very low 1 affinity of the biphenylyl derivative 4d 
indicates that the biphenylyl residue is sterically too demanding for the binding pocket of the 
1 receptor. 
arylation of the regioisomeric thiophene derivatives 10 and 11 led to slightly reduced 1 
affinities compared with the 1 affinities of their parent compounds 10 and 11. However, some 
of the arylated compounds show Ki values below 20 nM (e.g. 6a: Ki = 16 nM; 6d: Ki = 16 nM; 
6h: Ki = 12 nM), indicating considerable 1 affinities. High 1 affinities are achieved with either 
an unsubstituted aryl residue (e.g. 6a (phenyl): Ki = 16 nM; 6h (naphthyl): Ki = 12 nM) or an 
electron deficient aryl residue in 2-position (e.g. 6d (nitrophenyl): Ki = 16 nM; 6j (3-pyridyl): Ki 
= 2.5 nM). As seen for the series 4 spirocyclic thiophenes with an electron rich aryl moiety in 2-
position gave reduced 1 affinities (e.g. 6b (methoxyphenyl): Ki = 56 nM). The most promising 
1 ligands of this series are 5a without acetalic methoxy group (Ki = 2.4 nM) and the 3-pyridiyl 
derivative 6j (Ki = 2.5 nM) showing similar 1 affinities as the parent compounds 10 and 11. 
The highest 1 affinities were found for the -arylated spirocyclic thiophenes 7 and 8. In this 
compound class even compounds with donor substituents (e.g. 8b (methoxyphenyl): Ki = 7.1 
nM, compare the Ki values of 4b and 6b) interact in the low nanomolar range with 1 
receptors. Unfortunately, -arylation of 10 and 11 with acceptor substituted aryl iodides failed 
to give the arylated products. 
Generally the 1 affinities decreased in the order 7/8 > 5/6 > 4. This tendency is depending on 
the orientation of the aryl moiety. In compounds 7/8, the phenyl ring adopts a position at the 
“top” of the molecule, which is favorable for receptor interaction. Due to the increased C-S 
bond length and the larger size of the S-atom, the spirocyclic thiophenes 5/6 with the S-atom 
in the “bottom” position direct the aryl moiety in a position similar to its position in 7/8, 
whereas in the regioisomers 4 with the S-atom in the “top” position the additional aryl moiety 
is directed in an unfavorable position. 
With exception of the naphthyl derivative 6h and the unsubstituted compound 10, the ς2 
affinities of the (arylated) spirocyclic thiophenes 4-11 are very low indicating high selectivity 
for the 1 subtype over the ς2 subtype. Despite the moderate ς2 affinity of 10 (Ki = 147 nM), its 
1/2 selectivity is still high (147) due to the very high 1 affinity. On the contrary the naphthyl 
derivative 6h shows the lowest 1/2 selectivity (12) of this series of compounds. 
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Molecular modeling of ligand/protein interactions 
To investigate the role played by the position of the aromatic moiety on the thiophene ring in 
determining the affinity of our compounds towards the 1 receptor, we applied a sequential 
molecular modeling procedure, based on the following steps: i) generation of a 3D 
pharmacophore model for the present series of compounds; ii) 3D pharmacophore-guided 
docking of all ligands into the putative binding site of our 3D 1 receptor model, iii) estimation 
of their binding affinity via the MM-PBSA methodology, and iv) comparison with the available 
experimental activities. 
 
Pharmacophore model generation 
These pharmacophore models can be used in different ways in drug design programs, e.g., 1) 
as 3D query tools in virtual screening to identify potential new compounds from 3D databases 
of drug-like molecules with patentable structures different from those already discovered; 2) 
to predict the activities of a set of new compounds yet to be synthesized or, as in the present 
case, 3) to understand the possible mode/mechanism of drug/receptor interaction. 
3D pharmacophore hypothesis generation by the Catalyst software is one of the popular 
approach that has been successfully used in drug discovery and toxicology research so far. The 
most critical aspect of Catalyst pharmacophore hypothesis generation is the selection of the 
molecular training set; however, some basic guidelines could be find in Material & Methods 
chapter. 
On the basis of the above criteria, a set of 10 pharmacophore hypothesis was generated with 
Catalyst using 27 training set compounds listed in Scheme 3.1.5. 
The results of the hypotheses, which include different cost values calculated during hypothesis 
generation along with the corresponding root-mean-square deviation (rmsd), correlation 
coefficient (), and pharmacophore features, are listed in Table 3.1.10. 
The total hypothesis cost of these ten best models varies between 122.9 for the best ranked 
model (Hypo1) to 178.9 for the lowest ranked one (Hypo10). Such a confined difference (56 
bits) reflects both the homogeneity of the generated hypotheses and the adequacy of the 
molecular training set. The difference between the null and the fixed cost, which should be 
higher than 70 to guarantee a robust correlation, is 89.6 in our case. This corresponds to a 
chance of true correlation in the data greater than 90%. Furthermore, in all the generated 
hypotheses the total costs are much closer to the fixed cost (115.7) than to the null cost 
(205.3), indicating that meaningful models are obtained. Finally, the root mean square 
deviations (RMSD) and the correlation coefficients (ρ) between estimated and experimental 
 
 
109 
 
affinities range from 0.922 to 1.874, and from 0.905 to 0.695, respectively. As all the generated 
pharmacophores map the molecules of the training set in a similar way, the first model 
(Hypo1), characterized by the highest cost difference, the lowest RMDS, and the best ρ values, 
was selected for further analysis. 
In analogy with other pharmacophore models formerly developed for 1 ligands, 
1,10,39,48the 
main features of the present Hypo1 are a positive ionizable group (PI), an hydrogen bond 
acceptor group (HBA), two hydrophobic moieties (HY), and one hydrophobic aromatic point 
(HYAr) (see Figure 3.1.19). 
 
 
 
 Scheme 3.1.5 Chemical structures of the 27 training set compounds. 
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Table 3.1.10 Composition (features), costs (bits), and statistical parameters (rmsd and ) associated with 
the 10 best hypotheses (pharmacophore models) generated with Catalyst using the training set 
molecules (Scheme 3.1.5). 
 
 
Hypothesis total cost cost
a
 rmsd  features
b
 
1 122.9 82.6 0.922 0.905 HBA, HYAr, HY, HY, PI 
2 131.5 73.8 1.305 0.839 HBA, HY, HY, HY, PI 
3 136.4 68.9 1.319 0.832 HBA, HYAr, HY, HY, PI 
4 137.8 67.5 1.377 0.813 HBA, HYAr, HYAr, HY, PI 
5 139.6 65.7 1.418 0.792 HBA, HY, HY, HY, PI 
6 142.8 62.5 1.490 0.775 HBA, HYAr, HY, PI 
7 148.5 56.8 1.558 0.760 HBA, HY, HY, PI 
8 153.4 51.9 1.704 0.739 HBA, HYAr, HYAr, PI 
9 173.6 31.7 1.792 0.701 HBA, HYAr, HY, PI 
10 178.9 26.4 1.874 0.695 HBA, HYAr, HY, PI 
 
 
The affinities of the 27 compounds for the 1 receptor estimated using Hypo1 are reported in 
Table 3.1.11, along with the experimental values and the relevant errors (expressed as the 
ratio between estimated and experimental values). This Table clearly shows that 20 out of 27 
molecules in the training set have errors equal or less than 2.2, whilst the remaining 7 have 
errors less than 5.0. 
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    (A)      (B) 
  
 
 
 
 
 
 
 
(C) 
 
Figure 3.1.19 Geometrical relationships (A,B) among the features of the top-scoring pharmacophore 
Hypo1 (C). The hypothesis features are portrayed as meshed spheres, color-coded as follows: red, PI; 
light blue, HYAr; pink, HY; light green, HBA. HBA is actually represented as a pair of spheres (the smaller 
sphere represents the location of the HBA atom on the ligand and the larger one the location of an HB 
donor on the receptor).  
 
Pharmacophore mapping of compounds belonging to series 3 and 8 – all bearing an aromatic 
ring in the top position with respect to the tetrahydropyran ring - indicates that these 
molecules can map all 5 pharmacophore features quite nicely (see Figure 3.1.20). Indeed, the 
presence of the N-benzylic group provides one of the aromatic function (HY) to the molecules, 
the other HY being provided by the thiophene ring. The piperidinic nitrogen atom is aptly 
positioned over the positive ionizable feature PI, the pyran ring oxygen fulfills the HBA 
requirement and, lastly, the phenyl substituent overlays the hydrophobic aromatic feature 
(HYAr) independently of its - (3b) or -position (8a) with respect to the heterocyclic sulfur 
atom. Referring to compounds 3b and 8a of Figure 4 as an example, the in silico estimated Ki 
(1) values (Ki = 1.2 nM for 3b and Ki = 3.4 nM for 8a, respectively) are in excellent agreement 
with the corresponding experimentally determined Ki values (1.0 nM for 3b and 5.4 nM for 8a, 
respectively, see Table 3.1.11). 
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Table 3.1.11 Experimentally determined and estimated Ki values of the training set compounds 
calculated on the basis of the pharmacophore hypothesis 1 (Hypo1). 
    1 affinity: Ki (nM)  
compd. this 
article 
compd. 
of ref.
22 
Aryl X estimated experimental Error
a 
- 2a - H 1.8 0.35 5.0 
- 2b C6H5 H 2.7 4.5 -1.6 
- 2c p-MeC6H5 H 2.8 3.6 -1.3 
- 2d 1-napthyl H 6.9 4.0 1.7 
- 3b C6H5 -OCH3 1.2 1.0 1.2 
- 3e p-MeOC6H5 -OCH3 3.1 2.2 1.4 
- 3g p-AcC6H5 -OCH3 3.5 1.6 2.2 
- 3h p-CNC6H5 -OCH3 0.51 0.25 2.0 
- 3i 3-pyridyl -OCH3 1.9 2.2 -1.1 
4a - C6H5 -OCH3 13 5.5 2.2 
4b - p-MeOC6H5 -OCH3 50 111 -2.2 
4c - p-CNC6H5 -OCH3 60 89 -1.5 
4d - p-biphenyl -OCH3 51 220 -4.3 
11 - - -OCH3 5.7 1.9 3.0 
6a - C6H5 -OCH3 23 16 1.4 
6b - p-MeOC6H5 -OCH3 67 56 1.2 
6c - p-MeC6H5 -OCH3 27 29 -1.1 
6d - p-NO2C6H5 -OCH3 51 16 3.2 
6e - p-AcC6H5 -OCH3 34 59 -1.7 
6f - p-CNC6H5 -OCH3 37 20 1.8 
6g - p-CF3C6H5 -OCH3 21 43 -2.0 
6h - 1-naphtyl -OCH3 22 12 1.8 
6i - p-biphenyl -OCH3 45 211 -4.7 
7a - C6H5 H 1.8 1.6 1.1 
8a - C6H5 -OCH3 3.4 5.4 -1.6 
8b - p-MeOC6H5 -OCH3 2.2 7.1 -3.3 
8c - p-MeC6H5 -OCH3 3.5 2.7 1.3 
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   3b      8a 
Figure 3.1.20 Mapping of compounds 3b and 8a onto the developed 1 3D pharmacophore model 
(Figure 3.1.19). Compounds are portrayed as atom-colored sticks (red, O; yellow, S; gray, C; blue, N; 
white, H). 
 
On the contrary, compounds belonging to series 4 and 6 featuring the aryl substituent in the 
left position are all endowed with a lower affinity towards the 1 receptor since all explored 
molecular conformations failed to access the HYAr feature, as exemplified for compounds 4a 
and 6a in Figure 3.1.21. The HYAr pharmacophore interaction point is, however, the only 
feature unmapped by compounds of series 4 and 6. Thus, given the excellent overlay between 
the molecular chemical moieties and the remaining 3D pharmacophore requirements shown in 
Figure 3.1.21, only a small decrease in 1 affinity for these two molecular series is predicted 
for, e.g., compounds 4a and 6a (Ki = 13 nM for 4a and Ki = 23 nM for 6a) in agreement with the 
experimental binding constants (Ki = 5.5 nM for 4a and Ki = 16 nM for 6a, see Table 3.1.11). 
 
 
 
 
   
   4a      6a 
Figure 3.1.21 Mapping of compounds 4a and 6a onto the developed 1 3D pharmacophore model 
(Figure 3.1.19). Compounds are portrayed as atom-colored sticks (red, O; yellow, S; gray, C; blue, N; 
white, H). 
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Importantly, however, the activity of compounds 4 and 6 is strongly affected by the presence 
of a substituent at the para position of the thiophene-linked phenyl ring. On the contrary, all 
derivatives 3 and 8 bearing the same substituted aromatic moieties are endowed with 
comparable (if not higher) 1 affinities with respect to the unsubstituted counterparts. 
   
    3e      8b 
   
    
 
 
  
  
   
 
    4b      6b 
Figure 3.1.22 Mapping of compounds 3e, 8b, 4b, and 6b onto the developed 1 3D pharmacophore 
model (Figure 3.1.19). Compounds are portrayed as atom-colored sticks (red, O; yellow,S; gray, C; blue, 
N; white, H). 
 
In this respect, the analysis of the top panels of Figure 3.1.22 indeed reveals how, for 
compounds 3e and 8b bearing the p-methoxyphenyl substituent in the top position, all five 3D 
pharmacophore features are mapped very well (as in the case of their unsubstituted analogs, 
see Figure 3.1.20), resulting in high predicted/experimental 1 affinity values (Ki(estimated) = 
3.1 nM/Ki(experimental) = 2.2 nM for 3e and Ki(estimated) = 2.2 nM/Ki(experimental) = 7.1 
nM for 8b, respectively, see Table 3.1.11). 
On the other hand, all derivatives characterized by the presence of the aromatic ring in the left 
position not only miss the HYAr feature as discussed above but the presence of the p-OCH3 
substituent on the phenyl ring induces a further conformational change so that all the 
remaining four pharmacophoric features are mapped less precisely with respect to the 
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unsubstititedunsubstituted compounds (compare the lower panels in Figure 3.1.22 and Figure 
3.1.21). Accordingly, for this set of compounds the model predicts lower 1 affinities for 4b (Ki 
= 50 nM) and 6b (Ki = 67 nM) in line with the experimental 1 affinities (Ki = 111 nM for 4b and 
Ki = 56 nM for 6b, see Table 3.1.11). 
Pharmacophore assessment and  cross-validation study 
The quality of the developed pharmacophore was assessed using the CatScramble technique 
available in Catalyst. The purpose of this technique is to randomize the affinity data among the 
training set compounds and to generate pharmacophore hypotheses using the same features 
and parameters used to develop the original pharmacophore hypothesis. If the randomized 
sets generates pharmacophores with similar or better cost values, rmsd, and correlation, then 
the original pharmacophore can be considered as generated by chance. The results of the 
CatScramble runs are listed in Table 3.1.12. Since a 98 % confidence level was selected for this 
test, 49 random hypothesis runs were performed. The results clearly indicate that 
randomization produced hypotheses with no predictive values similar or close to the 
corresponding Hypo1. Indeed, none of the outcome hypotheses had a lower cost score, better 
correlation or smaller root-mean-square deviation than the initial hypothesis. Table 3.1.12 lists 
the first 10 lowest total score values of the resulting 49 hypotheses for our training set 
molecules. In conclusion, there is a 98 % chance for the best hypothesis to represent a true 
correlation in the training set affinity data for the present classes of compounds. 
Table 3.1.12 Output parameters of the 10 lowest cost hypotheses resulting from the statistical 
evaluation according to the CatScramble validation procedure. 
 
Hypothesis  rmsd total cost 
1 0.812 1.154 142.9 
2 0.717 1.389 151.9 
3 0.700 1.397 154.0 
4 0.724 1.453 155.1 
5 0.622 1.496 157.1 
6 0.603 1.601 160.6 
7 0.576 1.657 163.8 
8 0.558 1.708 165.7 
9 0.515 1.755 167.8 
10 0.507 1.823 168.9 
Hypo1 0.905 0.922 122.9 
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Finally, a further statistical test, the leave-one-out method, which consists of re-computing the 
hypothesis by excluding from the training set one molecule at a time, was carried out. 
Basically, this test is performed to verify whether or not the correlation is strongly dependent 
on one particular compound in the training set. The test is positive if the affinity of each 
excluded molecule is correctly predicted by the corresponding one-missing hypothesis. The 
value of , the feature composition of the pharmacophore, and the quality of the predicted 
affinity of the excluded molecule were used as measures for the assessment of the statistical 
test. For each of the 27 new hypotheses generated according to this method we did not obtain 
meaningful differences between Hypo1 and each hypothesis resulting from the exclusion of 
one compound at a time. 
 
Pharmacophore validation using test set compounds 
A critical step in automated pharmacophore generation is model validation, especially in those 
cases where the model has been generated for the purpose of predicting the activity either of 
external sets of compounds or to estimate the activity of newly conceived molecular entities 
prior to their synthesis. Thus, to check the robustness of our correlation we used the 
pharmacophore model (Hypo1) to predict the affinity of a further set of molecules, also called 
the test set, composed of 13  additional molecules from our series (see Scheme 3.1.6). 
 
 
 
Scheme 3.1.6 Chemical structures of the 13 test set compounds. 
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Interestingly, a good correlation coefficient 0.80 was observed when a regression analysis was 
performed by mapping the test set onto the features of the best pharmacophore hypothesis 
Hypo1. The predicted and the experimental Ki(1) values for the test set along with the 
respective errors are shown in Table 3.1.13. The average error in predicting the affinity of the 
test set molecules is 3.0. Given the inherent simplicity of the pharmacophoric approach, and 
considering the intrinsic variability of the biological responses, we can conclude that the ability 
of the present 3D pharmacophore model to predict the affinity of these series of 1 receptor 
ligands is quite satisfactory. 
 
Table 3.1.13 Experimentally determined and estimated Ki values of the test set compounds calculated on 
the basis of the pharmacophore hypothesis 1 (Hypo1). 
    1 affinity: Ki (nM)  
compd. 
this 
article 
compd. 
of ref.
22 
Aryl X estimated Experimental Error
 
- 
3a 
- -
OCH3 
1.8 0.22 7.7 
- 2e p-MeOC6H5 H 1.6 1.5 1.1 
- 2f p-NO2C6H5 H 3.4 1.7 2.0 
- 2g p-CNC6H5 H 2.7 3.4 -1.3 
- 
3c 
p-MeC6H5 -
OCH3 
1.1 2.0 -1.9 
- 
3f 
p-NO2C6H5 -
OCH3 
3.6 1.0 3.6 
- 
3j 
p-CF3C6H5 -
OCH3 
2.1 5.7 -2.7 
- 
3d 
1-naphtyl -
OCH3 
5.8 5.0 1.2 
- 
3k 
p-biphenyl -
OCH3 
18 30 -1.7 
9 
- 
- -
OCH3 
2.0 0.32 6.3 
10 - - H 3.2 1.0 3.2 
5a - C6H5 H 11 2.4 4.6 
6j 
- 
3-pyridyl -
OCH3 
5.4 2.5 2.2 
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Docking of ligands into the 1 receptor 3D model and affinity scoring via MM-PBSA calculations 
Following our pioneer work,1 the putative binding site and binding modes of all compounds 
considered in this work in the 1 receptor 3D homology model structure were retrieved 
exploiting the currently available preliminary information on sequence-structure relationships 
and  mutagenesis studies, and the ligand-binding pharmacophore requirements presented 
above. Having localized the protein binding site as described in paragraph 3.1.2, a thorough 
search for a sequence satisfying the chemical features imposed by Hypo1 was performed, and 
successfully retrieved. Thus, all compounds were docked into the putative binding site of 
receptor 3D model. In the set of docked ligand conformations, for each compound a solution 
was found that best reproduced the key 3D pharmacophore requirements. 
 
 
  
Figure 3.1.23 (Left) Comparison between the best conformation assumed by compound 3h upon 
mapping the 3D pharmacophore model (purple sticks) and after docking in the putative 1 binding site 
(green sticks-and-balls). (Right) Equilibrated MD snapshots of the 1 receptor in complex with 3h. The 
image is a zoomed view of the receptor binding site. The ligand is portrayed in green sticks-and-balls, 
while the protein residues mainly involved in the interaction with 3h are highlighted as colored sticks and 
labeled. Salt bridge and H-bonds interactions are shown as black lines. Water, ions and counterions are 
not shown for clarity. 
 
Taking compound 3h as a prototypical example of the class of compounds featuring the phenyl 
ring in the top position, from the top panel of Figure 3.1.23, we can observe the striking 
similarity between the molecular conformation adopted by the compound in mapping the 3D 
pharmacophore model and that assumed by the same compound in the 1 pocket upon 
binding. Most importantly, however, the best binding mode detected for 3h after docking 
satisfies all ligand/protein intermolecular interactions required by pharmacophore hypothesis 
Hypo1. In detail: i) the piperidinic nitrogen is engaged in a salt bridge with Asp 126 (PI feature); 
ii) the pyran oxygen atom H-bonds with the–NH group of the backbone peptidic linkage 
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between Thr151 and Val152 (HBA feature); iii) the aryl group linked to the thiophene ring is 
involved in stabilizing interactions with the aromatic components of Trp121 and Tyr 120 (HYAr 
feature); and iv) a network of hydrophobic interactions stabilizes the position of the thiophene 
and the N-benzylic rings among the residues Tyr173, Ile128, and Phe133, respectively (2 HY 
features). 
  
 
 
 
Figure 3.1.24 (Left) Comparison between the best conformation assumed by compound 6a upon 
mapping the 3D pharmacophore model (purple sticks) and after docking in the putative 1 binding site 
(green sticks-and-balls). (Right) Equilibrated MD snapshots of the 1 receptor in complex with 6a. The 
image is a zoomed view of the receptor binding site. The ligand is portrayed in green sticks-and-balls, 
while the protein residues mainly involved in the interaction with 6a are highlighted as colored sticks and 
labeled. Salt bridge and H-bonds interactions are shown as black lines. Water, ions and counterions are 
not shown for clarity. 
 
Considering compound 6a as a representative example of the derivatives featuring the phenyl 
ring in the left position, from the top panel of Figure 3.1.24 we can appreciate that, also in this 
case, the best molecular conformation mapping the 3D pharmacophore Hypo1 and the best 
binding mode of 6a into the 1 binding pocket are superimposable. Quite surprisingly, 
however, the detailed inspection of the binding pose of 6a reveals that, in order to comply 
with the pharmacophoric requirements upon protein binding, this molecule must adopt a 
“reverse” orientation with respect to that assumed by, e.g., 3h, as shown in the bottom panel 
of Figure 3.1.24. Accordingly, the basic nitrogen of 6a creates a salt bridge with Glu123 (PI 
feature,), the oxygen atom of the pyran ring is engaged in a H-bond with the side-chain –OH 
group of Thr131 (HBA feature,), and the thiophene ring is stabilized by hydrophobic 
interactions with the side-chains of both Tyr173 and E172 (HY feature). Notably, at variance 
with 3h, the remaining hydrophobic pharmacophore requirement is fulfilled by the thiophene-
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linked phenyl ring, which aptly fits a small hydrophobic cavity lined by the side chains of Ile128 
and Phe133. 
All 40 receptor/drug complexes obtained from the pharmacophore-based docking procedure 
were then relaxed by energy minimization and molecular dynamics (MD) simulations and, 
finally, the relevant values of the free energy of binding - Gbind - between all compounds and 
the 1 receptor were evaluated by applying the well-known Molecular Mechanics/Poisson-
Boltzmann Surface Area (MM-PBSA) computational ansatz6,30,49, as listed in Table 3.1.14. 
 
Table 3.1.14 Experimentally determined (Gbind.(exp)) and calculated (Gbind) free energy of ligand - 
1 receptor complexes
a 
compd. 
this 
article 
compd.  
of ref.
22 
Aryl X H (kcal/mol) 
-TS 
(kcal/mol) 
Gbind 
(kcal/mol) 
Gbind,(exp)
a
 
(kcal/mol) 
- 2a - H -36.66 (0.18) 23.56 (0.37) -13.10 (0.41) -12.91 
- 3a - -OCH3 -36.90 (0.19) 23.67 (0.39) -13.23 (0.43) -13.18 
- 2b C6H5 H -37.40 (0.18) 25.76 (0.42) -11.64 (0.45) -11.39 
- 2e p-MeOC6H5 H -38.36 (0.21) 25.83 (0.39) -12.53 (0.44) -12.04 
- 2c p-MeC6H5 H -38.50 (0.19) 25.69 (0.38) -12.81 (0.42) -11.52 
- 2f p-NO2C6H5 H -38.70 (0.20) 25.91 (0.38) -12.79 (0.43) -11.97 
- 2g p-CNC6H5 H -38.63 (0.20) 26.02 (0.40) -12.61 (0.45) -11.56 
- 2d 1-napthyl H -39.06 (0.17) 26.18 (0.41) -12.88 (0.44) -11.46 
- 3b C6H5 -OCH3 -38.52 (0.22) 25.81 (0.37) -12.71 (0.43)  -12.28 
- 3e p-MeOC6H5 -OCH3 -38.71 (0.18) 25.77 (0.39) -12.94 (0.43) -11.82 
- 3c p-MeC6H5 -OCH3 -38.51 (0.20) 25.79 (0.39) -12.72 (0.44) -11.87 
- 3f p-NO2C6H5 -OCH3 -38.58 (0.18) 25.99 (0.40) -12.59 (0.45)  -12.28 
- 3g p-AcC6H5 -OCH3 -38.43 (0.17) 25.56 (0.40) -12.87 (0.43) -12.00 
- 3h p-CNC6H5 -OCH3 -39.11 (0.16) 25.82 (0.40) -13.29 (0.42) -13.10 
- 3j p-CF3C6H5 -OCH3 -38.13 (0.19) 25.64 (0.41) -12.49 (0.43) -11.25 
- 3d 1-naphtyl -OCH3 -38.38 (0.20) 26.03 (0.37) -12.35 (0.42) -11.33 
- 3i 3-pyridyl -OCH3 -38.67 (0.21) 25.98 (0.36) -12.69 (0.41) -11.82 
- 3k p-biphenyl -OCH3 -38.08 (0.20) 26.30 (0.38) -11.78 (0.43) -10.27 
9 - - -OCH3 -36.82 (0.20) 23.61 (0.37) -13.21 (0.42) -12.96 
4a - C6H5 -OCH3 -36.31 (0.18) 24.48 (0.39) -11.83 (0.43) -11.27 
4b - p-MeOC6H5 -OCH3 -34.83 (0.19) 24.82 (0.41) -10.01 (0.43) -9.49 
4c - p-CNC6H5 -OCH3 -34.78 (0.18) 24.79 (0.42) -9.99 (0.44) -9.62 
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4d - p-biphenyl -OCH3 -34.71 (0.22) 24.95 (0.36) -9.76 (0.42) -9.09 
10 - - H -36.61 (0.21) 23.60 (0.36) -13.01 (0.41) -12.28 
11 - - -OCH3 -36.78 (0.18) 23.71 (0.41) -13.07 (0.44) -11.90 
5a - C6H5 H -36.07 (0.19) 24.53 (0.39) -11.54 (0.43) -11.76 
6a - C6H5 -OCH3 -35.80 (0.19) 24.74 (0.39) -11.06 (0.43) -10.64 
6b - p-MeOC6H5 -OCH3 -35.62 (0.20) 24.68 (0.40) -10.94 (0.45) -9.90 
6c - p-MeC6H5 -OCH3 -35.78 (0.17) 24.61 (0.38) -11.17 (0.41) -10.29 
6d - p-NO2C6H5 -OCH3 -35.61 (0.17) 24.59 (0.37) -11.02 (0.40) -10.64 
6e - p-AcC6H5 -OCH3 -35.50 (0.17) 24.67 (0.41) -10.83 (0.42) -9.87 
6f - p-CNC6H5 -OCH3 -35.67 (0.21) 24.71 (0.38) -10.96 (0.43) -10.51 
6g - p-CF3C6H5 -OCH3 -35.49 (0.19) 24.70 (0.39) -10.79 (0.43) -10.05 
6h - 1-naphtyl -OCH3 -35.72 (0.21) 24.81 (0.40) -10.91 (0.45) -10.81 
6i - p-biphenyl -OCH3 -35.13 (0.20) 24.98 (0.40) -10.15 (0.45) -9.11 
6j - 3-pyridyl -OCH3 -36.08 (0.22) 24.82 (0.36) -11.26 (0.42) -11.74 
7a - C6H5 H -38.46 (0.18) 25.73 (0.38) -12.73 (0.42) -12.00 
8a - C6H5 -OCH3 -38.49 (0.18) 25.81 (0.38) -12.68 (0.42) -11.28 
8b - p-MeOC6H5 -OCH3 -38.51 (0.21) 25.91 (0.38) -12.60 (0.43) -11.12 
8c - p-MeC6H5 -OCH3 -38.69 (0.20) 25.88 (0.41) -12.81 (0.46) -11.69 
 
A plot of the Gbind values calculated from simulations vs. those obtained experimentally 
using the corresponding Ki(1) (Gbind,(exp), last column in Table 3.1.14) shows a very good 
correlation coefficient (R2 = 0.81, see Figure 3.1.25). 
 
  
 
Figure 3.1.25 Correlation displaying the experimental vs. estimated free energy of binding for all 40 
ligand/1receptor complexes considered in this work. 
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Although this might be a somewhat expected result, given the structural similarity of the 
compounds considered, it is interesting to observe how MM-PBSA is able not only to rank all 
molecules in the correct order with respect to their affinity towards the 1 receptor but also to 
discriminate between high affinity (eg., Gbind values ranging from approximately -12 
kcal/mol to > -13 kcal/mol), intermediate affinity (-10.5 kcal/mol < Gbind < -12 kcal/mol), and 
low affinity compounds (Gbind < -10.5 kcal/mol). The most notable results, however, is the 
fact that these calculations do support the “reverse” binding mode of the molecules with the 
phenyl substituent in the left position with respect to those featuring the same group in the 
top position. In fact, if we consider the MD snapshot of the ligand 3h/1 receptor complex 
shown in Figure 3.1.26(A), we can observe how the main interactions detected after docking 
are totally preserved along the MD trajectory: a permanent salt bridge (average dynamic 
distance (ADL) = 4.03  0.12 Å) is established between the pyperidine NH+ group and the –
COO- moiety of Asp126; a persistent H-bond, characterized by an ADL of 1.93  0.18 Å, is 
detected between the backbone NH group of Thr151 and Val152 and the O atom of the pyran 
ring of 3h; a number of stabilizing  interactions takes place, involving the side chains of 
Trp121 and Tyr173 and the ligand benzonitrile and thiophene rings, respectively; and, lastly, 
the N-benzyl group of 3h remains nicely encased within the hydrophobic pocket generated by 
residues Ile128 and Phe133. These plethora of favorable, stabilizing interactions results in a 
calculated value of Gbind of -13.29 kcal/mol, in excellent agreement with the corresponding 
experimental value (-13.10 kcal/mol, see Table 3.1.14), thereby confirming the ranking of 3h as 
one of the most potent 1 ligands of the entire series. 
In the case of compound 6a, template molecule representative of all derivatives bearing the 
phenyl ring in the left position, the protein/ligand interactions depicted at the end of the 
pharmacophore-assisted docking phase are again detected and preserved during the entire 
MD simulation. In detail, a stable H-bond (ADL = 1.88  0.15 Å) is found between the side chain 
–OH group of Thr181 and the pyran ring oxygen of 6a while a salt bridge (ADL = 3.98  0.22 Å) 
between the CO2- group of E123 Glu123 and the pyperidine NH+ of 6a is also evidence for the 
whole simulation period. Favorable hydrophobic interactions are generated between the 
phenyl substituent and the side chains of Ile128 and Phe133 and, lastly, the thiophene moiety 
of 6a is engaged in a positive -interaction with the aromatic side chain of Tyr173, and is 
further stabilized by the influence of the vicinal alkylic chain of E172Glu172. 
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(A)                    (B) 
Figure 3.1.26 Equilibrated MD snapshots of 3h (A) and 6a (B) in complex with the 1 receptor. The 
images are zoomed views of the receptor binding site. The protein structure is depicted as a transparent 
gray ribbon, while both ligands are shown in atom-colored sticks-and-balls (C, gray; O, red; S, yellow; N, 
blue. H atoms are omitted). The protein residues mainly involved in the interaction with the ligands are 
highlighted as colored sticks and labeled. Salt bridge and H-bond interactions are shown as black lines. 
Some water molecules, ions and counterions are displayed as atom-colored spheres (O, red; H, white; 
Na+, purple; Cl-, green). 
 
Conclusion 
The introduction of aryl moieties in - and -position of complex spirocyclic 1 ligands was 
performed by regioselective direct C-H bond arylation using the catalyst systems PdCl2/2,2’-
bipyridyl/Ag2CO3 and PdCl2/P[OCH(CF3)2]3/Ag2CO3, respectively. This late stage 
functionalization allows the synthesis of a large library of diversely substituted spirocyclic 1 
ligands, which represent the basis for the development of a pharmacophore model. The main 
features of the pharmacophore are a positive ionizable group, an hydrogen bond acceptor 
group, two hydrophobic moieties and one hydrophobic aromatic point. Validation using test 
set compounds confirms the high quality of the pharmacophore model. The interactions of the 
spirocyclic 1 ligands with the receptor protein were analyzed by docking into a 3D homology 
model of the 1 receptor. These docking experiments led to a very good correlation between 
the experimentally determined free energy of the ligand binding (calculated from the Ki value) 
and the estimated free energy form the model. The most striking result of these calculations is 
the reverse binding mode of ligands with the phenyl moiety in the “top” position compared 
with ligands bearing the aryl moiety in the “left” position. Moreover, the contribution of single 
amino acid residues to the overall binding of both types of ligands was analyzed using the 
docking experiments. 
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3.1.4 BINDING AFFINITY OF S1RA, A 1 RECEPTOR, LACKING A 
PHARMACOPHORE REQUIREMENTS49 
In the field of 1 drug discovery and development, during the past years several 
pharmacophore models for 1 ligands have been published. All these models share the 
common features of a basic amino group and at least two hydrophobic substituents at the N-
atom.48,50 Considering the chemical structure of S1RA, however, in a recent viewpoint article,51 
Wünsch observed that, whilst the 2-[1-(2-naphthyl)pyrazol-3-yloxy]-ethyl moiety of S1RA could 
satisfy the requirement of the first hydrophobic N-substituent, the second hydrophobic 
substituent was represented only by the morpholine ring. According to the reported 
pharmacophoric models the high affinity of S1RA is then somewhat unexpected, since this 
heterocyclic moiety alone is likely not sufficient to fill the second hydrophobic pocket of the 
binding site of the 1 receptor. Here we report a computational study to investigate the origin 
of this interesting molecular behavior. 
 
 
 
 
    A      B 
Figure 3.1.27 Chemical structure of S1RA (A) and the benzoxazolone derivative 1c (B). 
 
Results and discussion 
In order to find a molecular-based rationale for the low Ki1 value of S1RA (17 nM),9b) we 
first mapped the optimized molecular model of S1RA onto our 1 three-dimensional (3D) 
pharmacophore model, as shown in Figure 3.1.28. The corresponding mapping of our best 1 
ligand, the benzoxazolone derivative 1 (Figure 3.1.27, bottom, Ki1 = 0.098 nM), is also shown 
for comparison. 
As we can see, the oxygen atom of the S1RA ether group serves as an hydrogen bond acceptor, 
and the basic nitrogen of morpholine fulfills the positive ionizable pharmacophoric 
requirement. However, as predicted by Wünsch,51 whilst the 2-napthyl moiety of S1RA maps 
the first hydrophobic aromatic feature of the pharmacophore, the other hydrophobic 
pharmacophoric features remain unmapped. Accordingly, the pharmacophoric predicted Ki1 
is 148 nM. On the contrary, all suitable chemical groups of 1 nicely overlay the corresponding 
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pharmacophoric features, resulting in a predicted lower Ki1 value (0.27 nM), in line with 
experiment.  
  
Figure 3.1.28 Mapping of S1RA (left) and 1 (right) on the 1 3D pharmacophore model. The hypothesis 
features are portrayed as mashed spheres, color-coded as follows: red, positive ionizable (PI); light blue, 
hydrophobic aromatic (HYAr); pink, generic hy-drophobic (HY), light green, hydrogen bond acceptor 
(HBA). HBA is actually represented as a pair of spheres (the smaller sphere represents the location of the 
HBA atom on the ligand and the larger one the location of an HB donor on the receptor). 
 
To progress further with the analysis, the optimized struc-ture of S1RA was docked into the 
putative binding pocket on the 3D 1 homology model by applying a consolidated 
procedure,25,29 and the drug/protein free energy of binding (Gbind) was estimated via 
MM/PBSA calculations6,52 (see also Materiasl&Methods chapter). As shown in Figure 3.1.29 A, 
a typical snapshot of the MD-simulated 1/S1RA complex reveals the presence of a stable and 
persistent salt bridge between the –NH+ moiety of the S1RA morpholine ring and the COO- 
group of Asp126 on 1, characterized by an average dynamic length (ADL) of 3.90 ± 0.09 Å. 
Also, the pyrazole ring and the 2-napthyl moiety of the ligand are engaged in stabilizing  
interactions with the aromatic side chains of Tyr173 and Phe133, respectively, while a 
permanent H-bond is detected between the oxygen atom of the 2-aminoethoxy group of S1RA 
and the –NH group of the 1 backbone peptide bond between Thr151 and Val152 (ADL = 2.05 ± 
0.06 Å). Finally, several hydrophobic interactions via the side chains of the 1 residues Tyr120, 
Ile128, and Glu172 further contribute to drug/receptor binding stability (Figure 3.1.29 A). With 
respect to 1c, however, some crucial stabilizing contacts are clearly missing (Figure 3.1.29 B), 
such as van der Waals and electrostatic interactions between Arg119 and Glu172 with the p-Cl-
phenyl and the benzoxazolonic heterocycle of 1, a T-stacking  interaction between the 
protein residue Trp121 and the heteroaro-matic condensed rings of 1, and a parallel-stacking 
 interaction between the protein residue Tyr173 and the benzoxazolone phenyl ring of 1c. 
In agreement with the experimental findings, S1RA was endowed with a good affinity for 1, as 
the calculated Gbind = -10.41 kcal/mol. In accordance with the components of the binding 
free energy in Figure 3.1.30 A, for both complexes van der Waals (EVDW) and electrostatic 
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(EELE) interactions in the gas phase provide the major favorable contribution to ligand 
binding. Nonpolar solvation energies (GNP), resulting from the burial of S1RA solvent 
accessible surface area, also afford positive contributions to the binding affinity. Conversely, 
polar solvation energies (GPB) and entropy components (-TS) oppose binding by originating 
the unfavorable contribution to Gbind. 
  
Figure 3.1.29 Equilibrated MD snapshot of S1RA (A) and 1 (B) in complex with the 1 receptor. The 
ligands are shown in atom-colored sticks-and-balls whilst the secondary structure of the receptor is 
portrayed as an orange ribbon. The main protein residues involved in ligand/receptor interactions are 
evidenced as colored sticks and labeled. Salt bridges and hydrogen bonds are highlighted as dotted and 
continuous lines, respectively. Some Na+ and Cl- counterions are shown as light and dark gray spheres, 
respectively. Hydrogen atoms and water molecules are omitted for clarity. 
 
To analyze in details similarities and differences in the binding mode of S1RA and 1 to the 1 
receptor, the binding free energy was further decomposed into ligand-residue pairs to create 
the receptor/residue interaction spectrum shown in Figure 3.1.30 B. As we can see, the 
interaction spectra of the two complexes share some common features, e.g., the major 
stabilizing contributions stemming from a few groups centered around residues Asp126, 
Ile128, and Val151.  
However, for those interacting residues less shared by the two compounds upon binding to the 
1 receptor (e.g., Phe133 and Tyr173), a sort of compensatory effect is detected. Where the 
interaction spectra differ substantially is on the left-hand side: as mentioned above, 1 is 
strongly stabilized by hydrophobic and interactions between its p-Cl-phenyl ring and the 
side chains of Arg119 and Trp121, respectively. Such interactions are obviously absent in the 
case of S1RA, and this loss of stabilization is only partly compensated by a  interaction 
between the 2-naphtyl moiety of S1RA and the lateral chain of Phe133. Interestingly, this 
interaction is forbidden to 1 as, due to its conformation, it cannot penetrate so deeply into the 
corresponding hydrophobic pocket. 
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Figure 3.1.30 (A) Energy components for the binding of S1RA and 1 to the 1 receptor. EVDW, van der 
Waals energy; EELE, electro-static energy; GNP, nonpolar solvation energy; GPB, polar solvation 
energy; GNP,T = EVDW + GNP; GP,T = EELE + GPB; -TS, total entropy contribution; Gbind = 
(GNP,T + GP,T) –TS). (B) Per-residue free energy contribution to the binding of S1RA and 1 to the 1 
receptor. 
 
Table 3.1.15 Binding free energy (Gbind) and its components for S1RA and 1 in complex with the 1 
receptor. All energy values are in kcal/mol. The experimental and calculated Ki values (nM) are also 
reported for comparison. 
 
S1RA 1 
E
VDW
 -39.11 ± 0.07 EVDW -48.68 ± 0.05 
E
ELE
 -131.24 ± 0.10 EELE -192.98 ± 0.09 
E
MM
 -170.35 ± 0.12 EMM -241.66 ± 0.10 
G
PB
 147.96 ± 0.13 GPB 213.39 ± 0.15 
G
NP
 -5.72 ± 0.02 GNP -3.64 ± 0.03 
G
SOL
 142.24 ± 0.13 GSOL 209.75 ± 0.15 
H
bind
 -28.11 ± 0.18 Hbind -31.90 ± 0.18 
-TS
bind
 17.70 ± 0.28 -TSbind 19.85 ± 0.32 
G
bind
 -10.41 ± 0.33 Gbind -12.05 ± 0.37 
K
i(calcd)
 24 nM Ki(calcd) 1.48 nM 
K
i(exp)
 17 ± 7 nM Ki(exp) 
0.098 ± 0.03 
nM 
 
Perhaps the most important finding is that, according to the predicted binding mode, S1RA 
leaves a moiety with polar characteristic such as the morpholine ring partially exposed to the 
solvent. In fact, as seen in the MD trajectory, the morpholine oxygen atom is always 
surrounded by water molecules; this in turn, results in a lower desolvation energy upon 
binding of S1RA (GPB = +147.96 kcal/mol, Table 3.1.15) with respect to 1, for which the 
 
 
128 
 
deeply burying of the p-Cl-phenyl group into the binding pocket requires a substantial 
desolvation penalty (GPB = +213.39 kcal/mol, Table 3.1.15). 
 
Conclusions 
The present in silico study was spurred by the inspiring observation that S1RA - a potent 1 
antagonist that could possibly become the first 1 selective drug in clinical use – 
notwithstanding its molecular structure does not fulfill all well-established pharmacophoric 
requirements of 1 ligands, is still endowed with a high affinity for the receptor. The results of 
the investigation led to the discovery that, aside a substantial number of stabilizing 
interactions between S1RA and 1, a significant favorable contribution to binding is afforded 
by a low molecular desolvation penalty paid upon binding, due to the exposition of a polar 
moiety to the solvent. 
This underlying binding mode of S1RA (never described so far for any other 1 ligand), if aptly 
exploited in association with all other fundamental 1 ligand pharmacophoric requirements 
might lead to the design and synthesis of new molecules endowed with ideal affinity towards 
the receptor. And it is just under these exciting perspectives that our jointed laboratories are 
now spending their present efforts in computer-assisted design and synthesis of new, potent 
1 ligands. 
 
3.1.5 STUDY OF ENANTIOMERIC COMPOUND RC-33 AS 1 RECEPTOR 
AGONIST53 
In this study we present the synthesis, and biological investigation of new 1 receptor ligands 
based on arylalkenylamine and arylalkylamine scaffolds (Figure 3.1.31).54 
Among our compound library, the most promising molecule is 1-[3-(1,1’-biphen)-4-
yl]butylpiperidine hydrochloride (RC- 33·HCl, Figure 3.1.31), showing excellent 1 receptor 
affinity (Ki= 0.700.3 nm) along with high selectivity over the 2 subtype, m- and k-opioid 
receptors, and the PCP binding site of NMDA receptors.55 RC-33·HCl also turned out to be a 
potent 1 receptor agonist in our validated PC12 cell model of neuronal differentiation. 
Indeed, this molecule is able to potentiate both nerve growth factor (NGF)-induced neurite 
outgrowth and elongation in the absence of toxic effects and at lower doses than the well-
characterized 1 receptor agonist PRE-084.
55 Finally, RC-33·HCl was found to be metabolically 
stable in several biological matrices such as mouse and rat blood, and rat, dog and human 
plasma. Significant degradation was only observed in rat and human liver S9 fractions in the 
presence of NADPH.56 According to these results, we identified RC-33·HCl as an optimal 
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candidate for the hit-to-lead process. Because the enantiomers of a chiral biologically active 
molecule may behave differently under physiological conditions (i.e., they can exhibit different 
pharmacological and/or toxicological profiles), the investigation of enantiopure forms is a key 
step in the drug discovery and development processes.57 Accordingly, in the present work we 
directed our efforts toward investigating the role of chirality in the biological activity and 
metabolic processing of RC-33. To this end, we isolated the pure enantiomers of RC-33 by 
chiral chromatography and carried out the assignment of their absolute configuration. 
Ar NR1R2
N
RC-33
phenyl, 
4-methoxyphenyl 
3-metoxyphenyl 
naphth-2-yl 
bifen-4-yl
morpholine 
piperidine 
N,N-dimethylamine 
N-benzyl-N-methylamine
 
Figure 3.1.31 Structure of arylalkenyl- and arylalkylamines and of the most promising compound  RC-33. 
The binding of enantiopure RC-33 at the 1 receptor was then investigated both in silico, by 
molecular dynamics (MD) simulations using our recently developed homology model for the 1 
receptor,1 and in vitro, by competition experiments with radioligand. The in vitro binding 
affinities of RC-33 enantiomers for opioid receptors and the PCP binding site of the NMDA 
receptor were also investigated, together with their capacity to promote NGF-induced neurite 
outgrowth in PC12 cells. As the last step in the present hit-to-lead process, both RC-33 
enantiomers underwent toxicity and in vitro metabolic studies. 
 
Figure 3.1.32 Analytical separation of rac-1 on a Chiralcel OJ-H (0.46 cm diameter x 15 cm length, 5 µm) 
column. Mobile phase, methanol/diethylamine (100/0.1, v/v), flow rate, 0.5 ml/min; detection at 250 
nm. 
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Receptor binding studies 
The affinities of the pure RC- 33·HCl enantiomers for 1 and 2 receptors were determined in 
competition experiments with radioligands. The highly 1-selective radioligand [3H](+)-
pentazocine and homogenates of guinea pig brain cortex were used in the 1 assay. 
Nonspecific binding was recorded in the presence of non-radiolabeled (+)-pentazocine in large 
excess. In the 2 assay, membrane preparations of rat liver served as the source for 2 
receptors. The nonselective radioligand [3H]DTG was employed in the 2 assay because a 2-
selective radioligand is not yet commercially available. To mask the 1 receptors, an excess of 
non-tritiated (+)-pentazocine was added to the assay solution, while a high concentration of 
non-tritiated DTG was used to determine nonspecific binding. To investigate receptor 
selectivity, the binding properties of pure RC-33·HCl enantiomers were also investigated for m-
, k-, d-opioid receptors and the PCP binding site of NMDA receptors using guinea pig brain ( 
and ), rat brain () and pig brain cortex (PCP binding site of NMDA) as sources of receptor 
material. [3H]DAMGO (), [3H]U- 69,593 (), [3H]DPDPE (), and [3H]MK-801 (NMDA) were used 
as specific radioligands. Nonspecific binding was determined with unlabeled naloxone (), 
unlabeled U-69,593 (), unlabeled morphine () and unlabeled (+)-MK-801 (PCP binding site of 
NMDA). The residual binding of the radioligand is given at a test compound concentration of 1 
mm (opioid receptor binding assays) or 10 mm (NMDA receptor binding assays). Binding 
results are summarized in Table 3.1.16, together with data for RC-33·HCl, reported for 
comparison purposes. 
The enantiomeric arylalkylamines (S)-RC-33·HCl and (R)-RC-33·HCl herein presented showed 
interesting binding properties towards the ς1 receptor subtype (Ki values < 2 nM, Table 3.1.16) 
and a good selectivity over the ς2, -, -, - opioid, and the PCP binding site of NMDA 
receptors. As concerns the role of chirality in the ς1 receptor binding, the two enantiomers and 
RC-33·HCl are endowed with a comparable affinity for the ς1 receptor. Importantly, this finding 
supports the notion that the interaction of these compounds with this biological target is non-
stereoselective. 
Table 3.1.16 Affinities of compounds RC-33·HCl towards σ1, σ2, NMDA, -, 
- and -opioid receptors. 
Compd
[a]
  
Ki ± SEM (nM)
[b]
 Displacement (%) of specific radioligands 
1 2 -opioid -opioid -opioid NMDA 
RC-33 0.9±0.3 29±5 0 36 0 25 
(S)-RC-33 1.9±0.2 34±8 12 0 0 11 
(R)-RC-33   1.8±0.1 45±16 14 0 5 8 
[a] Compounds were tested as hydrochlorides. [b] Values are means ± SEM 
of three experiments. 
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MD simulations 
For a molecular-level explanation of the non-stereoselective binding of RC-33 enantiomers to 
the 1 receptor, the putative binding modes of (R)- and (S)-RC-33 on our 1 receptor 3D 
homology model were retrieved by exploiting the currently available preliminary information 
on sequence–structure relationships and mutagenesis studies.1,58 
The two enantiomers of RC-33 were docked into the putative binding site of our 3D receptor 
model, and their affinity toward the receptor was scored by MM/PBSA analysis.6 
In a typical structure of the MD-simulated 1–ligand complexes, both (R)- and (S)-RC-33 are 
oriented horizontally inside the receptor binding pocket and adopt similar binding poses, as 
illustrated in Figure 3.1.33 For both enantiomers, the -NH+ moiety of the ligand piperidine ring 
is anchored around the negatively charged side chain of Asp126 from the 1 protein, 
interacting with each other through a permanent salt bridge. 
 
 
 
 
 
 
 
 
 
Figure 3.1.33 A) Overlay of representative structures for (R)-RC-33 (light blue balls-and-sticks) and (S)-RC-
33 (spring green balls-and-sticks) in complex with the σ1 receptor (orange ribbon), taken from 
equilibrated MD snapshots. Some Na+ and Cl- ions are also shown as purple and light green spheres, 
respectively. Hydrogen atoms and water molecules are not shown for clarity. B) Zoomed view of the 
binding modes of (R)-RC-33 and (S)-RC-33 in the σ1 binding pocket. In this image, the protein is portrayed 
as transparent ribbon, colored according to the respective ligand. 
 
As tracked by MD simulations, the average distance for the salt bridge through the proton at 
the cationic moiety of RC-33 and the COO- group of 1 Asp126 is 2.9 ± 0.1 Å  for the R 
enantiomer and 2.7 ± 0.1 Å  for the S enantiomer (Figure 3.1.34). The two aromatic rings of RC-
33 are packed parallel to Tyr120 and perpendicularly with respect to Tyr173, resulting in 
strongly stabilizing  interactions. Lastly, as can be appreciated from Figure3.1.3 4, in both 
cases the entire RC-33 molecule is nicely lined by the side chains of several other 1 residues, 
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and the relevant hydrophobic interactions which originate from these intermolecular contacts 
all contribute to stabilize receptor– ligand binding. 
 
Figure 3.1.34 Equilibrated MD snapshots of A) (R)-RC-33 and B) (S)-RC-33 in complex with the ς1 
receptor. The images are zoomed views of the receptor binding site. The protein structure is depicted as 
a transparent light blue and light green ribbon, respectively, while both enantiomers are shown in atom-
colored sticks-and-balls (C, gray; N, blue; H atoms are omitted). The protein residues mainly involved in 
the interaction with the ligands are highlighted as colored sticks and labeled. Salt bridge interactions are 
shown as dotted black lines. Water molecules and counterions are not shown for clarity. 
 
The similar binding mode and the equivalent type and number of interactions predicted for 
(R)- and (S)-RC-33 in complex with the 1 receptor constitute the molecular rationale, 
according to which our MM/PBSA estimated binding affinities (Gbind) for these two 
enantiomers for the protein are nearly identical, that is, Gbind = -11.42 ± 0.29 kcal mol-1 for 
(R)-RC-33 and Gbind = -11.15 ± 0.31 kcal mol-1 for (S)-RC-33. In accordance with the 
components of the binding free energy in Figure 3.1.35 a, for both 1–RC-33 enantiomer 
complexes, van der Waals (EVDW) and electrostatic (EELE) interactions in the gas phase 
provide the major favorable contributions to ligand binding. Nonpolar solvation energies 
(GNP), resulting from the burial of RC-33 solvent-accessible surface area, also afford positive 
contributions to the binding affinity. Conversely, polar sol-vation energies (GPB) and entropy 
components (-TS) oppose binding by making unfavorable contributions to Gbind. 
To analyze in detail the similarities and differences in the binding modes of the two RC-33 
enantiomers with the 1 receptor, the binding free energy was further decomposed into 
ligand–residue pairs to create the receptor–residue interaction spectrum shown in Figure 
3.1.35b. As can be observed, the interaction spectra of the two complexes are similar to each 
other, with the major contributions stemming from a few groups centered around residues 
Asp126, Tyr120, and Glu172 in both cases, as expected. Furthermore, for interacting residues 
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that are not shared by the two enantiomers of RC-33 upon binding to the s1 receptor (i.e., 
Thr127, Trp169, and Met170 for the R enantiomer, and Arg119, Trp121, and Phe133 in the 
case of the S enantiomer), a sort of compensatory effect is present, ultimately resulting in the 
non-stereoselective binding of the 1 receptor to RC-33. 
 
 
Figure 3.1.35 A) Energy components for the binding of (R)-RC-33 and (S)-RC-33 to the σ1 receptor. 
∆EVDW, van der Waals energy; ∆EELE, electrostatic energy; ∆GNP, nonpolar solvation energy; ∆GPB, 
polar solvation energy; ∆GNP,T = ∆EVDW + ∆GNP; ∆GP,T = ∆EELE + ∆GPB; -T∆S, total entropy 
contribution; ∆Gbind = ∆GNP,T + ∆GP,T –T∆S. B) Per-residue free energy contribution to the binding of 
(R)-RC-33 and (S)-RC-33 to the σ1 receptor.   
 
NGF-induced neurite outgrowth in PC12 cells and cytotoxicity 
Pure enantiomers of RC-33·HCl were tested in our validated PC12 cell model of neuronal 
differentiation to analyze their effect on NGF-induced neurite outgrowth. In previous 
experiments on PC12 cells rac-RC-33·HCl displayed an agonist profile, consistently and 
significantly potentiating NGF-induced neurite outgrowth at concentrations as low as 0.25 
mm.55 Therefore, we chose this concentration to test (S)- and (R)-RC-33·HCl on PC12 cells. rac-
RC-33·HCl and its enantiomers appear to be almost equally effective. Indeed, both 
enantiomers were able to increase the percentage of cells with neurite outgrowth with respect 
to NGF alone (152.8±7.6 %, p<0.01 and 143.1 3.8% p<0.01 for (S)- and (R)-RC-33·HCl, 
respectively), showing an effect very similar to that of rac-RC-33·HCl (157.7±11.0 %, p<0.001) 
(Figure 3.1.36). Additionally, their effect was totally blocked by co-administration of the 
selective 1 antagonist NE- 100. Taken together, these results confirm that (S)- and (R)-RC- 
33·HCl similarly modulate NGF-induced neurite outgrowth, specifically acting as 1 receptor 
agonists. 
Finally, an MTT-based cytotoxicity assay, performed after treating HaCaT cells with (S)- or (R)-
RC-33·HCl and with rac-RC- 33·HCl for 48 h (Figure 3.1.37) or 72 h confirmed that, similarly to 
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the racemic mixture, both enantiomers are nontoxic at the concentration used in our NGF-
induced neurite outgrowth experiments. 
 
Figure 3.1.36 Potentiating effect of σ1 receptor ligands RC-33·HCl and enantiomers (at 0.25 M) on NGF 
(2.5 ng mL-1)-induced neurite outgrowth. NE-100 (3 ) co-administration totally blocked the 
potentiating effect. Histograms represent the mean ± SEM of at least three different experiments. Data 
are expressed as percentage of control (CTR) (NGF alone). ANOVA: p<0.0005; Tukey’s post-hoc test: 
***=p<0.001; **=p<0.01 vs NGF alone. °°°=p<0.001 vs (-)-(R)-RC-33•HCl; #=p<0.05 vs (+)-(S)-RC-33•HCl. 
 
Figure 3.1.37 Effect of σ1 receptor ligands RC-33·HCl and enantiomers on HaCaT cell viability. Values are 
the mean ± SEM of at least three different experiments. ANOVA: p<0.0001; Tukey’s post-hoc test: 
*=p<0.0001 CTR vs (R)-RC-33·HCl;  (S)-RC-33·HCl and rac-RC-33·HCl. 
 
In vitro metabolic stability studies 
To investigate the role of chirality on metabolic processes, the hepatic metabolic stability of 
RC-33·HCl enantiomers was tested in vitro using rat and human liver S9 fraction. We previously 
described rac-RC-33·HCl in vitro metabolic stability in several biological matrices, such as 
mouse and rat blood, rat, dog and human plasma, as well as rat and human liver S9 fractions, 
containing microsomes (metabolic enzymes of phase I) and cytosol (metabolic enzymes of 
phase II).56 rac-RC-33·HCl showed high metabolic stability in all the investigated matrices, with 
the only exception of liver S9 fractions in the presence of NADPH. Therefore, in the present 
work we addressed our attention at evaluating the hepatic metabolism of (R)- and (S)-RC-
33·HCl in rat and human liver S9 fractions both in the presence and in the absence of NADPH. 
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To this aim, our previously validated and reproducible method using an ultrafast liquid 
chromatography system interfaced with a photodiode array detector (UPLC/UV/PAD, Acquity, 
Waters) was applied. 
Briefly, UPLC/UV/PAD analyses were carried out with a BEH Shield RP18 column, eluting with a 
mixture of water and methanol, containing 0.1% formic acid, in gradient at a flow rate of 0.5 
mL min-1. Calibration curves in the range of 1–200 mm (eight points of calibration) were 
determined, adding known concentrations of each enantiomer of RC-33·HCl to each 
considered biological matrix, previously deproteinized. In all cases calibration curves with a 
quadratic correlation coefficient (R2) of 0.9999 were obtained. Quantification was performed 
by comparing the chromatographic peak areas for test solutions with those of external 
standard. The matrices could be directly analyzed by UPLC without clean-up steps. 
Similarly to the racemate, both RC-33·HCl enantiomers underwent relatively weak non-
oxidative metabolism, with degradation of ~30% within 4 h at 37° C, both in rat and human 
(Figure 3.1.38). In contrast, they were subjected to a relevant oxidative metabolism in both rat 
and human liver S9 fractions within the same frame time at 37° C. Notably, degradation of 
~50% in both rat and human was evidenced for (R)-RC-33·HCl, while degradation of ~70% in 
both the biological matrices was observed for (S)-RC-33·HCl (Figure 3.1.39a,b). Moreover, as 
clearly shown in the semi-logarithmic plots shown in Figure 3.1.39 c,d, the oxidative 
degradation of both enantiomers follows first-order kinetics, with a half-life (t1/2) of 112 min 
in rat and 130 min in human for (S)-RC-33·HCl, and of 225 min in rat and 246 min in human for 
(R)-RC-33·HCl. Overall, results of the in vitro hepatic metabolic stability studies clearly show 
that RC-33·HCl enantiomers are similarly metabolized by non-oxidative processes in both rat 
and human; on the other hand, their degradation in the presence of NADPH was unequivocally 
proven to be enantioselective with a preference for the S enantiomer in both species. 
 
 
Figure 3.1.38 Degradation time-courses of A) (S)-RC-33·HCl and B) (R)-RC-33·HCl in rat and human liver 
S9 fraction in absence of NADPH at 37°C. Data are expressed as the mean  SD of two independent 
experiments. 
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Figure 3.1.39 Degradation time-courses of (S)-RC-33·HCl (open circles) and (R)-RC-33·HCl (full circles) in 
A) rat and B) human liver S9 fraction in presence of NADPH at 37°C. Data are expressed as the mean  SD 
of two independent experiments. Enantiomers of RC-33·HCl showed a significant degradation in liver S9 
fraction in the presence of NADPH, following a first order kinetic, as confirmed by the semilogaritmic plot 
C) for rat and D) for human. 
Conclusions 
In the present work we addressed the role of chirality in the biological activity of RC-33, 
recently studied by us in its racemic form. RC-33 enantiomers were isolated by 
enantioselective semi-preparative HPLC, and their absolute configuration was assigned by 
applying an integrated CD analysis/chemical correlation strategy. Their in vitro binding 
affinities toward , opioid, and PCP binding site of the NMDA receptors were investigated, and 
their agonist/antagonist profiles at 1 receptor were derived. In synthesis, (R)-RC-33 and (S)-
RC-33 showed nearly the same affinity for the 1 receptor and were equally effective as 1 
receptor agonists, without toxic effects at the concentration shown to be effective. To provide 
a rational in silico explanation of the experimental evidence that the interaction between RC-
33 enantiomers and the 1 receptor is non-stereoselective, the two enantiomers were docked 
into the putative binding site of our 3D receptor model, and their affinity toward the receptor 
was scored by MM/PBSA analysis. The results of our modeling investigations confirm that both 
enantiomers of RC-33 can be accommodated within the 1 binding site and establish the same 
network of stabilizing interactions with the target, supporting the non-stereoselective binding 
of RC-33 to the 1 receptor. Lastly, the hepatic metabolic stability RC-33 enantiomers was also 
tested in vitro using rat and human liver S9 fractions. (S)- and (R)-RC-33 were similarly 
metabolized by non-oxidative processes in both rat and human. 
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Interestingly, compared with the corresponding enantiomer, (S)-RC-33·HCl was preferentially 
metabolized in the presence of NADPH in both rat and human, thus proving that the oxidative 
metabolic processes possess the same enantiomeric preference in both species. 
In summary, based on the overall results of the biological investigations, (R)-RC-33 emerged as 
the eutomer. Because 1 receptor agonists such as PRE-084 were recently shown to be 
promising candidates for a therapeutic strategy for ALS,59 (R)- RC-33 represents the optimal 
candidate for the in vivo investigation. 
Its pharmacokinetic profile and results of both shortand long-term investigations as drug 
candidate in an animal model of ALS will be reported in due course. 
 
3.1.6 THE SIGMA ENIGMA: IN SILICO/IN VITRO SITE DIRECTED 
MUTAGENESIS STUDIES UNVEIL 1 RECEPTOR LIGAND BINDING 
Several synthetic molecules belonging to different structural classes were thus found to bind 
to the 1 receptor. (+)-Pentazocine (PTZ) represents a very potent and highly selective 1 
agonist, which is used as a “gold standard” in 1-ligand binding studies.  
Membrane/protein model generation.  
The CHARMM-GUI Lipid Builder web application60,61 was used to insert our 1 3D model in a 
pre-equilibrated membrane. The membrane was built using 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC), 1-palmitoyl-2-oleoyl-sn- glycero-3-phosphoethanolamine (POPE) and 
cholesterol in a 2:2:1 proportion. 125 and 115 lipid molecules constituted the top and bottom 
membrane leaflets, respectively. Both sides of the membrane were solvated by two layers of 
0.150 M NaCl solution of TIP3P water molecules,16 each extending 20 Å from the membrane 
lipid polar heads. The entire system was parameterized using the lipid1162  and ff0317 force 
fields for the lipids and the protein, respectively. After an initial relaxation (for details see 
Materials&Methods chapter), the systems was allowed to equilibrate for 50 ns adopting a 
semi-isotropic constant surface tension of 15.0 dyne/cm. Once an equilibrated value of area 
per lipid was reached, all remaining constraints were finally released, and additional 50 ns of 
MD NPT simulations were performed. At the end of the MD simulation, we taken the final 
snapshot and we separated the protein from the membrane. Then, we used this optimized 
protein structure as starting conformation for the subsequent docking studies. 
Docking Studies.  
The model structures of PTZ was sketched and geometrically optimized using Discovery Studio 
(DS, version 2.5, Accelrys). The optimized structure of PTZ was then docked into the ς1 putative 
binding pocket by applying a consolidated procedure, already described in this thesis.  All 
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docking experiments were performed with Autodock 4.3/Autodock Tools 1.4.6 on a win64 
platform.  
 
Molecular Dynamics simulations.  
The ligand/receptor complex obtained from the docking procedure was further reinserted into 
the membrane and subsequently refined in Amber 1263 as follow: each system was relaxed by 
500 steps of steepest descent followed by 500 other conjugate-gradient minimization steps 
and then gradually heated to a temperature of 300 K in intervals of 50 ps of NVT MD, using a 
Verlet integration time step of 1.0 fs. The Langevin thermostat was used to control 
temperature, with a collision frequency of 2.0 ps-1. The SHAKE method18 was used to constrain 
all of the covalently bound hydrogen atoms, while long-range nonbonded van der Waals 
interactions were truncated by using dual cutoffs of 6 and 12 Å. The particle mesh Ewald (PME) 
method  was applied to treat long-range electrostatic interactions. All simulations were carried 
out with periodic boundary conditions. The density of the system was subsequently 
equilibrated via MD runs in the NPT ensemble, with isotropic position scaling and a pressure 
relaxation time of 1.0 ps, for 50 ps with a time step of 1 fs. Each system was further 
equilibrated using NPT MD runs at 300 K, with a pressure relaxation time of 2.0 ps. Three 
equilibration steps were performed, each 2 ns long and with a time step of 2.0 fs. To check the 
system stability, the fluctuations of the rmsd of the simulated position of the backbone atoms 
of the ς1 receptor with respect to those of the initial protein were monitored. All chemico-
physical parameters and rmsd values showed very low fluctuations at the end of the 
equilibration process, indicating that the systems reached a true equilibrium condition. The 
equilibration phase was followed by a data production run consisting of 15 ns of MD 
simulations in the NVT ensemble. Only the last 10 ns of each equilibrated MD trajectory were 
considered for statistical data collections. 
 
Free energy of binding analysis. 
The binding free energy, ΔGbind, between PTZ and the 1 receptor was estimated by resorting 
to the MM/PBSA approach.6 The free energy was calculated for each molecular species 
(complex, receptor, and ligand), and the binding free energy was computed as the difference..  
A per residue binding free energy decomposition was performed exploiting the MD trajectory 
of each given compound/receptor complex, with the aim of identifying the key residues 
involved in the ligand-receptor interaction. This analysis was carried out using the MM/GBSA 
approach,27,64 and was based on the same snapshots used in the binding free energy 
calculation. 
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Computational mutagenesis.  
For the computational mutagenesis studies, mutation of the selected residues into alanine was 
performed on the membrane-bound equilibrated structure of the wild-type 1 receptor 
complex. Each mutated complex was equilibrated in a 0.150M NaCl TIP3P water solution to 
relax eventual conformational perturbations induced by residue mutation. Each system was 
then first subjected to 100 energy minimization steps, followed by further solvent equilibration 
for 100 ps of MD at 310 K. Finally, the entire system was equilibrated for 2 ns at 310 K. The 
subsequent MD simulation was carried out with the Amber 12 program as described above. 
Results 
To better understand the structure and ligand binding of the 1 receptor we have now carried 
out a coupled in vitro/in silico site-directed mutagenesis study of the receptor. Specifically, on 
the basis of preliminary in silico information 23 mutants of the 1 receptor were cloned, 
expressed, and their interactions with PTZ were determined experimentally (Figure 3.1.40c). 
As described below, all direct and indirect effects exerted by the mutant residues on the 
receptor/agonist interactions could be reproduced in silico and rationalized at the molecular 
level (Table 3.1.17). 
At first we considered those 1 residues belonging to the protein putative ligand binding site. 
To the purpose, the interaction of PTZ with the wild-type (wt) 1 receptor 3D model was 
simulated using molecular dynamics (MD): the corresponding estimated drug/receptor affinity 
value   
 = 45 nM (Table 3.1.18) compares well with the experimentally measured value of   
 = 
15 nM (19). Specifically, the following interactions were found to be essential for PTZ binding 
(Figure 3.1.41 a): i) a permanent salt bridge between the NH+ moiety of PTZ and the COO- 
group of D126 (average dynamic length (ADL) = 3.93 ± 0.09 Å); ii) a stable hydrogen bond 
between the carboxylate group of E172 and the hydroxyl substituent of PTZ (ADL = 1.98 ± 0.04 
Å); iii) a T-stacking π-π interaction between the side-chains of Y120 and W121 and the 
heteroaromatic condensed rings of PTZ; and iv) highly stabilizing van der Waals and 
electrostatic interactions between R119, I128 and Y173 and the aliphatic/aromatic portions of 
the ligand. These receptor/ligand interactions were quantified via a per residue deconvolution 
of the free energy of binding (Figure 3.1.40 b,c). 
Accordingly, the salt bridge and the hydrogen bond involving D126 and E172 are responsible 
for stabilizing contributions of -2.89 kcal/mol and -1.83 kcal/mol. Substantial van der Waals 
and electrostatic interactions are further contributed by R119 (-0.98 kcal/mol), Y120 (-1.49 
(kcal/mol), W121 (-1.37 kcal/mol), I128 (-2.04 kcal/mol), and Y173 (-1.95 kcal/mol). T151 and 
V152 additionally contribute in stabilizing PTZ/1 binding by -0.36 kcal/mol and -0.38 kcal/mol, 
respectively. 
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Table 3.1.17 In silico site-directed mutagenesis of the selected 1 residues. In silico estimated free energy 
of PTZ binding (Gbind) of different mutants of the human  1 receptor as generated by computational 
mutagenesis. Errors are given in parenthesis as standard errors of the mean (SEM). aGbind = 
Gbind,wt – Gbind,mutant. bBy definition, a negative value of Gbind indicates a favorable 
contribution for the wt residue in that position and vice versa. 
 
1 residue ΔGbind (kcal/mol) 
a,b
ΔΔGbind (kcal/mol) 
wt -10.02 (0.05) - 
S101A -8.16 (0.08) -1.86 
Y103A -7.89 (0.09) -2.13 
F107A -8.05 (0.05) -1.97 
Y120A -9.34 (0.08) -0.68 
W121A -8.48 (0.06) -1.54 
S125A -8.57 (0.09) -1.45 
D126A -7.01 (0.10) -3.01 
D126E -9.13 (0.07) -0.89 
T127A -8.78 (0.11) -1.24 
I128A -7.55 (0.06) -2.47 
V145A -9.89 (0.07) -0.13 
F146A -9.42 (0.09) -0.60 
Y147A -8.80 (0.06) -1.22 
E172A -8.00 (0.05) -2.02 
E172D -7.88 (0.06) -2.14 
Y173A -7.32 (0.11) -2.70 
R175A -8.00 (0.10) -2.02 
T181A -9.99 (0.11) -0.03 
F184A -10.55(0.07) 0.53 
T189A -9.87 (0.07) -0.15 
F191A -9.13 (0.10) -0.89 
217Stop -8.80 (0.06) -1.22 
 
 
 
 
 
141 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.40 Site-directed mutagenesis of the 1 receptor. (a) 3D structure of the 1 receptor embedded 
in a 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine (POPC)/1-Palmitoyl-2-oleoyl-sn-
glycero-3-phosphoethanolamine (POPE)-cholesterol (2:2:1) membrane model. Water is evidenced via its 
light blue van der Waals surface, while some Cl- and Na+ ions are visible as dark blue spheres. The polar 
heads of POPC/POPE lipids are portrayed as forest green sticks-and-balls, their solvent accessible surface 
area being highlighted in transparent forest green. The lipid hydrophobic tails are shown as grey sticks. 
Cholesterol molecules are evidenced as light green CPK spheres, while the 1 receptor is depicted as a red 
ribbon. (b) Cross section of the system in (a) (water and ions not shown). (c) Specific [3H]-(+)-pentazocine 
(PTZ) binding (SB) at a concentration of 40 nM to different alanine mutants of the human σ1 receptor (n ≥ 
2). SB is referred to the PTZ binding of the wild-type (wt) receptor (100 %, first column). **Significance 
level p ≤ 0.001; *Significance level p ≤ 0.01. Red lines: SB < 30 % indicates high influence of the particular 
amino acid on ligand binding; 30% ≤ SB ≤ 70% indicates moderate influence on ligand binding; SB > 70 % 
indicates no influence on ligand binding. 
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Table 3.1.18 In silico predicted affinity of PTZ for the wild-type 1 receptor. Binding free energy (Gbind) 
and its components PTZ in complex with the wt 1 receptor. All energies are in kcal/mol. Errors are given 
as the standard deviation from the mean. The calculated Ki values (nM) are also reported. The   
  value 
is obtained from the corresponding Gbind using the fundamental relationship Gbind = -RTln(1/  
 ). 
 
E
VDW
 -36.31 ± 0.06 
E
ELE
 -130.29 ± 0.10 
E
MM
 -157.00 ± 0.12 
G
PB
 141.88 ± 0.18 
G
NP
 -2.84 ± 0.01 
G
SOL
 139.04 ± 0.18 
H
bind
 -27.56 ± 0.22 
-TS
bind
 17.54 ± 0.39 
G
bind
 -10.02 ± 0.45 
  
  45 nM 
  
  15 nM 
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Figure 3.1.41 In silico mutagenesis of 1 receptor binding site residues. (a) Equilibrated MD snapshot of 
the wt 1 receptor in complex with PTZ. The image is a zoomed view of the receptor binding site. The 
ligand is portrayed in colored sticks-and-balls (C, gray; N, blue; O, red). The protein residues mainly 
involved in the interaction with PTZ are highlighted as labeled colored sticks. Salt bridges and H-bonds 
interactions are shown as continuous and dotted black lines, respectively. The yellow shadow portrays 
the hydrophobic pocket generated by the side-chains of I128 and Y173. (b) Per residue energy 
decomposition for wt 1 receptor in complex with PTZ. Only 1 amino acids from position 100 to 200 are 
shown, as for all remaining residues the contribution to ligand binding is irrelevant. (c) Expanded view of 
(b) showing those 1 residues for which Hbind ≥ 0.5 kcal/mol. Comparison of the equilibrated MD 
snapshots of the wt 1 receptor (blue) with (d) I128A (sienna) and (e) Y173A (sandy brown) mutants in 
complex with PTZ. The ligand is portrayed in sticks-and-balls colored according to the respective protein 
complex. In panels a, d, and e hydrogen atoms, water molecules, ions, and counterions are omitted for 
clarity. 
 
R119, I128 and Y173 are essential residues for PTZ binding.  
The results of the site-directed mutants of those residues identified in silico as crucial for PTZ 
binding are listed in Table 3.1.19. We see that mutating residues R119, I128, and Y173 within 
the 1 binding site into alanine leads to an almost complete loss of ligand binding, as predicted 
from simulation (Table 3.1.19, Figure 3.1.40 c, 3.1.41 d,e and Figure 3.1.42). Indeed, residues 
I128 and Y173 afford a significant contribution to PTZ/1 complex (Figure 3.1.41 c), as their 
side-chains generate a hydrophobic pocket tailored to encase the methylbut-2-enyl moiety of 
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PTZ (Figure 3.1.41 d,e). Accordingly, the favorable hydrophobic interactions exerted by these 
two residues in binding PTZ are lost upon alanine substitution (I128: SB = 1%, Gbind = -2.47 
kcal/mol; Y173: SB = 0.4%, Gbind = -2.70 kcal/mol, Figure 3.1.40 c). On the contrary, the 
affinity of the Y120A and W121A 1 mutants for PTZ was only partly reduced (SB = 62% and 
76%, respectively). Interestingly, the relevant modeling analysis reveals that, although each of 
these two aromatic residues concur in stabilizing PTZ binding mainly via  interactions 
(Figure 3.1.41 and Figure 3.1.42), the effect of mutating either of these two positions into 
alanine results in an apt rearrangement of the alternative residue side chain within the binding 
site and, hence, in a partial compensation of the receptor affinity loss (Gbind = -0.68 
kcal/mol for Y120A and -1.54 kcal/mol for W121A, respectively, Table 3.1.19). 
 
Table 3.1.19 In vitro/in silico site-directed mutagenesis of 1 residues directly involved in PTZ binding. 
Specific PTZ binding of different alanine mutants of the human 1 receptor and in silico estimated free 
energy of binding (Gbind) of the same 1 alanine mutants as generated by computational mutagenesis. 
Errors are given in parenthesis as standard errors of the mean (SEM). aGbind = Gbind,wt – 
Gbind,mutant. 
b
By definition, a negative value of Gbind indicates a favorable contribution for the wt 
residue in that position and vice versa. 
 
1 residue specific binding of PTZ [%] ΔGbind (kcal/mol) 
a,bΔΔGbind (kcal/mol) 
wt 100 -10.02 (0.05) - 
R119A 26 (3.5) -8.31 (0.05) -1.71 
Y120A 62 (10) -9.34 (0.08) -0.68 
W121A 76 (12) -8.48 (0.06) -1.54 
I128A 1.1 (0.6) -7.55 (0.06) -2.47 
Y173A 0.4 (0.4) -7.32 (0.11) -2.70 
D126E 54 (3) -9.13 (0.07) -0.89 
E172D 0 (0.1) -7.88 (0.06) -2.14 
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Figure 3.1.42 In silico mutagenesis of 1 receptor binding site residues. Comparison of the equilibrated 
MD snapshots of the wt 1 receptor (blue) with (A) R119A (khaki), (B) Y120A (orchid) and (C) W121A 
(pink) mutants in complex with PTZ. The images are a zoomed view of the receptor binding site. The 
ligand is portrayed in sticks-and-balls colored according to the respective protein complex. In both panels 
hydrogen atoms, water molecules, ions, and counterions are omitted for clarity.  
 
D126 and E172 are strategically located within the 1 binding site.  
The anionic amino acids D126 and E172 are known to be essential for ligand (i.e., haloperidol) 
binding,5 and our combined study indeed confirms their role in binding PTZ (Figure 3.1.40 c 
and 3.1.41 b,c). To substantiate this prediction, however, we decided to swap these two 
residues by each other instead of replacing them by alanine in the corresponding site-directed 
mutagenesis experiments. Interestingly, the E172D 1 mutant was totally devoid of PTZ 
binding, while the D126E isoform preserved 54% of the wt affinity. These results clearly 
demonstrate the specific and strategic location of these two negative charges within the 1 
binding site: while the elongation of the side chain from aspartate to glutamate at position 126 
is somewhat tolerated (Gbind = -0.89 kcal/mol, Table 3.1.19), resulting in a mild 
rearrangement of the protein binding pocket which preserves the main network of 
interactions between the ligand and the protein, the corresponding reduction of the chain 
length in the E172D mutant fully abrogates the ability of the protein to bind the radioligand 
(Gbind = -2.14 kcal/mol, Table 3.1.19). In detail, the substitution of D/E at position 126 leads 
to a longer – and hence less stable – salt bridge between the -NH+ group ion PTZ and the –
COO- group of E126 side chain (ADL = 4.85 ± 0.08 Å), leaving all other ligand/receptor 
A B 
C 
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interactions almost unaltered (Fig. 3.1.43 a). Upon E172D substitution, however, the missing 
H-bond between position 172 and the –OH group on PTZ leads to a global readjustment of the 
protein binding site (Fig. 3.1.43 b) which ultimately leads to an overall decrease of the 
favorable contributions to ligand binding.  
 
 
 
 
 
Figure 3.1.43 In silico mutagenesis of 1 receptor binding site residues D126E, E172D, D126A and E172A. 
Comparison of the equilibrated MD snapshots of the wt 1 receptor (blue) with (a) D126E (goldenrod), 
(b) E172D (forest green), (c) D126A (red) and (d) E172A (firebrick) mutants in complex with PTZ. The 
images are a zoomed view of the receptor binding site. The ligand is portrayed in sticks-and-balls colored 
according to the respective protein complex. In panels a-c hydrogen atoms, water molecules, ions and 
counterions are not shown for clarity. (e) Comparison of 1 residue contributions to PTZ binding for the 
wt and the E172D mutant protein. (f) Expanded view of (e) showing those 1 residues for which Hbind 
≥ 0.5 kcal/mol in the wt receptor. 
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To further corroborate this fundamental finding we also performed in silico mutagenesis of 
D126 and E172 into alanine. As expected, the prominent role exerted by D126 and E172 in 
binding PTZ is reflected in the highly unfavorable affinity predicted for the D126A and E172A 
mutants (Gbind = -3.01 kcal/mol and -2.02 kcal/mol, respectively, Table 3.1.17). The missing 
of the critical salt bridge and H-bond interactions in which these residues are engaged in the 
wt protein bound to PTZ results in a catastrophic loss of drug interaction when mutated to 
alanine (Figure 3.1.43 c-f). These predictions match the results previously reported by Seth et 
al.5 on in vitro PTZ binding assays of the D126G and E172G 1 mutants; taken together, these 
results ultimately confirm the obligatory nature of the highly conserved D126 and E172 
residues for the ligand binding function of the 1 receptor. 
Polar residues are required in the SBDLI domain to maintain binding site geometry.  
Next, we explored the effect of mutations on residues belonging to the SBDLI, and SBDLII 1 
domains by performing a systematic substitution of the polar (S, T) and aromatic (F, Y) amino 
acids of these protein regions with alanine. The results are shown in Table 3.1.20. Mutating the 
polar and aromatic amino acids of the SBDLI (S101, Y103, and F107) into alanine both in silico 
and in vitro led to a considerable reduction of PTZ binding (SB = 18÷30%, Gbind = -2.13 ÷ -
1.86 kcal/mol, Table 3.1.20, rows 1-3). A sensible explanation for these results is that all three 
alanine-mutated residues lie in proximity of the transmembrane domain of the 1 receptor 
(Figure 3.1.44 a) and, during the long MD simulation, they promote a substantial modification 
of both the entire binding site and the surrounding protein regions. 
 
Table 3.1.20 In vitro/in silico site-directed mutagenesis of 1 residues belonging to the SBDLI and SBDLII 
motifs. Specific PTZ binding of different alanine mutants of the human 1 receptor and in silico estimated 
free energy of binding (Gbind) of the same 1 alanine mutants as generated by computational 
mutagenesis. Errors are given in parenthesis as standard errors of the mean (SEM). 
a
Gbind = 
Gbind,wt – Gbind,mutant. 
1 residue 
domain specific binding of PTZ 
[%] 
ΔGbind 
(kcal/mol) 
aΔΔGbind 
(kcal/mol) 
S101A 
SBDL I 
30 (27) -8.16 (0.08) -1.86 
Y103A 22 (12) -7.89 (0.09) -2.13 
F107A 18 (11) -8.05 (0.05) -1.97 
T181A 
SBDL II 
93 (7.5) -9.99 (0.11) -0.03 
F184A 124 (18) -10.55 (0.07) 0.53 
T189A 99 (1.1) -9.87 (0.07) -0.15 
F191A 88 (14) -9.13 (0.10) -0.89 
201Stop  1.0 (0.6) - - 
209Stop  0.9 (0.5) - - 
217Stop  37 (7.7) -8.80 (0.06) -1.22 
 
 
148 
 
 
 
Figure 3.1.44 In silico mutagenesis of 1 receptor residues at the SBDLI and SBDLII domains. (a) Zoomed 
view of the residues belonging to the 1 SBDLI and II domains, represented as forest and light green 
sticks, respectively. The ligand is in element-colored sticks-and-balls (C, gray; N, blue; O, red) with its van 
der Waals surface shown in blue. The membrane phospholipids are portrayed as semi-transparent light 
yellow balls-and-stick . (b) General secondary structure description of the 1 receptor (aa 100-223) 
during MD simulations of the wt, Y103A, and F184A PTZ complexes. aPercentage of specific secondary 
structure for each 1 residue. (c) RMSD of the coordinates of the heavy atoms of PTZ along the MD 
simulation compared with those of the initial structure. Comparison of the equilibrated MD snapshots of 
the wt 1 receptor (blue) with (d) Y103A (dark olive green) and (e) F184A (orange) mutants in complex 
with PTZ. The images are a zoomed view of the receptor binding site. The ligand is portrayed in sticks-
and-balls colored according to the respective protein complex. In panels d and e hydrogen atoms, water 
molecules, ions and counterions are not shown for clarity. 
 
 
149 
 
Taking the PTZ/1 (Y103A) complex as a proof-of-concept, we observed a different 
rearrangement of the secondary structure of this protein portion with respect to the PTZ/wt 
assembly (Figure 3.1.44 b, top and central panels), ultimately resulting in an expansion of the 
receptor binding pocket from an average dynamic volume (ADV) of 509 ± 5 Å3 to 573 ± 7 Å3. 
Accordingly, the ligand binds the receptor more loosely, as its interactions with the protein 
residues lining the binding site become weaker (Figure 3.1.44c). This effect is clearly seen in 
the behavior of the root mean square deviation (RMSD) of the heavy atom of PTZ during the 
MD simulation (Figure 3.1.44d): after equilibration, the ligand assumes a stable conformation 
in the wt binding pocket with an average RMSD values of 1.01 ± 0.06 Å, while larger RMDS 
fluctuations (RMSD = 2.18 ± 0.35 Å) and longer time-to-equilibrium are observed for the Y103A 
mutated 1/PTZ complex. 
 
Residues in the SBDLII domain scarcely contribute to ligand binding. 
In stark contrast, analogous mutations in the SBDLII domain barely influenced PTZ binding if at 
all (SB = 93÷100%, Gbind = -0.59 ÷ -0.03 kcal/mol, Table 3.1.20). A comparison of the 
membrane-bound wt and SDBLII mutated 1 isoforms reveals that the presence of mutations 
at the SBDLII domain does not lead to substantial alteration of both the membrane and the 
protein binding site/overall structure. Indeed, in the representative example of the PTZ/1 
(F184A) complex, the fingerprint of the protein secondary structure is conserved (Figure 
3.1.44b, top and bottom panels), and the average dynamic volume is essentially unchanged 
(507 ± 7 Å3). Moreover, PTZ maintains a very stable conformation in the binding site during the 
entire MD simulation, as substantiated by the relevant RMSD deviation (1.01 ± 0.07 Å, Figure 
3.1.44c). Lastly, all ligand/receptor interactions detected for the wt complex are maintained in 
this as well as in all other SBDLII mutated complexes examined with no significant differences 
in binding mode and strength (Figure 3.1.44e). Remarkably, in a previous study the SBDLII was 
postulated to be part of the ς1 ligand binding site
7. Our results clearly do not support this 
hypothesis. It has been further proposed that the SBDLII is responsible for anchoring the 1 
receptors to the membrane and, in so doing, stabilizing the 3D structure of the protein. Once 
again, our combined in vitro/in silico experiments point in the opposite direction. Taken 
together, our findings lead to the conclusion that, while the SBDLI domain is part of the 
binding site of the 1 receptor, and as such mutations at this domain lead to a drastic decrease 
of receptor/ligand affinity, the SBDLII domain does not belong to the 1 ligand binding site. 
Accordingly, mutations in this protein domain exert only a marginal effect on ligand binding, if 
at all. 
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Even small deletions in the 1 C-terminal end abrogate ligand binding. 
As briefly mentioned above, 1 ligand binding is abrogated when more than 15 amino acids are 
removed from the C-terminal end of the protein.65 Thus, we further investigated this aspect by 
deleting 7, 15 and 23 amino acids, respectively, from the C-terminal end of the 1 receptor and 
determined the affinity of the truncated receptors for PTZ. As expected, elimination of 15 and 
23 amino acids resulted in the loss of PTZ binding ability (Figure 3.1.40c, Table 3.1.20). More 
interestingly, also the removal of only 7 residues from the receptor C-terminal end led to a 
considerable reduction of PTZ binding (SB = 37%). Again, these experiments were rationalized 
by the corresponding in silico assays. While the major deletions resulted in a partially unfolded 
structure of the receptor missing a large portion of the ligand binding site, the affinity of the 7-
residue truncated protein still preserved a low affinity for PTZ (Figure 3.1.45a), as quantified by 
the value of Gbind = -8.80 kcal/mol. The corresponding Gbind = -1.22 kcal/mol nicely 
correlates with the 63% affinity reduction with respect to the wt protein reported by in vitro 
mutagenesis. The 7 deleted amino acids are not directly involved in ligand binding; however, 
the missing sequence YLFGQDP results in a structural modification of the receptor that, like a 
domino effect, propagates along the protein backbone to the binding site (Figure 3.1.45b). This 
overall configuration rearrangement directly affects three 1 residues most important for 
ligand binding: R119, D126, and E172. Specifically, the interaction of D126 with PTZ becomes 
less favorable by 1.54 kcal/mol with respect to the wt isoform, while E172 decreases its 
contribution by -1.68 kcal/mol. 
 
Figure 3.1.45 In silico mutagenesis of 1 receptor residues: deletion of the 7-residue sequence YLFGQDP 
from the protein C-terminal domain. (a) Comparison of the equilibrated MD snapshots the wt (blue) and 
C-terminal 7 residue truncated 1 receptor (magenta) in complex with PTZ. The image is a zoomed view 
of the receptor binding site. The ligand is portrayed in sticks-and-balls colored according to the 
respective protein complex. Hydrogen atoms, water molecules, ions and counterions are not shown for 
clarity. (b) Comparison of 1 residue contributions to PTZ binding for the wt and the C-terminal 7-residue 
truncated protein. 
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Distal residues also concur in shaping the 1 binding site.  
Lastly, to determine whether other 1 receptor residues could play a critical role in binding 
PTZ, several alternative positions between the SBDLI and II protein domains were substituted 
by alanine. In silico mutagenesis results suggested that the hydrophobic V145 and the 
aromatic F146 and Y147 residues, when mutated to alanine, result in minor (if any) changes in 
the protein binding site conformation (Table 3.1.21). These results are confirmed by the 
corresponding in vitro experiments, showing that for these 3 residues the SB values range 
between 57% and 121%. However, the alanine mutants of the basic amino acid R175 and of 
the two polar residues of S125 and T127 show a moderate (S125A, T127A) to strong (R175A) 
influence on PTZ binding, as testified by the drastically less favorable Gbind values of -1.45 
kcal/mol, -1.24 kcal/mol, and -2.02 kcal/mol, respectively (Table 3.1.21) and supported by the 
corresponding SB values (49%, 45%, and 10%). The two mutations S145A and T127A transform 
the environment in proximity of the negatively charged D126 from polar to hydrophobic 
which, in turn, decreases the strength of its salt bridge with PTZ (ADL = 4.76 ± 0.07 Å and 4.69 
± 0.10 Å for S145A and T127A, respectively).  
 
Table 3.1.21 In vitro/in silico site-directed mutagenesis of 1 residues belonging to the region between 
the protein SBDLI and SBDLII motifs. Specific PTZ binding of different alanine mutants of the human 1 
receptor and in silico estimated free energy of binding (Gbind) of the same 1 alanine mutants as 
generated by computational mutagenesis. Errors are given in parenthesis as standard errors of the mean 
(SEM). aGbind = Gbind,wt – Gbind,mutant. 
1 residues specific binding of PTZ [%] ΔGbind (kcal/mol) 
aΔΔGbind (kcal/mol) 
wt 100 -10.02 (0.05) - 
S125A 49 (1.5) -8.57 (0.09) -1.45 
T127A 45 (2.3) -8.78 (0.11) -1.24 
V145A 78 (14) -9.89 (0.07) -0.13 
F146A 57 (0.3) -9.42 (0.09) -0.60 
Y147A 121 (4.1) -8.80 (0.06) -1.22 
R175A 10 (4.1) -8.00 (0.10) -2.02 
 
The case of the R175A mutant is more complex, as experiments detect a drastically reduced 
affinity of this mutant 1 isoform for PTZ (SB = 10%). The calculated free energy of binding 
differs considerably from the wt 1 complex (Gbind=-2.02 kcal/mol) although this residue is 
not directly involved in PTZ binding. Importantly, however, along the entire MD course R175 
forms a stable, bifurcated H-bond with Y120 and R114. These residues, in turn, stabilize the 
conformation of the Y173 for productive binding via another direct H-bond (Figure 3.1.46a). All 
these interactions translate into a -2.72 kcal/mol global favorable enthalpic contribution of 
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these 4 amino acids to ligand binding, as detailed in Table 3.1.22. As discussed above, both 
tyrosines Y120 and Y173 play a major role not only in direct PTZ binding but also in shaping the 
entire 1 binding site. Thus, replacing R175 by alanine results in an almost complete loss of the 
H-bond interaction network (Figure 3.1.46b): the aromatic interaction between Y120 and PTZ 
is lost, the entire binding site is enlarged, and the corresponding complex stabilization energy 
drops dramatically (-0.89 kcal/mol, Table 3.1.22). 
 
Table 3.1.22 Per-residue free-energy decomposition for wt and R175A mutant 1 receptor in complex 
with PTZ. All energy values are in kcal/mol. Data standard deviations are in the range ± 0.01 ÷ ± 0.10. 
wt Y120 Y173 R175 
R114 0.02 -0.91 -0.88 
Y120 * -0.26 -0.71 
Y173 * * 0.02 
R175 * * * 
∑Hbind    -2.72 
R175A Y120 Y173 A175 
R114 -0.01 -0.73 0.02 
Y120 * -0.03 -0.12 
Y173 * * -0.02 
A175 * * * 
∑Hbind    -0.89 
 
 
Figure 3.1.46. In silico mutagenesis of 1 receptor residues: deletion of the 7-residue sequence YLFGQDP 
from the protein C-terminal domain. Details of the residues involved in a structurally stabilizing 
interaction of the (a) wt and (b) R175A mutant 1 receptor in complex with PTZ as obtained from 
equilibrated MD simulation snapshots. The protein backbone is portrayed as a transparent ribbon 
colored by secondary type (orange, -helices; cyan, -sheets; light gray, coils). The main residues 
involved in the interactions are shown as labeled green sticks. PTZ is depicted in sticks-and-balls and 
colored by element (C, gray; O, red; N, blue). In all panels, hydrogen atoms, water molecules, ions and 
counterions are omitted for clarity. 
Conclusion 
The combined in vitro/in silico mutagenesis study reported in the present work confirmed 
some previous knowledge about the structural features of the 1 receptor and its binding site 
but also, and perhaps more importantly, qualified and quantified the role of several receptor 
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residues which play a prominent role in receptor-ligand binding. Specifically, among those 
residues belonging to the putative receptor binding pocket, replacing I128 and Y173 with 
alanine almost abrogates PTZ binding, consistently with a drastic reduction of stabilizing, 
hydrophobic interactions. The specific nature of the anionic residue E172 is critical for PTZ 
binding in that not only its replacement with alanine but also an exchange with a residue of 
similar nature but smaller side chain (E172D) results in the total failure of receptor ligand 
binding. The role of 1 amino acids belonging to the SBDLI and II domains has been 
differentiated and rationalized: while a critical role in maintaining the protein secondary 
structure of this protein portion with respect to the cellular membrane has been verified for 
those residues belonging to the first domain, mutagenesis performed on residues in the SDBLII 
region did not affect the receptor affinity for PTZ. The removal of small sequences in the C-
terminal part of the protein (e.g., 7 residues) resulted in a substantial reduction of ligand 
binding activity, as these deletions result in a general reconfiguration of the receptor binding 
pocket, ultimately involving those residue which constitute the PTZ main anchor points. Finally, 
this combined approach unveiled the substantial role exerted by other 1 residues in ligand 
binding; for instance, the series of polar residues S125, T127, and R175 all concur in 
maintaining the high affinity of 1 receptor for PTZ, and their replacement with the small, 
apolar alanine result in a neat decrease of receptor ligand binding activity. 
 
3.2 SELF-ASSEMBLY OF AMPHIPHILIC DENDRIMERS FOR FUNCTIONAL 
siRNA DELIVERY  
This work was carried out in collaboration with the group of Dr. Ling Peng, CINaM, 
Marseille (France) 
 
Introduction 
In this work we report the self-assembly of a series of amphiphilic dendrimers into nanosized 
supramolecular structures and their resulting capacity to effectively deliver siRNA.  
Self-assembly is a fundamental concept in modern molecular science. It relies on non-covalent 
interactions to assemble molecular building blocks into supramolecular entities in a reversible, 
controllable, and specific manner, yet with relatively little synthetic input.66,67 Of particular 
value is the ability of self-assembled nanosized superstructures to behave as more than the 
sum of their individual parts, and exhibit completely new properties. As an example, we 
present here our investigation on the self-assembly of amphiphilic dendrimers into 
nanostructures and the underlying mechanism for their delivery of siRNA therapeutics. Our 
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findings reveal that supramolecular nanostructures generated via the self-assembly of 
amphiphilic dendrons hold a great potential for future applications in siRNA delivery and gene 
silencing. 
 
Over the past few years, our group has been actively engaged in developing dendrimers as 
nanovectors to deliver RNA therapeutics,68,69 especially synthetic small interfering RNAs 
(siRNA), as a novel therapeutic strategy for the specific inhibition and knockdown of disease 
genes by RNA interference (RNAi).70 The main challenge facing RNAi therapeutics is the safe 
and efficient delivery of the siRNA, the molecules that mediate RNAi.71 An ideal delivery vector 
is one that assembles and compacts the siRNA within a complex, protects it from degradation, 
allows it to enter cells, and finally releases it from the endolysosomal compartment into the 
cytoplasm, where the RNAi machinery is located.71 The most common non-viral vectors for 
siRNA delivery can be classified as lipids and polymers,72-74 with cationic dendrimers (a special 
family of polymers) emerging as promising vectors by virtue of their well-defined structural 
architecture, intriguing features of multivalency, and high cargo payload within a nanosized 
volume. 
 
Chemical synthesis 
We have recently constructed a small amphiphilic dendrimer bearing a hydrophobic alkyl chain 
of 18 carbon atoms and a hydrophilic dendritic portion (4 in Figure 3.2.1), which proved to be 
efficient for siRNA delivery by combining the advantageous features of lipid and dendrimer 
vectors.68 Preliminary results revealed the importance of the hydrophobic alkyl chain in the 
amphiphilic dendrimers, as the dendrimer without the hydrophobic chain was devoid of 
delivery activity.68 We surmised that the hydrophobic alkyl chain promoted self-assembly of 
the amphiphilic dendrimers to generate supramolecular structures resembling the structural 
definition of covalent dendrimers of high generations. In order to confirm this hypothesis and 
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study the impact of self-assembly of the amphiphilic dendrimer vectors on their resulting 
siRNA delivery capacity, we designed a series of dendrimers featuring hydrophobic tails of 
different lengths (1-6 in Figure 3.2.1) or a hydrophilic pentaethylene glycol (PEG) chain (7 in 
Figure 3.2.1). The hydrophobic portions are thus the alkyl chains of 12 to 22 carbon atoms in 
length, and the PEG tail is similar in length to the hydrophobic chain in 4 but is hydrophilic in 
nature, thus obviating dendrimer amphiphilicity. Dendron 8 is a small hydrophilic 
poly(amidoamine) dendrimer without any tail and served as a reference control. We 
systematically investigated these dendrimers for their self-assembly, their siRNA binding and 
delivery capacity using both experimental approaches and computational modeling. Our 
results demonstrate that the ability of these amphiphilic dendrimers to bind and deliver siRNA 
critically depended on their self-assembly which, in turn, was strongly controlled by the length 
of the hydrophobic alkyl chain. Consequently, the choice of an appropriate hydrophobic chain 
appears to be a key issue for successful siRNA delivery. 
All dendrimers studied in this work (Figure 3.2.1) were synthesized via “click” chemistry using 
our protocol,68 and fully characterized.  
 
 
 
 
 
Figure 3.2.1 Dendrimers investigated in this study: the amphiphilic dendrimers 1-6, the dendrimer 7 
bearing a hydrophilic pentaethylene glycol (PEG) chain, and dendron 8 without any chain. 
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Scheme 3.2.1 General procedure for the synthesis of dendrimer 1-7.  
 
The self-assembly of these different dendrimers was first investigated using dynamic light 
scattering (DLS). We detected the predominant formation of nanoparticles around 7.0 nm in 
size in solutions containing dendrimers 3-6 respectively (Table 3.2.1), while no stable 
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nanostructures were observed with dendrimers 1 or 2, the hydrophilic PEG-tail dendrimer 7 or 
the no-tail dendron 8. Further results of transmission electron microscopic (TEM) imaging 
clearly revealed the formation of spherical nanoparticles with a diameter of about 7 nm 
(Figure 3.2.2), confirming the apparent self-assembly of dendrimers 3-6 indicated by our DLS 
data. The size of these nanostructures was in the range of typical micelles, thus acknowledging 
the tendency of these compounds to self-assemble into micellar supramolecular 
nanostructures. An increase in the alkyl chain length from C16 to C22 (3 to 6), was 
accompanied by an increase in the size of the micelles (Dexp) from 6.6 to 7.8 nm (obtained 
using DLS), consistent with the values (Dcal) predicted by related molecular simulations (Table 
3.2.1 and Table 3.2.2). Additionally, the increasing alkyl chain length (1 to 6) was accompanied 
by a fall in the values of critical micelle concentration (CMCexp) from 398 to 8.6 μM, indicating 
an inverse relationship between hydrophobic chain length and CMCexp, i.e., the more effective 
packing of the longer hydrophobic chains results in better self-assembly. The relatively large 
values of CMCexp for 1 and 2 explain the absence of micelle formation observed during DLS 
analysis, whereas for dendrimer 7 and dendron 8, which are devoid of amphiphilicity, no 
CMCexp (and, hence, no self-assembled micelles) could be determined. 
 
Table 3.2.1 The experimental values for micelle diameter (Dexp) and critical micelle concentration 
(CMCexp) for the amphiphilic dendrimers 1-6 together with the calculated values for the packing 
parameter (P), free energy of micellisation (Gmic), critical micelle concentration (CMCcal) and micelle 
diameter (Dcal) 
 
 
 
Dexp 
(nm) 
CMCexp 
(μM) 
P 
ΔGmic 
(kJ/mol) 
CMCcal 
(μM) 
Dcal 
(nm) 
1 -* 398±22 0.13 -38.7 415 5.6±0.1 
2 -* 116±11 0.12 -44.4 127 5.9±0.1 
3 6.6±0.1 49.9±3.3 0.11 -50.5 37.2 6.2±0.1 
4 6.8±0.1 15.6±1.1 0.10 -56.4 11.4 6.4±0.1 
5 7.3±0.1 11.2±0.6 0.10 -57.5 9.13 7.1±0.2 
6 7.8±0.2 8.24±3.8 0.10 -57.8 8.50 8.1±0.2 
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Table 3.2.2 Aggregation number Nagg, surface charge density σm and micellar diameter Dcalc for the self-
assemblies of dendrimers 1-6 as obtained from molecular simulations.. 
 
 
Compound Nagg (-) σm (e/nm
2) Dcalc (nm) 
1 5 0.41 5.6 ± 0.1 
2 6 0.44 5.9 ± 0.1 
3 7 0.46 6.2 ± 0.1 
4 8 0.50 6.4 ± 0.1 
5 10 0.50 7.1 ± 0.2 
6 13 0.50 8.1 ± 0.2 
 
 
 
 
Figure 3.2.2 TEM images of the self-assembled supramolecular micellar structures formed with 3 (A), 4 
(B), 5 (C) and 6 (D), respectively, in phosphate buffer, at pH 7.4. 
 
 
 
 
 
 
159 
 
Molecular modeling  
We went on to inspect the self-assembly of these dendrimers using computational methods. 
For 1-6, the estimated value of their critical packing parameter P, an effective ratio of the 
relative sizes of the polar and apolar domains of an amphiphilic compound, was well below 
0.33 (Table 3.2.1), implying their tendency to self-assemble into spherical micelles.75,76 This was 
confirmed by corresponding TEM imaging (Figure 3.2.2) and mesoscopic molecular simulation 
77 (Figure 3.2.3 A-B). In addition, the associated free energy of micellization values ΔGmic were 
largely negative, indicating that micellization was a spontaneous and highly favorable process 
for all the amphiphilic molecules 1-6. The ΔGmic did however decrease substantially (i.e., 
become less negative and, hence, less favorable) with decreasing chain length from 6 to 1 
(Table 3.2.1). Accordingly, the predicted CMC values (CMCcal) follow the expected increasing 
trend as the hydrophobic character of the dendrimers decreases, in agreement with the 
experimental data. Since the hydrophilic dendron architecture was the same in all dendrimers, 
the main differential contribution to ΔGmic - and hence to CMCcal – must stem from the size of 
the hydrophobic component (see also SI for more details). Altogether, this combined 
experimental/theoretical approach allowed us to appreciate and understand the impact of the 
hydrophobic alkyl chain on the self-assembly of the amphiphilic dendrimers. 
We next assessed the ability of these dendrimers to complex with siRNA molecules using 
fluorescent ethidium bromide (EB) displacement assay. The no-tail dendrimer 8, the PEG chain 
dendrimer 7, and dendrimer 1 bearing the shorter alkyl chain were all unable to effectively 
displace EB from siRNA (Figure 3.2.4A), presumably due to their inability to self-assemble 
under the adopted assay conditions. For the dendrimer series 2-6, the C50 value decreased 
with increasing alkyl chain length, with dendrimer 6 being the most efficient at binding siRNA 
(Figure 3.2.4A and Table 3.2.2). Notably, these data were consistent with the results of siRNA 
binding obtained using gel shift assessment (Figure 3.2.4B), and confirmed the correlation 
between alkyl chain length and binding strength: the dendrimer bearing the longest alkyl chain 
was the most effective siRNA binder. In other words, these results concur to indicate that 
dendrimers endowed with self-assembly properties are the most effective at achieving siRNA 
binding.  
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Figure 3.2.3 Mesoscopic modeling of dendrimers 1-8 in panel A. Panel B shows only the micellar cores 
and panel C a zoomed view of the micelles formed by dendrimers 1-6. Color legend: purple and lilac, 
hydrophilic dendron beads; light grey, hydrophobic tail beads; green, linker beads. Water and 
counterions are portrayed as a light blue field (panel A) or as a white field (panels B and C) for clarity. 
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Figure 3.2.4 siRNA binding revealed by (A) ethidium bromide displacement assay; (B) gel retardation of 
200 ng siRNA in agarose gel with dendrimer at N/P charge ratios ranging from 0 to 10; (C) size and size 
distribution of siRNA/dendrimer complexes obtained from dynamic light scattering (DLS) analysis and (D) 
mesoscale modeling at N/P ratio 10 alongside (E) zoomed view of the siRNA/dendrimer system by 
dendrimers 1-8 respectively. Color legend for panels: siRNA molecules, thick red sticks. 
 
This concept was further established by DLS investigation of the siRNA/dendrimer complexes 
(Figure 3.2.4C). As shown in Table 3.2.3, dendrimers 3-6 bearing C16, C18, C20, and C22 alkyl 
chains, respectively, were able to form siRNA nanoparticles around 100 nm in size. 
Nevertheless, the nanoparticles formed with 5 and 6 were less uniform as indicated by the size 
distribution (Figure 3.2.4C) and the values of polydispersity index (PDI) (Table 3.2.3). On the 
other hand, dendrimers 1, 2, 7, and 8 formed much larger sized aggregates with siRNA, 
implying an ineffective interaction with the nucleic acid fragment and, hence, its inefficient 
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compaction into complexes, the resulting dimensions of which are far too large for effective 
delivery.  
 
Table 3.2.3 siRNA/dendrimer binding data (C50) obtained from experiments of ethidium bromide 
displacement, size (D) and polydispersity index (PDI) of siRNA/dendrimer complexes obtained from 
dynamic light scattering analysis together with free energy of binding (ΔGbind), free energy of effective 
binding (ΔGbind,eff), number of effective charges (Neff) and effective-charge-normalized free energy of 
binding (ΔGbind,eff⁄Neff) for siRNA/dendrimer complexes as derived from molecular dynamics simulations. 
﹡not available 
 
 
Complex 
C50 
(M) 
D 
(nm) 
PDI 
Gbind 
(kcal/mol) 
Gbind,eff
 
(kcal/mol) 
Neff (-) 
Gbind,eff/Neff 
(kcal/mol) 
1/siRNA -﹡ 474±12 -﹡ -8.23±0.91 -2.47±0.32 13±1 -0.19±0.03 
2/siRNA 42.0±2.0 198±0.3 0.03 -13.4±1.1 -4.30±0.45 18±1 -0.24±0.03 
3/siRNA 16.9±0.5 126±0.1 0.02 -17.1±1.3 -6.00±0.36 22±1 -0.27±0.02 
4/siRNA 7.0±0.3 95.5±0.1 0.06 -22.6±1.2 -12.7±0.41 31±3 -0.41±0.04 
5/siRNA 5.3±0.4 92.8±0.1 0.18 -46.6±1.6 -28.9±0.70 49±3 -0.59±0.04 
6/siRNA 4.8±0.1 92.3±0.1 0.20 -57.8±2.3 -34.7±0.62 62±5 -0.56±0.05 
7/siRNA -﹡ 501±1.0 -﹡ - - - - 
8/siRNA -﹡ 486±6.0 -﹡ - - - - 
 
Additional mesoscale molecular simulations were performed at this point to investigate the 
interactions between these dendrimers and the siRNA molecules. The morphology of the self-
assembled micelles and siRNAs is presented in Figures 3.2.4D and 3.2.4E. As can be seen, at 
the same N/P ratio, from dendrimers 1 through to 6, the siRNA molecules are more uniformly 
distributed and better encased within the micellar network, indicative of an efficient 
protection from the external environment. For the non-self-assembling systems like 7 and 8, 
the siRNA molecules are less well protected from possible external access. Collectively, all 
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these findings clearly demonstrate that dendrimers displaying the highest self-assembly 
properties offer the best interaction with and optimal compaction of siRNA. 
 
In vitro assay 
In order to investigate the siRNA delivery capacity of our series of amphiphilic dendrimers, 
siRNA molecules targeting either heat shock protein 27 (Hsp 27) or translationally controlled 
tumor protein (TCTP) were tested in human castration-resistant prostate cancer PC-3 and C4-2 
cells. As we can see, dendrimer 4 bearing a C18 alkyl chain clearly revealed the best siRNA 
delivery capacity, leading to potent gene silencing with no discernible toxicity.24 Interestingly, 
dendrimers with longer hydrophobic tails (5 and 6) were less effective, whereas those bearing 
shorter aliphatic chains (1-3), hydrophilic (PEG) chain (7) or no chain (8) failed to elicit any 
discernible gene silencing. These results could be sensibly rationalized in light of the previous 
discussion: because of the intrinsic incapacity of 7 and 8 to self-assemble, or the inability of 1-3 
to generate stable micellar nanostructures at the concentrations employed in the transfection 
experiments, none of these five dendrimers was effective in siRNA delivery. In other words, 
the multivalency of the positive dendritic structure alone is not sufficient to efficiently bind, 
protect and deliver siRNA to cells. The reason why 5 and 6 are less effective than 4 in siRNA 
delivery and subsequent gene silencing might be ascribed to the fact that the siRNA/5 and 
siRNA/6 complexes are too stable to dissociate, thus impairing the siRNA release within the 
cell and ultimately decreasing the efficiency of gene silencing.  
To verify this hypothesis, we then performed a quantitative characterization of micelle/siRNA 
interactions at a fully atomistic level to rank the affinity of each dendrimer micelle towards 
siRNA by molecular dynamics (MD) simulations based on the morphological information 
gathered by mesoscopic modeling. As presented in Table 3.2.3, the micelles formed by 4 
possessed a total surface charge of +64, 31 of which were effectively engaged in complexing 
siRNA (Figure 3.2.6A), resulting in a ΔGbind,eff⁄Neff value of -0.41 kcal/mol (Table 3.2.3). On the 
other hand, the self-assembled nanocarriers generated by 5 and 6 were not only able to 
exploit 49 and 62 (out of their total 80 and 102 positive charges, respectively), to constantly 
bind siRNA (see Figure 3.2.6A), but they also did it more effectively, as testified by the higher 
favorable ΔGbind,eff⁄Neff values of -0.59 and -0.56 kcal/mol (Table 3.2.3). 
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Figure 3.2.5. Dendrimer-mediated siRNA delivery and gene silencing of heat shock protein 27 (Hsp27) 
and translationally controlled tumor protein (TCTP) in human prostate cancer PC-3 (A, B) and C4-2 (C, D) 
cells, respectively. Hsp27 and TCTP protein expression quantified using western blot 72 h post-treatment 
with the corresponding siRNA/dendrimer complexes at N/P ratio of 10. 
 
These higher values of ΔGbind,eff⁄Neff definitely characterize the two dendrimers 5 and 6 as the 
strongest siRNA binders of our series, in agreement with the corresponding experimental 
evidence obtained with the EB fluorescent assay and gel shift (Figures 3.2.4A and 3.2.4B). The 
siRNA binding affinity of micelles formed with 5 and 6 might indeed be too strong to allow 
intracellular siRNA release. It is tempting therefore to speculate that 5 and 6 achieve more 
effective siRNA binding - as indicated by both experiments and simulation - at the expense of 
effective siRNA release, as the complex simply becomes too “strongly bound” and cannot be 
broken apart.  
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Figure 3.2.6 (A) Atomistic MD simulations of amphiphilic dendrimer self-assembly in the presence of 
siRNA. In all panels, the dendrimers are shown as forest green, with the terminal charged amine groups 
highlighted as chartreuse green sticks-and-balls. The siRNA is represented as a red ribbon and some 
representative Cl- and Na+ ions and counterions are portrayed as light and dark gray spheres, 
respectively. Water is omitted in all panels for clarity. The binding interface region between each micelle 
and siRNA is also shown in each complex. 
 
To further support this finding, we examined the siRNA dissociation from the corresponding 
dendrimer complexes using the heparin-coupled ethidium bromide (EB) assay. In this method, 
heparin, a highly negatively charged polysaccharide, is employed for competing with siRNA for 
dendrimer binding. Displacement of siRNA by heparin from the dendrimer complex allows the 
intercalation of the fluorescent EB probe, which then emits a strong fluorescence. siRNA could 
be almost completely displaced from its complex with 4, while it was only partly released from 
those complexes formed either with 5 or 6. These results demonstrate that the self-assembled 
nanocarrier generated by 4 is bestowed with optimal siRNA binding strength and siRNA 
releasing ability, enabling it to safely carry the siRNA cargo along its journey to the cell and 
efficiently discharge the payload upon reaching its final destination.  
4/siRNA 
5/siRNA 
6/siRNA 
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Overall, these results fully illustrate that 4 mediates a uniquely effective siRNA delivery and 
gene silencing. The sensible molecular rationale for this is that an optimal balance has been 
reached between the hydrophobic chain length and the hydrophilic dendron structure in 4 
providing this amphiphilic dendrimer molecule the ideal properties to efficiently self-assemble 
into supramolecular structures. Such structures are able to easily form nanocomplexes with 
siRNA before their disassembly during endosome release, ultimately resulting in the best 
siRNA delivery and the most potent gene silencing of the entire dendrimer series presented in 
this work.  
Conclusion 
In conclusion, we gained a unique and detailed insight into the ability of the amphiphilic 
dendrimers to self-assemble into nanosized micellar structures and consequentially interact 
with siRNA molecules for functional delivery using a powerful combination of experimental 
and theoretical approaches. Our dual investigation strategy revealed that an optimal balance 
between the hydrophobic alkyl chain length and the hydrophilic dendritic portion plays a 
crucial role in the self-assembly and thus in the excellent siRNA delivery activity displayed by 
the amphiphilic dendrimer 4. The supramolecular nanostructures generated by 4 resemble 
somewhat the well-defined traditional covalent dendrimers of higher generation. The ability of 
carefully designed building blocks to spontaneously assemble into complex nanostructures 
underpins developments in a wide range of technologies, from materials science to molecular 
biology, highlighting huge potential for implementation in future applications. 
 
3.3 INVESTIGATION OF THE ROLE OF S45F  CATENIN MUTANT AS 
MARKER OF AGGRESSIVENESS IN DESMOID TUMORS 
This work was carried out in collaboration with Unit of Clinical Epidemiology and Trial 
Organization and Laboratory of Experimental Molecular Pathology, Istituto dei Tumori, 
Milan (Italy) 
Introduction 
Desmoid tumors (DTs) are rare mesenchymal lesions with fibroblastic proliferation 
characterized by a variable clinical course. In a clinical study involving 179 patients a high 
frequency of mutations (85%) in the gene encoding for -catenin protein was found78. 
Interestingly, only three different point mutations in two different codons (41 and 45) have 
been identified in mutated samples: ACC to GCC in codon 41 (T41A; replacement of threonine 
by alanine); TCT to TTT in codon 45 (S45F; replacement of serine by phenylalanine), and TCT to 
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CCT in codon 45 (S45P; replacement of serine with proline)79; these two codons are targets for 
phosphorylation by GSK-3β and CK1, respectively. 80 
Among solid tumors it is unusual to demonstrate only three specific mutations in CTNNB1; 
most other neoplasms harboring exon 3 CTNNB1 mutations have wider mutational variability 
at multiple critical codons81,82, suggesting that these specific CTNNB1 mutations may be critical 
in the development of desmoid-type fibromatosis and the type of CTNNB1 gene mutation 
could affect the levels β-catenin signaling, thereby impacting on desmoid formation and/or 
recurrence.   
In summary three different mutants were identified: T41A, S45F and S45P. All this residues are 
phosphorylation/regulation sites for this protein. Specifically, phosphorylation of Serine 45 
increases the affinity of -catenin for GSK3, thus promoting its ubiquitination and degradation. 
Actually, only S45F mutant seems to play a fundamental role in tendency for local recurrence 
after complete surgical resection. Exploiting molecular simulation technique, we then studied 
the interactions of the wild-type (WT) and T41A, S45P, and S45F -catenin mutants with GSK3. 
Of note, a proprietary 3D homology model of the full -catenin structure was employed in this 
study.  
Experimental section 
Inclusion criteria and clinical database 
Patients with primary sporadic DT histological diagnoses surgically treated at one of four 
sarcoma referral centers (Fondazione IRCCS, Istituto Nazionale dei Tumori, Milano, Italy; The 
University of Texas MD Anderson Cancer Center [UTMDACC], Houston, Texas, USA; Institute 
Gustave Roussy [IGR], Paris, France; Leiden Medical Center, Leiden, Netherlands) between 
April 1998 and March 2011 were included in this study. Of note none of the UTMDACC 
patients included in the current study were part of the previously published patient cohort79.  
Patients with FAP-related DT, recurrent disease at presentation, or incomplete surgical 
resection were excluded. Data retrieved included gender, anatomical site, tumor size, date of 
surgery, status of margins including microscopic positive (R1) and negative margins (R0), 
results of CTNNB1 mutational analysis, type of other treatments eventually administered 
before and/or after surgery, date of recurrence, treatment of recurrence, date and status at 
last follow up. Anatomical sites were classified as extra abdominal (including extremity and 
head/neck), abdominal/thoracic wall, and intra-abdominal. Tumor size was defined as the 
greatest DT dimension in the surgical specimen reported by the original pathologists. Surgical 
excisions were considered as macroscopically complete in the absence of gross residual 
disease. All macroscopically complete resections were classified according to the closest 
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surgical margin, which was microscopically categorized as positive (tumor within 1 mm from 
the inked surface) or negative (absence of tumor within 1 mm from the inked surface).  
Non-surgical treatments were administered in the primary or recurrent phase of the disease 
on an individualized basis or as part of clinical trials and included radiotherapy, chemotherapy 
(frequently methotrexate and vinorelbine) and medical therapy- hormonal agents (tamoxifene, 
toremifene), NSAIDs (COX2 inhibitors). 
Mutational analysis 
Mutational analysis was performed on formalin-fixed-paraffin-embedded tissue in each 
participating institution using the same standardize technique. Microscopic dissection of 7 µm 
methylene blue-stained tissue sections (with >80% tumour cells) allowed the precise 
separation of neoplastic and normal tissues. Genomic DNA was extracted using the Qiamp 
DNA Kit (Qiagen, Chatsworth, CA, USA) as per manufacturer’s instructions. CTNNB1 mutational 
analysis was made by polymerase chain reaction (PCR) using 100 ng of genomic DNA. Exon 3 of 
the CTNNB1 gene was amplified using the specific primers ex3F (5’-
ATGGAACCAGACAGAAAAGC-3’) and ex3R (5’-GCTACTTGTTCTTGAGTGAAG-3’) and following 
the PCR conditions: 30 sec at 95°C, 30 sec at 56°C  and 30 sec at 72°C for 35 cycles. The PCR 
products were purified by using exoSAP and sequenced with 3500 Dx Genetic Analyzer 
(Applied Biosystems, Foster City, CA, USA).  Each sequence was performed at least twice, 
starting from an independent amplification reaction and evaluated by means of ChromasPro 
software. Three different mutations were identified at the codon 3 of the gene encoding for β-
catenin, CTNNB1 (T41A, S45F, S45P). Patients without a specific mutation were classified as 
wild type (WT). Since the number of S45P cases was small, for purposes of the statistical 
analysis T41A and S45P were grouped together and termed “other”. 
Molecular modelling 
All simulations were performed with AMBER 11 suite of programs15. Since the lack of the 
overall 3D structure of -catenin protein in the Protein Data Bank (PDB), a validate homology 
modeling protocol was applied to the PDB codes = 2Z6H83, 2G5784 using as template importin 
PDB code= 3OQS85 and refined using different minimization rounds. Once obtained the 
complete WT structure, the GSK3-receptor (PDB code = 3SAY) was docked through 
HADDOCK server86 and the complex subjected to molecular simulation dynamics to minimize 
the energy. Then the involved mutations of -catenin were introduced in the wild type 
structure following a well-validate procedure. Each mutant complex was then solvated and 
energy minimized using a combination of molecular dynamics techniques. The mutants -
catenin complex were generated taking into account different rotamers for each substitution 
and evaluating the one most probable.  
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We worked with a neutralized system, obtained by the addition of Cl- and Na+ in grids with the 
Coulombic potential around the protein largest positive or negative; sequentially, a correct 
number NaCl molecules were added to ensure physiological ionic strength (150mM). All the 
simulations were run in explicit solvent, immersing the complex in a TIP3P box16 of water of a 
length of at least 10 Å in each dimensions.   
In all simulation, long-range electrostatic interactions were treated by particle Mesh Ewald 
(PME). A dielectric costant of 1 was applied and a cutoff of 9Å for nonbonded interactions was 
set. 10 ns MD were run for data production. 
MM/PBSA calculation6 was performed, the affinity of wild type and mutated catenin with 
GSK3 (Gbind) was calculated as the sum of the van der Waals, polar solvation, electrostatic 
and entropic contributions.   .    
 
Results&discussion 
In this series of 179 patients with DT surgically treated at four referral centers over a 10 years 
time span, CTNNB1 gene mutation was the only significant prognostic factor for relapse. 
Patients affected by DTs harboring S45F CTNNB1 mutation had a poorer RFS (recurrence free 
survival) as compared to those having DTs harboring T41A/S45P and those having DTs with a 
WT CTNNB1 gene (Figure 3.3.1). These data reproduce the previously reported MDACC 
results79.   
The impact of specific mutation on the pathogenesis of DTs and their predisposing role in local 
relapse remains uncertain. Only three different point mutations in two different codons (41 
and 45) have been identified to date in desmoid-type fibromatosis. In particular, specific amino 
N terminal residues (Ser45 by CK1α, and Thr41, Ser 37, and Ser33 by GSK-3β in this sequential 
order) represent the phophorylation targets that mediate the degradation of β-catenin, a 
crucial step in maintaining low β-catenin cytoplasmic levels. In fact, deregulation of β-catenin 
activity is associated with cancer and other human diseases, due to its key involvement in the 
Wnt pathway. The identification of two different types of point mutation in the 45 position 
and the correlation between 45F and aggressive behavior suggests but does not prove a 
potential critical role of phophorylation mediated by GSK3. In this context, phophorylation in 
the position 45 amino acid residue by CK1α comprises the first step in β-catenin ubiquitination, 
a process that apparently cannot begin if a mutation in this specific residue is present.  
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Figure 3.3.1 RFS of patients grouped according to the specific mutation
80
 (A); RFS of patients who 
underwent surgery alone (B) or surgery plus other treatments (C) grouped according to specific 
mutation; RFS of patients grouped according to specific anatomical site (D ). 
 
In fact CTNNB1 mutations occur within this exon of the gene in the region encoding for 
sequence that contains different Serine/Threonine. 
Molecular simulation techniques were applied to evaluate the importance of these residues 
for catenin ubiquitination, CK1 and GSK3 sequentially phosphorylate the amino terminal region 
of -catenin resulting in its recognition by B Trcp, an E3 ubiquitin ligase subunit, and leading to 
ubiquitination and proteasomal degradation. 
The available structures of catenin in the protein data bank (PDB code=2G57, PDB 
code=2Z6H) correspond, respectively, to the regions of the “phosphorilation motif”  and the 
“Armadillo repeats domain” with C-ter part. An extensive study required preferentially the 
complete protein, for this reason we built the N- and, partially, C-terminal parts resorting to an 
homology modeling protocol well validated. 
The first step of this procedure consists on the prediction of the secondary structure, 
employing the online available programs DISOPRED and PredictProtein, obtaining partially 
disordered regions involving the C-terminal part. 
Then the obtained results were considerate under the light of the protein template identified; 
it requires an in-depth search, through MODWEBand SWISSPROTEIN, for the most suitable 
template. The output gave a considerable similarity of the specific portion required, more than 
45%, with the protein importin-, then the receptor/protein sequence was aligned and 
checked using the Build Homology model of DS. 
The first structure was adjusted, inserting the already known regions, deriving from NMR 
study, and subjected to extensive MD simulation in explicit solvent to reach an energetically 
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reasonable conformation, monitoring different parameters (RMSD, Total Energy, 
Temperature) to evaluate the good success of dynamic (Figure 3.3.2A). 
The reliability of the model was further verified through different tools (Whatif, Prosa), 
evaluating the scoring factor obtained and correlate it with the data present in literature. 
Figure 3.3.1 showed a positive structural output resulting from the Ramachandran plot, most 
of the residues, more than 95%, are located in favored regions while only a small portion stay 
in generously allowed regions and only 1% in less favorable area. Therfore, the validated 3D 
homology model of the full -catenin structure was employed in this study (Figure 3.3.3).  
 
 
 
 
 
 
 
Figure 3.3.2 A) (from left to right) RMDS of the coordinates of the backbone atoms of the homology 
model of the  catenin along the 15 ns MD simulation, temperature of the  catenin 3D model in water 
during the same MD simulation and time behavior of the total potential energy; B)Ramachandran plot 
generated from the MD refined 3D homology model of the catenin. 
 
Figure 3.3.3 Final 3D homology model structure of -catenin; in green the phosphorylation motif, in red 
C- and N- terminal parts, in yellow armadillo repeats domain. 
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As already known, all the residues mutated in -catenin are phosphorylation/regulation sites 
for this protein. Specifically, phosphorylation of Serine 45 increases the affinity of -catenin for 
Glycogen synthase kinase 3 (GSK3), thus promoting its ubiquitination and degradation. 
Actually, only S45F mutant seems to play a fundamental role in tendency for local recurrence 
after complete surgical resection. In order to verify whether the amino acidic changes caused 
by mutation in the exon 3 of CTTNB1 were actually responsible for the deregulation of 
catenin, the S45F and S45P mutations were introduced into the Wild Type (WT) catenin 
and investigated in complex with GSK3.   
First of all the 3D structure of GSK3 was downloaded by PDB and the identification of the 
putative interaction site was carried out exploiting Haddock server. Different interesting point 
emerged: i) catenin bound GSK3 with P-Ser45, contained in the N-terminal and in particular in 
the phosphor motif; ii) GSK3 accepts the P-Ser45 in a pocket create by the loop region from 
Arg93 to Lys20587. Having localized the putative interactive zone in this region we docked the 
three different systems by Haddock (Figure 3.3.4). The resulting docked conformation was 
then subjected to MD simulation in explicit solvent and evaluated the different conformation 
for the three complexes (WT, S45P, S45F). The procedure for protein-protein interaction 
molecular modeling study was considered as in well described different works35,88-90.   
The all long simulation highlighted the importance of the side chains of the mutated Ser45 that 
seems to play a crucial role in binding and stabilizing GSK3 in the interaction zone. Actually, the 
side chain of F45 reaches deeply into the specific phospho-serine pocket, thus preventing the 
disruption of the complex and, contextually, hampering the kinase activity of GSK3 on T41, S33 
and S37. S45 plays a fundamental role in the conformational properties and dynamics of the 
pocket to keep the dynamic equilibrium of this “sliding” mechanism.  
 
 
Figure 3.3.4 Complex of WT catenin (in red) in complex with GSK3 (in blue); in light blue is depicted the 
surface of GSK3. 
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During 10 ns of MD simulation we observed that the steric hindrance of the phenylalanine side 
chain compared to serine reflects in a rearrangement of the equilibrium, altering the 
ubiquitination machine (Figure 3.3.5).  
All these findings were confirmed by the thermodynamic data resulted from MMPBSA 
application, as showed in Table 3.3.1A H of 45F has the strongest affinity for GSK3; on the 
other hand the presence of a proline seems to exert a minor perturbation to the destruction 
complex. 
In particular, analyzing the deconvolution of energies per residues, we noticed that Phe45 and, 
gains about 6 kcal/mol compared to the WT (WT -4,8 kcal/mol to D473Y -3,2 kcal/mol) and in 
this mutant also the neighboring residues seems to affect the overall energies (Table 3.3.1B).  
 
 
 
  
A      B 
 
C 
Figure 3.3.5 Modeled complex of GSK3 in complex with  catenin a) WT, b) S45P, and c) S45F, showing 
the key interaction zone proposed, highlighted the key residues involved in the mutations.  
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Table 3.3.1 A) Enthalpic contributions H (kcal/mol) for GSK3 in complex with  catenin wt, S45F and 
S45P. Errors are given in parenthesis as standard errors of the mean; B)Per residue binding free energy 
decomposition for GSK3 in complex with catenin WT (in blue), S45F (in red), and S45P (in green). Only 
catenin amino acids from position 37 to 47 are shown, since the interest in the phosphorylation motif. 
 
Conclusion 
The clinical data confirmed that patients with S45F mutated primary and completely resected 
DTs exhibit a higher tendency for local recurrence. The detailed analysis of the binding free 
energy and its per residues deconvolution for all these supramolecular complexes shows that 
replacing Serine with Phenylalanine results in a stronger interaction of -catenin with GSK3. 
The results of this in silico investigation support the clinical evidence for the high 
aggressiveness of the S45F mutant.     
 
3.4 EFFECTS OF A DOUBLE MUTATION ON c-KIT RECEPTOR AFFINITY FOR 
IMATINIB91  
Here we report for the first time a case of GIST whose molecular characterization revealed the 
presence of two mutations in KIT exon 11, one of which never described before, causing the 
double aminoacidic substitution W557G/Y578C. Based on the presence of KIT mutations in 
exon 11, the patient was subsequently treated with Imatinib, and responded well to this TKI-
based therapy. In keeping, in silico (i.e., computer-based molecular simulations) and in vitro 
experiments demonstrated that the KIT receptor carrying the W557G/Y578C double mutation 
displays constitutive phosphorylation which can be switched-off upon Imatinib treatment.  
Materials and Methods 
Patient history 
On November 2009, a 68-year-old man with a history of hypertension and atrial fibrillation 
owing to severe abdominal pain underwent an X-ray computed tomography (CT scan) that 
revealed hemoperitoneum due to an abdominal mass. An emergency surgery with resection of 
  H (kcal/mol) 
WT -57,44 (±0,92) 
S45F -116,00 (±0,99) 
S45P -75,74 (±0,91) 
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the mass probably arising from stomach was carried out, providing a diagnosis of 
hemangiopericytomas. 
Six months later, a CT scan showed multiple peritoneal lesions and the patient underwent to 
surgery of all peritoneal metastasis. Histological review of primary tumor was performed at 
Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy) with a diagnosis of GIST. 
On September 2010, due to peritoneal progression of disease, the patient was administered 
400 mg Imatinib per day. Disease assessment, including CT scan, was done before starting 
Imatinib. The patient underwent also a complete cardiac evaluation. Routine liver and renal 
function tests were within normal ranges. The last follow up visit was in November 2012.  
GIST diagnosis 
A paraffin-embedded formalin-fixed representative block of the primary tumor, previously 
diagnosed as hemangioperycitoma, was received by the Fondazione IRCCS Istituto Nazionale 
dei Tumori (Milan, Italy) for a second pathological opinion. Diagnosis of GIST was rendered 
based on tumor morphology, featuring a spindle and epithelioid cells growth, and on 
immunophenotyping, positive for CD117 (clone A4502, Dako) with a dot like decoration, DOG1 
(clone-K9, Novocastra, Leica Biosystems), PKC theta (clone 27/PKCθ, BD Transduction, Franklin 
Lakes, NJ USA), PDGFRA (clone-sc338, Santa Cruz Biotechnology, Inc.) and focally for 
citokeratins (clone AE1/AE3, Dako). The mitotic count revealed 60 mitoses/HPF that, along 
with the tumor mass diameter (> 5 cm), categorized the tumor as a high risk GIST.92 
KIT and PDGFRA molecular analysis 
The mutation hot spots of both KIT and PDGFRA receptors were analyzed by direct sequencing 
of exons 9, 11, 13, and 17 of KIT, and exons 12, 14, and 18 of PDGFRA genes as previously 
described93. 
The PCR product of KIT exon 11 amplification was subcloned into a pGEMT vector (Promega) 
following manufacturer’s instructions, and transformed into DH-5 E. Coli competent cells 
(Life Technologies). 30 bacterial ampicillin resistant colonies were selected, and their DNA was 
amplified for KIT exon 11 to verify the presence of the subcloned DNA. These PCR products 
were subsequently sequenced as previously described93.  
Computational details 
All KIT three-dimensional (3D) mutant models (W557G, Y578C and the double mutant 
W557G/Y578C) were obtained starting from our optimized wild-type (WT) KIT model 93-96. The 
validated structures of the 559 and T670I KIT mutants97 were also considered as reference for 
an Imatinb responsive and a resistant TK isoform, respectively. 
All computer simulations were performed using the AMBER 11 suite of programs on 256 
processors of the IBM PLX-GPU supercomputer (CINECA supercomputer center, Bologna, Italy) 
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as previously reported30,52,93,94,96. The affinity of the mutant KIT isoforms for ATP and Imatinib, 
expressed as the value of the corresponding free energy of binding  Gbind, was estimated 
according to the Molecular Mechanics/Poisson-Boltzmann Surface Area (MM/PBSA) method6 
(see details in Material&Methods chapter). 
Expression vector construction, transient transfection and Western blot analysis 
KIT W557G and Y578C mutants have been obtained by site-directed mutagenesis of pCDNA3 
expression vector containing a wild-type (WT) KIT97 by Site-Directed Mutagenesis kit (Promega, 
Madsion WI) following manufacturer’s instructions, using the following primers: 
5'-CAACACAACTTCCTTGTGATCACAAATGGGAG-3' and 
5'-CTCCCATTTGTGATCACAAGGAAGTTGTGTTG-3' for W557G mutation; 
5'–CATGTATGAAGTACAGGGGAAGGTTGTTGAGG-3’ and 
5'-CCTCAACAACCTTCCCCTGTACTTCATACATG-3' for Y578C mutation.  
These latter were employed to produce the W557G/Y578C double mutant using the KIT 
W557G expression vector as a template. 
HEK293 cells were cultured and transfected as previously described.98 Cells were harvested 48 
hours after transfection following overnight serum starvation. Cell lysates were produced in 
RIPA modified buffer, and Western blot analysis was performed as previously described98. Anti 
c-KIT (clone H300) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA); anti-phospho c-KIT, AKT and phospho AKT (Ser473) antibodies were from Cell Signal 
Technology (Beverly, MA, USA); ERK1/2 and phospho ERK1/2 antibodies were from Sigma-
Aldrich (St. Louis, MO, USA). 
Images were acquired by G-Box (Syngene) and densitometric analysis of the bands was 
performed by Image Quant software. Data are expressed as the ratio of phosphorylated/total 
c-KIT and normalized for untreated sample. 
Patient evaluation after Imatinib treatment 
Patient response to Imatinib treatment was assessed by whole-body CT scan after the first and 
the third month of treatment then every three months. Radiologic evaluation was done 
according to RECIST (Response Evaluation Criteria in Solid Tumors) criteria. The CT scan after 
the first month showed a complete response to therapy (Figure 3.4.1). During the treatment 
the patient underwent follow-up visit every month during the first three months of therapy, 
and subsequently, every three months.  The toxicity, assessed thought blood-cell counts and 
blood chemical values, was analyzed every month. 
Up To date, after 27 months of treatment, the patient on Imatinib (400 mg /daily) is still on 
response with no signs of toxicity.  
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Figure 3.4.1  Response to Imatinib. Peritoneal metastasis from gastric GIST treated with Imatinib: 
computed tomography scan (arterial phase after contrast medium). A RECIST complete response after 1 
month of treatment with Imatinib was obtained and the therapy is ongoing. 
 
Molecular analysis of the GIST tumor 
KIT gene sequencing of the primary tumor revealed a double mutation in exon 11 (T1669G and 
A1733G), present in heterozygous status and responsible for the W557G and Y578C 
substitutions on the KIT receptor. To assess whether both mutations were located on the same 
allele, the PCR fragment comprising the whole KIT exon 11 was subcloned into a pGEMT 
vector99. Sequencing of the subcloned DNA identified a co-presence of both W557G and Y578C 
KIT mutations in 26 out of the 30 E. coli colonies analyzed, thus confirming mutation 
heterozygosis. Accordingly, in the tumor the mutated KIT receptors were characterized by the 
presence of the double aminoacidic substitution. The W557G mutation, already  detected in 
GISTs, is one of the most frequent point mutations in exon 11. Patients with GIST but also with 
melanoma 100 carrying this KIT mutation responded to Imatinib101,102. However, to our 
knowledge, in vitro data aimed to the analysis of intrinsic activity and Imatinib sensitivity of 
W557G KIT have not been reported so far. Furthermore, the Y578C mutation has never been 
described before, neither in GISTs nor in any other pathology (Sanger Institute, Cosmic 
database, www.sangerinstitute.com); notably, it is located closed to the KIT 
activating/Imatinib-resistant L576P substitution93. 
In order to determine the effect of the Y578C substitution, alone and in combination with the 
other detected mutation, W557G, on KIT receptor activity and sensitivity towards Imatinib, we 
performed a thorough study based on coupled in-silico/in-vitro experiments. 
Molecular modeling 
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The upper half of Table3.4.1 lists the total free energy of ATP binding values that were 
calculated for the 559, T670I, W557G, Y578C, and the W557G/Y578C double KIT mutant 
receptors, respectively. The value of  Gbind for the  559 KIT with respect to ATP was found 
to be  Gbind = - 24.20 kcal/mol, in agreement with our previous simulations97 (Figure 3.4.2). 
As suggested by the Gbind (=Gbind,wt – Gbind,mut) values in the last row of the top half 
of Table 3.4.1, all KIT mutants showed an affinity for ATP comparable to that of the 559 
reference protein, thus confirming the activating character of these mutations. 
 
 
 
Figure 3.4.2  Zoomed view of Imatinib in complex with 559 KIT. The inhibitor is depicted as atom-
colored sticks-and-balls (color code: O, red; N, blue, C, gray). The main residues interacting with Imatinib 
are highlighted as colored sticks (A621, orchid; Glu640; turquoise; Val643, goldenrod; Thr670, red; 
Tyr672, medium blue; Cys673, pink; Leu799, chartreuse; his790, sienna, Leu 783, blue. H-bonds are 
evidenced by black broken lines. H atoms, water molecules, ions are counterions are omitted for clarity. 
 
As the affinity for Imatinib is concerned, the calculated free energy of binding values listed in 
lower part of Table 3.4.1 show that the double-mutant receptor is endowed with an affinity 
towards Imatinib (Gbind = -8.17 kcal/mol) slightly lower than that of the activating but 
Imatinib-responsive ∆559 isoform (Gbind = -0.98 kcal/mol) (see Figure 3.4.3, panels A and 
B). Conversely, the presence of the Y578C alteration seems to exert a minor perturbation to 
Imatinib binding, as the corresponding Gbind value (-8.89 kcal/mol) is comparable to that of 
the 559-mutated receptor (Gbind = -0.26 kcal/mol) (see Figure 3.4.3, panels C and D). 
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Intriguingly, the Y578C substitution involves a residue that is close to L576. KIT mutations at 
this position (e.g., L576P) have been shown not only to activate the receptor but also to confer 
a high degree of resistance to Imatinib93,103. Of note, the W557G KIT mutant is predicted to be 
utterly similar to the reference 559-mutated receptor in its affinity towards both ATP and 
Imatinib (see Figure 3.4.3, panels E and F), in agreement with previous findings104, whereas the 
T670I is found very resistant to the TK inhibitor, as expected. 
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Figure 3.4.3 (A) Superposition of MD equilibrated snapshots of ∆559 (blue) and the W557G/Y578C 
double mutant (orange) KIT in complex with Imatinib. (B) Details of Imatinib in complex with the 
W557G/Y578C double mutant KIT. (C) Superposition of MD equilibrated snapshots of ∆559 (blue) and the 
Y578C mutant (yellow) KIT in complex with Imatinib. (D) Details of Imatinib in complex with the Y578C 
mutant KIT. (E) Superposition of MD equilibrated snapshots of ∆559 (blue) and the W557G mutant 
(magenta) KIT in complex with Imatinib. (F) Details of Imatinib in complex with the W557G mutant KIT. 
In panels A, C, and E, Imatinib is portrayed in a stick-and-ball representation colored according to the 
protein isoform which is bound to. In panels B, D, and F, the inhibitor is depicted as atom-colored sticks-
and-balls (color code: O, red; N, blue, C, gray). The main residues interacting with Imatinib are 
highlighted as colored sticks (A621, orchid; Glu640; turquoise; Val643, goldenrod; Thr670, red; Tyr672, 
medium blue; Cys673, pink; Leu799, chartreuse; his790, sienna, Leu 783, blue. H-bonds are evidenced by 
black broken lines. In all images, H atoms, water molecules, ions are counterions are omitted for clarity. 
 
Effect of W557G and Y578C mutations on KIT receptor activity 
Next, we investigated the effect of W557G, Y578C and W557G/Y578C mutations on KIT 
receptor activity and Imatinib response in intact cells. KIT mutants were transiently transfected 
in HEK293 cells and KIT expression and phosphorylation in the absence or in the presence of 
Imatinib (1 and 5 µM) were analyzed by Western blot (Figure 3.4.4A). ∆559 and T670I KIT 
mutants were used as control for Imatinib sensitivity and resistance, respectively. 
In untreated cells a delay of processing was observed for ∆559, W557G, and W557G/Y578C KIT 
mutants with respect to the others, as the 145 kDa fully glycosylated form was barely 
detectable with anti-KIT antibodies. However, such difference was abrogated by Imatinib 
treatment (Figure 3.4.4 A, top panel).  
For all KIT mutants Western blot with anti-phospho-KIT antibodies showed constitutive 
phosphorylation of both 145 and 125 kDa forms. KIT phosphorylation levels of W557G, Y578C, 
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and W557G/Y578C KIT mutants were comparable to those of ∆559 mutant (Figure 3.4.4 A), as 
also observed by quantitative analysis. These data demonstrate that the Y578C mutation, 
alone or in association with W557G, induce constitutive KIT receptor activation, in agreement 
with the modeling results shown in Table 3.4.1. Quantitative analysis of relative KIT 
phosphorylation levels is reported in the graph of Figure 3.4.4 A. As expected, 1 and 5µM 
Imatinib treatment reduced ∆559 but not T670I mutant phosphorylation. 
Imatinib treatment of cells expressing W557G mutant produced a reduction of receptor 
phosphorylation at both doses. Similarly, phosphorylation of the Y578C mutant receptor was 
decreased by treatment with both 1µM and 5µM Imatinib, indicating sensitivity of this 
mutation to the TKI, in accordance with in silico analysis prediction. 
The double W557G/Y578C mutation displayed the same features of the single W557G and 
Y578C mutations: constitutive phosphorylation was reduced by at least 70% by Imatinib 
treatment, once again in agreement with the computer-based results. Moreover, as shown in  
Figure 3.4.4 B, KIT inhibition by Imatinib blocked the signaling pathways triggered by 
W557G/Y578C mutant receptor, as ERK1/2 and AKT phosphorylation were reduced, similarly 
to the effect shown for the ∆559 Imatinib sensitive KIT mutant (Figure 3.4.4 B)98. 
 
Table 3.4.1 Binding free energies (ΔGbind) and binding free energy differences (Gbind)a for the 559, 
T670I, W557G, Y578C, and W557G/Y578C KIT receptors in complex with ADP and Imatinib. All values are 
in kcal/mol. 
 
ATP-binding 559 T670I W557G Y578C W557G/Y578C 
Gbind 
-24.20 ± 
0.82 
-25.14 ± 
0.94 
-23.98 
± 0.22 
-24.72 ± 
0.52 
-24.97 ± 0.69 
Gbind - +0.94 -0.22 +0.52 +0.77 
Imatinib-
binding 
559 T670I W557G Y578C W557G/Y578C 
Gbind 
-9.15 ± 
0.12 
-6.38 ± 
0.11 
-9.02 ± 
0.09 
-8.89 ± 
0.06 
-8.17 ± 0.07 
Gbind - -2.77 -0.13 -0.26 -0.98 
aAccording to its definition (Gbind = Gbind,wt – Gbind,mut), negative values calculated for Gbind 
indicate that the considered amino acid substitution at a given position of KIT is unfavorable in terms of 
ATP/Imatinib affinity, whereas positive Gbind values indicate that the considered mutation is 
favorable 
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Figure 3.4.4 Effect of W557G and Y578C mutations on KIT receptor activity and sensitivity to Imatinib. 
(A) Western blot analysis (top) of HEK293 cells transiently transfected with the indicated KIT mutant 
constructs, untreated (0) or treated with 1 or 5 mM Imatinib. Quantitative analysis of relative KIT 
phosphorylation (bottom) expressed as ratio between phosphorylated and total KIT levels and referred to 
untreated. The data represent the average of two independent experiments. (B) Effect of Imatinib on 
ERK1/1 and AKT phosphorylation induced by expression of 559 and W557G/Y578C KIT mutants in 
transiently transfected HEK293 cells. Arrows indicate the 145 and 125 kDa KIT receptor forms. 
 
Overall, these data suggest that each single W557C and Y578G mutation causes constitutive 
activation of the KIT receptor and is sensitive to Imatinib treatment. Moreover, the 
concomitant presence of the W557G and Y578C mutations on the same molecule does not 
alter the effect of single mutations on KIT receptor activation and sensitivity to Imatinib. 
 
Conclusions 
The data presented in this work indicate that the unusual combination of two KIT mutations, 
one of which reported for the first time and located close to the Imatinib insensitive mutation 
L567P, does not influence the overall sensitivity of KIT mutant towards Imatinib. In vitro 
analyses coupled with in silico studies once again proven to be a reliable and complete tool to 
predict drug affinity for mutated receptors. This is particular true in the light of the clinical 
response observed in the patient here reported after Imatinib treatment, and emphasizes the 
potent role of this jointed approach, able to yield consistent results (in a few hours as in silico 
analyses are concerned) in driving the choice for a suitable patient treatment in presence of 
unknown mutations whose drug sensitivity is lacking. 
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3.5 PRIMARY AND ACQUIRED RESISTANCE TO HEDGEHOG INHIBITOR 
VISMODEGIB THROUGH SMOOTHENED (SMO) RECEPTOR MUTATION IN 
BASAL CELL CARCINOMA 
In collaboration with Head and Neck Medical Oncology Unit and Laboratory of 
Experimental Molecular Pathology, FondazioneIRCCS Istituto Nazionale dei Tumori, 
Milan (Italy) 
Two patients enrolled in a phase II trial were evaluated to assess the safety of vismodegib in 
metastatic or locally advanced BCC, showing a pattern of primary and acquired resistance to 
the drug, respectively. 
The first patient was a 82-years old woman presenting with a BCC metastatic to liver, lungs and 
bones. Histological confirmation of metastasis was obtained by liver biopsy. She received 
radiation therapy to lumbar (L2-L4) and cervical (C3) metastasis, then she started vismodegib 
150 mg/die. After 2 months of continuous treatment CT scans showed disease progression at 
all sites compared (primary resistance).  
The second patient was a 78-years old man presenting with a large (12 cm) and ulcerated 
lesion of the sovrascapular skin, that was biopsied and diagnosed for BCC (Figure 3.5.1, left). As 
a surgical approach would lead to substantiall morbidity, this patient was also set on a 150 
mg/die vismodegib regimen. The lesion dramatically reduced after the first month, and a 
complete clinical response was obtained at the 6th month of treatment (Figure 3.5.1, left). 
However, at month 11, 2 subcutaneous nodules appeared within the area of the previous 
lesion, which were surgically removed. Histological exams showed a pattern of recurrent BCC 
(acquired resistance).  
 
Methods 
PTCH1 and SMO mutational analysis 
Formalin-fixed paraffin-embedded (FFPE) tumor specimens of pre-treatment BCC liver 
metastasis (first case), and of bothpre-treatment primary tumor and recurrence arisen during 
vismodegib regimen (second case) were reviewed for tumor content and subjected to 
macrodissection. Genomic DNA was extracted using the Qiamp FFPE DNA kit (Qiagen, 
Chatsworth, CA), following manufacturer’s instructions. 
Exons 1-23 of PTCH1 and 8-10 of SMO were amplified by PCR using specific primers. All PCR 
primer sequences are available upon request. The PCR products were subjected to direct 
sequencing using an ABI Prism 3500 DX Genetic Analyzer (Applied Biosystems, Foster City, CA, 
USA), and then evaluated by means of the ChromasPro software. 
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Figure 3.5.1 Clinical appearance of the soprascapular BCC at diagnosis (left) and after 5 months of 
vismodegib (right). 
 
In silico experiments 
The free energies of binding Gbind for the wild-type (WT) and mutant SMO/vismodegib 
complexes were obtained using an extensively validated procedure based on the Molecular 
Mechanics/Poisson-Boltzmann Surface Area (MM-PBSA) methodology30,52,91. Accordingly, 
Gbind values are calculated for equilibrated structures extracted from the corresponding 50 
ns molecular dynamics (MD) trajectories.  
Steered molecular dynamics (SMD) simulations were performed to study vismodegib entry 
within the receptor binding pocket. With the adopted settings, 3.0 nm were covered in 1000 ps 
of SMD simulation. 
Calculations were carried out using the AMBER 12 platform63 with Amber ff03 and GAFF force 
field105 on the EURORA supercomputer (CINECA, Bologna, Italy). 
 
Molecular analysis 
To explore possible mechanisms of Hh pathway activation, we firstly performed genomic 
sequencing of all 23 coding exons of PTCH1. In the case showing primary resistance, no PTCH1 
mutation was observed by analyzing the pre-treatment BCC liver metastasis biopsy. By 
contrast, in the pre-treatment primary tumor biopsy of the second case, PTCH1 analysis 
revealed the presence of the nonsense mutation CAG>TAG creating a premature STOP codon 
(pQ64) in the exon 2 (Fig. 3.5.2 A). This PTCH1 mutation predicts translation to a heavily 
truncated protein and of primary importance since loss of function mutation in the PTCH1 
gene have been associated with SMO activation. As expected, the same PTCH1 mutation was 
also observed in the recurrence samples taken obtained from the patient during vismodegib 
regimen (Fig. 3.5.2 B). 
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Next, we evaluated the mutational status of SMO - the direct protein target of vismodegib. In 
the case showing primary resistance, the pre-treatment BBC liver metastasis revealed the 
occurrence of the SMO missense mutation GGG>TGG, leading to the amino acid substitution 
G497W at exon 9 of the corresponding protein (Fig. 3.5.2 C). By contrast, in the pre-treatment 
primary tumor samples of the BCC second case, no SMO mutations were detected (Fig. 
3.5.2D); however in the recurrence specimens obtained during vismodegib treatment SMO 
sequencing found the missense mutation GAC>TAC at exon 8, leading to the single amino acid 
substitution D473Y in the SMO receptor.  
 
Figure 3.5.2. PTCH1 and SMO mutational analysis.  Pre-treatment BCC liver metastasis of the first case 
(primary resistance) showed PTCH1 wild type gene (panel A) and the SMO G49W mutation (panel C). 
Pre-treatment primary tumor and BCC recurrence (panel B) of the second case (acquired resistance) 
carried the nonsense Q84Stop PTCH1 mutation; the SMO D473Y mutation was observed only in the 
recurrence BCC sample (panel D).  
 
In silico experiments 
Our in silico experiments revealed that, in the presence of the two SMO mutations detected in 
our patients, the estimated sensitivity of the receptor for vismodegib is reduced. In particular, 
for the SMO D473Y mutant isoform, the calculated IC50 value is 159 nM (Gbind = -9.27 ± 0.10 
kcal/mol), resulting in an almost two order of magnitude lower affinity with respect to the WT 
protein (IC50 = 2.5 nM, Gbind = -11.75 ± 0.31 kcal/mol). Accordingly, a direct effect on drug 
binding is at play in the presence of the missense D/Y mutation at position 473 of the SMO 
receptor. In the case of the G497W point substitution, the calculated IC50 for vismodegib is 
also diminished albeit to a considerable lesser extent: IC50 = 69 nM and Gbind = - 9.78 ± 0.10 
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kcal/mol. Hence, another molecular mechanism of resistance should be at play in the case of 
primary resistance. Further, advanced simulations revealed that, in the presence of the G497W 
mutation, the drug pathway to the binding site is quite hampered, due a conformational 
rearrangement of the protein region surrounding the mutation. So, a higher energy is required 
to vismodegib to reach the mutant protein binding site, as discussed in detail below. 
 
Discussion  
To our knowledge, this study presents for the first clinical, molecular, and in silico evidences of 
primary and acquired resistance to vismodegib in BCC.  
The G497W missense mutation in the SMO receptor characterizes the liver metastasis of the 
first patient showing a progression of disease after two months of vismodegib treatment. Even 
if less frequent than PTCH1 mutations in BCC106, activating SMO mutations cause constitutive 
ligand-independent signal transduction thus making mutated SMO an oncogene in BCC107. In 
addition to a possible oncogenic function, we hypothesized that the mutation G497W likely 
represents the molecular mechanism associated with vismodegib primary resistance in BCC. To 
support this assumption we explored in silico the effects exerted by this mutation on the 
inhibitor binding to the mutated SMO protein.  
Mutation G497W is in a distal position with respect to the protein drug binding site (Fig. 3.5.3). 
Accordingly, only a moderate direct effect on the protein affinity for the inhibitor can be 
anticipated. Indeed, in a sort of domino effect, a slight overall readjustment of the binding site 
residues is observed for the SMOG497W isoform. Accordingly, the estimated free energy of 
binding Gbind and the corresponding IC50(est) value for the SMOG497W/vismodegib 
complex are 9.78 ± 0.10 kcal/mol and 69 nM., respectively, which are somewhat but not 
dramatically higher than the corresponding values obtained for the WT/inhibitor complex 
(Gbind = -11.75 ± 0.31 kcal/mol and IC50(est)= 2.5 nM) (Table 3.5.1). Thus, other molecular 
mechanisms are likely contributing to the primary resistance of SMOG497W to vismodegib. A 
direct comparison of the WT/mutated protein structures in the area surrounding position 497 
revealed that, in the presence of the tryptophan mutant residue, the entire region undergoes a 
conformational rearrangement, thus resulting in a narrowing of the protein drug entry site. For 
this reason, in the presence of the G497W mutation vismodegib might be less able to reach 
the protein binding pocket and, hence, less effective in its inhibitory activity. To support this 
mechanism we then devised and conducted steered molecular dynamics experiments of the 
binding process of vismodegib to the WT and SMO G497W isoforms. Figures 3.5.3 B and C 
show the different course of these binding processes. As we can see, not only quite a higher 
force, and hence energy, is required to vismodegib to reach its binding site in the presence of 
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the mutant residue (Figure 3.5.3 B) but also, and perhaps even more interestingly, contrarily to 
the WT case, for SMOG497W the drug has not yet reached its correct orientation within the 
protein binding pocket after the same time lag (Figure 3.5.3 C). In practical terms this 
fundamentally implies that, in time, the effective vismodegib concentration within the 
SMOG497W binding site is significantly lower than in the case of the WT receptor and this, is 
our opinion, constitutes a novel and effective mechanism of drug primary resistance. 
In this respect, the identification of such a mutation could become a biomarker for vismodegib 
primary resistance, in a panorama where any predictive marker able to identify patients not 
responding to this drug is totally absent.  
 
 
Figure 3.5.3 (A) Zoomed view of the SMOG497W binding site in complex with vismodegib. The receptor is 
shown as a secondary-structure colored ribbon (orange, -helices; purple, -sheets; gray, coils). 
Vismodegib is portrayed as atom-colored sticks-and-balls (red, O; blue, N; green, Cl; S, sulfur; gray, C). 
Residue W497 is evidenced as dark red sticks. (B) Rupture force vs. time during the entry process of 
vismodegib within the wt (green) and SMOG497W binding site. (C) SMD snapshots of vismodegib 
entering the receptor binding pocket. The protein is shown using the same color scheme of panel A. 
Vismodegib is highlighted by its green/red van der Waals surface. In panels A and C, hydrogens atoms, 
ions, counterions and water molecules are omitted for clarity. 
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Concerning the second patient, the PTCH1 inactivating mutation observed in the pre-
treatment primary lesion along with absence of SMO mutation could explain the complete 
clinical response obtained after 6month of continuous vismodegib treatment. Essentially, loss 
of PTCH1 function by inactivating mutations relieves normal SMO inhibition and leads to the 
activation of Hh target genes such as GLI1. 
Despite the presence of the premature STOP codon in PTCH1, 5 months later the patient 
developed BCC recurrence. Sequencing of PTCH1 in recurrence samples confirmed the 
presence of the same nonsense PTCH1 mutation. To characterize the mechanism of relapse we 
performed SMO sequencing and unveiled the appearance of the nucleotide mutation 
GAC>TAC coding for the missense D473Y substitution in the SMO transcript. This sequence 
alteration was not detected in any of the primary lesion samples examined. Notably, another 
amino acid substitution of the same SMO conserved aspartic acid  (D473H) was reported and 
designated as the mechanism of vismodegib resistance in medulloblastoma108. Coherently, in 
an elegant in vitro study the same group characterized the role of D473 in SMO function by 
replacing aspartic acid with every other amino acid and showing that all mutant were resistant 
to vismodegib109. Our in silico data of SMO D473Y are in line with these findings and added 
convincing evidence about the pivotal role played by D473 in drug binding. 
Our in silico analysis of the molecular effect of the SMO missense mutation D473Y clearly 
revealed a direct effect of the mutated residue on vismodegib binding. Indeed, the estimated 
affinity of the inhibitor for this mutated protein IC50 = 159 nM (Gbind = -9.27 ± 0.10 kcal/mol 
is almost two order of magnitude lower than the one measured/estimated for the WT 
counterpart (IC50(exp)= 3 nM, IC50(est) = 2.5 nM, respectively) (Table 3.5.1). Importantly, we 
discovered amino acid D473 is part of a peculiar triad of residues composed, besides D473, by 
R400 and H470. These triad forms is engaged in a small but fundamental network of hydrogen 
bonds which keeps the SMO binding pocket in the proper size and shape to tailor-fit 
vismodegib binding (Figure 3.5.4 A). In the presence of the D473Y mutation, a considerable 
effect on the binding site geometry is induced, required for the proper accommodation of the 
residue aromatic side chain, ultimately leading to the total disruption of the stabilizing 
hydrogen bond network. The inhibitor is hence shifted from its optimal position, the only 
surviving interaction with the receptor being an intermitted hydrogen bond with Y394 (Figure 
3.5.4 B). These evidences are substantiated by the per residue energy deconvolution of the 
free energy of binding, as shown in Figures 3.5.4 C and 3.5.4 D. As we see, all receptor residues 
mainly involved in vismodegib binding undergo a severe reduction in the stabilizing 
contribution to inhibitor binding in the presence of the mutation (Figure 3.5.4 C). Analogously, 
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upon disruption of the hydrogen bond network among the SMO triad residues, the relevant, 
favourable contribution to receptor/inhibitor binding plummets drastically (Fig. 3.5.4 D). 
 
 
 
 
 
Figure 3.5.4 Zoomed views of the WT (A) and SMOD473W mutant binding sites in complex with 
vismodegib. The receptor secondary structure is outlined as a semi-transparent ribbon (orange, -
helices; purple, -sheets; gray, coils). Vismodegib is portrayed as atom-colored sticks-and-balls (red, O; 
blue, N; green, Cl; S, sulfur; gray, C). The triad of residues involved in the hydrogen-bond network are 
highlighted colored sticks: R300, dark magenta; H470, olive drab; D/Y473, dark cyan. Y394 is also shown 
as dark red sticks. H-bonds are evidenced as black lines. (B) Comparison of vismodegib binding energy 
contributions from WT (green) and D473Y (red) SMO residues. (C) Comparison between hydrogen bond 
network stabilization energies for SMO residues belonging to the WT (green) and SMOD473Y triad 
residues in the relevant vismodegib complexes. X denotes either D or Y residue at position 473. 
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Table 3.5.1 In silico estimation of free energy of binding (DGbind) for  WT and SMO
D473H mutant receptor 
in complex with vismodegib. Errors are given in parenthesis as standard errors of the mean (SEM). 
a
Gbind = Gbind,wt – Gbind,mutant. By definition, a negative value of Gbind indicates that the 
WT/vismodegib complex is favored with respect to the mutated one, and vice versa. 
 
 
 
 
Conclusion 
Similarly to medulloblastoma, our data further raise the issue of overcoming the resistance 
related to mutation of the drug target. Under this perspective, efforts aimed at identifying 
second generation drugs showing potent activity against SMO mutants are mandatory. To this 
goal, a panel of compounds has already been screened in vitro and several promising 
antagonists able to inhibit tumor growth mediated by drug-resistant SMOs were selected in 
murine allograft model of medulloblastoma. 
Another strategy worth pursuing is the inhibition of the Hh pathway through other 
mechanisms, the activity of itraconazole or arsenic oxide in blocking vismodegib-resistant BCC 
both in vitro and in vivo being prime examples110.  
An alternative approach for combating vismodegib resistance could consist in exploring other 
signaling pathways implicated in BCC in order to identify new therapeutic targets. Inhibition of 
the PI3K pathway seems already to be an exciting therapeutic possibility for treating resistant 
medulloblastoma patients109,111. 
It may be speculated that the emergence of such mutations causing drug-resistance could 
represent a clonal alteration of all BCC cells and/or it might interest only a fraction of the 
tumoral cells, thus justifying a prolonged regimen of vismodegib beyond progression, in 
combination with other therapeutic strategies. Future molecular studies on tumor 
heterogeneity are currently in progress in order to answer this question. 
Considering that median duration of response to vismodegib in previous clinical trial was 7.6 
months, the issue of acquired resistance is an important point to debate in order to exploit the 
activity of this drug to its full potential. In particular, it has been proposed that other 
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therapeutic schedules (i.e,. intermittent dosing) may alter resistance mechanism 
development111. Moreover, different schedules of administration might help in increasing the 
compliance, as in previous clinical experiences a patient percentage varying from 12% to 54% 
discontinued vismodegib due to the occurrence of adverse events112  
There is also much debate about BCC rebound after vismodegib cessation for adverse events, 
with conflicting reports supporting both evidences.  However, in patients with basal-cell nevus 
syndrome assuming vismodegib the rate of new BCC development after inhibitor cessation for 
adverse events was slower than in control group receiving placebo. This could imply the 
absence of mutation occurrence without drug pressure, at variance with tyrosine kinase 
inhibitors, sometimes experiencing disease flare after treatment cessation. 
Our 2 cases of vismodegib resistance occurred in patients who had not received previously 
radiation therapy. It is possible that Hh inhibitor resistance outbreak could be higher in 
patients having received a radiation pressure, because of the increased susceptibility of cancer 
cells to genetic mutations. 
In this report we discussed 2 different SMO mutations able to explain primary and secondary 
resistance to vismodegib developed in two distinct BCC cases. We are aware that several 
possible, alternativemechanisms can be at play to evade SMO inhibition at different levels, 
such as abnormal downstream pathway activation, with Gli2 or Cyclin D1 overexpression, or 
upregulation of PI3K-AKT-mTOR signaling pathway. However, the screening for the reported 
SMO mutations and the search for new therapeutic strategies to overcome these resistance 
mechanisms should constitute one fundamental step in for a better exploitation of Hh 
inhibitors in the near future. 
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Conclusions 
In the late ’90s the discovery of a drug would have changed the world scenario on the 
approach to treat cancer; the ATP antagonist imatinib has been the first case of targeted 
therapy against chronic mieloyd leukemia (CML). This success triggered a series of studies that 
profoundly changed our understanding not only of cancer therapy but also of the classification 
of cancers, since the same drug, due to its intrinsic mechanism of action, beside inhibiting 
tyrosine kinase activity, was also found capable of inhibiting other enzymatic activities, such as 
those expressed by several RTKs including KIT, PDGFRA and PDGFRB. 
However a couple of year later, even if, till today, it is the first line therapy for different kind of 
cancer, a target-associated resistance has also been observed; the gatekeeper residue of BCR-
ABL1, T315, relapsed on treatment. A similar case was observed in a casa of melanoma treated 
by a RAF inhibitor, vemurafenib; a young man with BRAF-mutant melanoma, refractory to 
several therapeutic regimens, was treated with vemurafenib. After 16 weeks on the drug, the 
patient experienced widespread disease relapse, which by 23 weeks involved most previous 
sites of visceral and subcutaneous disease; vemurafenib was discontinued. Why this? 
A detailed understanding of the mechanisms by which tumors aquire resistance to targeted 
anticancer agents should speed the development of treatment strategies with lasting clinical 
efficacy.  
In this work we evaluated the possibility of applying molecular simulation techniques to 
understand mechanism behind resistance and identify new selective target. 
In fact the systematic approach of molecular modeling and simulation in the selection of new 
drugs, mostly, replace the biologically based, time-consuming, large-scale screening of 
molecules, and become a very useful tool for the rapid ranking and selection of a smaller set of 
molecules to be tested in the laboratory by traditional functional assays, as we demonstrated 
for the development of selective ligands for 1 receptor. This new, in silico approach will 
undoubtedly contribute to paving the way towards truly personalized treatment in the 
foreseeable future, and we are confident that, through a strong interaction between in silico 
techniques and high throughput technologies, we will be able to design multi-drug approaches 
which are effective on the treatment of different kind of cancer. 
Targeted therapies require new approaches to determine optimal dosing, to assess patient 
adherence to therapy, and to evaluate treatment effectiveness. The cost of these agents, 
which can exceed several thousand dollars per month, may become an important issue in 
health care economics. 
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Finally, our work on targeted therapy in GIST, BCC and desmoid tumors, particularly as regards 
the understanding the mechanism of the ‘‘resistance’’ phenomenon, has resulted in a novel 
multidimensional approach, which is also supported by an in silico dimension, to predict 
clinical results. 
In fact, thanks to the availability of the crystallographic coordinates of some receptors and 
having available a well validate homology modeling procedure, all the relevant 3D structure 
could be determined. As shown in this thesis, thanks to molecular modeling – a combination of 
computer-based simulation techniques on the basis of thermodynamic parameters which are 
calculated on a three-dimensional protein model derived either from crystallography or by 
homology techniques – we are able to estimate the affinity of a given inhibitor towards its 
target receptor with great accuracy. Likewise, in the case of acquired resistance, the sensitivity 
and affinity of these drugs for the ‘‘resistant receptor’’ can be predicted in the same way. 
One important aspect that has to be taken in consideration is the structural alterations 
induced by these mutations that can confer resistance to the drug. In particular, in the case of 
RTK inhibitors two distinct pathways could be indentified: i) a perturbation in the general 
conformation of the ATP pocket or ii) a transition from the closed form toward the activated 
form. The molecular mechanisms underlying these two pathways has been analyzed in this 
thesis to a finer level using molecular modeling and studying the energy contribution of the 
different structure for the affinity with drug or other protein.  
Briefly, the last two decades have witnessed enormous progress in our knowledge and 
understanding of the molecular basis of neoplastic transformations. The complete sequencing 
of the human genome has represented one milestone on this path and, as it was anticipated at 
the beginning of the genome project, the completion of this enterprise brought particularly 
significant advancements to our understanding of cancer. Analyzing these cases we can point 
out the efficacy of a practice which leads us from bed to bench and back, i.e. the route which 
moves from the patient’s molecular profile to the modeling of the molecular target and the 
examination of its data, the identification of the best available drug, the evaluation of clinic 
response and the possibility, even in the presence of relapse and thus of resistance to the 
treatment, of restarting along this virtuous circle moving from the molecular profiling this time 
of the reactivated tumor which developed a secondary resistance, to new modeling and data 
mining which in turn lead to the design of a new treatment with a new drug. 
The combination of computer-based molecular modeling and parallel assessment of 
biochemical and biological properties by experimental methods can open new avenue in this 
field of scientific research by providing powerful tools for rationale design of new drugs and to 
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help the clinician in finding the best treatment related to its personal genetic profile, a kind of 
“ad personam” therapy. 
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